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 Sense-antisense transcripts (SATs) are messenger RNA (mRNA) transcripts that 
have regions that are complementary to regions of other mRNA transcripts. SATs may 
play an influential role in the regulation of gene expression. One evolutionary event that 
has had a dramatic impact on many genomes is the widespread dispersal of repetitive 
sequences which includes transposable elements (TEs) as well as simple and tandem 
repeats. Approximately 45% of the human and 37.5% of the mouse genomes are 
composed of repeats derived from transposable elements. A group of SATs was 
identified as resulting from transposable elements integrating into the coding strand of 
some genes and into the template strand of the coding region of other genes. These SATs 
may add to the complexity of an organism's regulatory network or they may be the result 
of rather recent TE activities yet to succumb to sequence divergence.  
 The human, mouse and bovine genomes were analyzed for SATs using publicly 
available datasets and bioinformatics analysis tools. Each sense-antisense binding region 
(SABR) was aligned to transposable elements from the RepBase repeat database 
revealing many SABRs containing TE sequence in a large portion of the sequence. A 
Gene Ontology analysis on subsets of the data showed enrichments for the functional 




An analysis of the substitution rates in human and mouse across the 3' UTRs of 
transcripts containing SABRs at the 5' end of their 3' UTRs showed that the substitution 
rate in the region of the SABR was lower than compared to the beginning of the 3' UTR. 
The lower percent GC composition found at the 3' end of the 3' UTRs could be attributed 
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 Sense-antisense transcripts (SATs) are messenger RNA (mRNA) transcripts that 
have regions complementary to other mRNA transcripts. SATs have been demonstrated 
to function in gene regulation by two types of mechanisms depending on their genomic 
arrangement. SATs located at the same genomic locus may regulate each other's 
expression through transcriptional interference as was demonstrated by using atomic 
force microscopy showing RNA polymerases stalled during simultaneous transcription of 
cis genes (Crampton et al. 2006). SAT regulation in trans by non-coding transcripts has 
also been demonstrated with the binding of separate mRNA transcripts at the post-
transcriptional level of gene expression resulting in the reduction of the 
polygalactouronase enzyme (Smith et al. 1988). These two forms of gene regulation 
demonstrate the potential for SATs to regulate expression levels in cis or trans at either 
the transcriptional or post-transcriptional phases of gene expression. Understanding gene 
regulation and how SATs may play a role is important in designing antisense treatments 
for diseases such as cancer in which gene expression has often been significantly altered 
by changes in biological mechanisms or regulatory elements (Hanahan and Weinberg 
2000; Wacheck and Zangemeister-Wittke 2006).   
 
Sense-Antisense Transcripts 
 Although antisense transcripts have been a well-known phenomenon in 
prokaryotes  for  many  years   (Simons 1988),   they  were  discovered  more  recently  in  
                                  





eukaryotes (Knee and Murphy 1997).  The first evidence of antisense RNA transcription 
was reported by Williams and Fried in 1986 using mouse as a model organism (Terryn 
and Rouze 2000). Sense-antisense transcripts may be transcribed from the same genomic 
locus (cis) or from different loci (trans). The cis SATs can be grouped into three main 
categories: convergent, divergent and containment (Figure 1).  
Convergently overlapping pairs were the most abundant class of cis SATs found 
in some organisms (Jen et al. 2005; Zhang et al. 2006). However, a different cis SAT 
identification approach found the divergent class to be more abundant than convergent 





Figure 1.    
Genomic arrangement of three types of cis SATs. Convergent (A), divergent (B) and containment 
(C) arrangements of genes at the same locus that form SATs. 
  
 Although the roles of SATs are not fully known, specific SATs have been 
demonstrated to play active roles in genomic imprinting (Sleutels et al. 2002), skeletal 




proliferation inhibition (Chao and Spicer 2005) and circadian cellular process regulation 
(Kramer et al. 2003). SATs have been found to be co-expressed in some tissues and 
differentially expressed in others (Vanhee-Brossollet and Vaquero 1998; RIKEN 2005). 
Tissue specific gene expression of trans SATs in Arabidopsis thaliana indicated that 
most trans SAT pairs were co-expressed in the same tissues and cells suggesting that 
trans SATs have the potential for interaction in the cell (Wang et al. 2006). The X 
inactivation gene Xist is negatively regulated by a cis antisense transcript called Tsix 
which is implicated in Xist chromatin modification (Ohhata et al. 2008). 
Naturally occurring non-coding antisense RNA transcripts target specific RNAs 
for regulatory purposes (Wagner and Simons 1994). Therefore, the sense-antisense 
binding regions (SABRs) of coding transcripts forming SATs may also play an influential 
role in gene regulation. Some researchers have suggested that SATs play a role in gene 
regulation by forming the long duplexes essential for post-transcriptional regulatory 
mechanisms, mRNA transport and RNA stability (Lipman 1997; Kumar and Carmichael 
1998). Antisense transcripts have been demonstrated to regulate gene expression in vivo 
such as the trans regulation of polygalactouronase (PG) levels within a transformed plant 
containing a 730 nucleotide (nt) fragment from the PG clone DNA (cDNA) (Smith et al. 
1988). Also antisense post-transcriptional gene silencing was accomplished using an 
antisense gene in Virginia pine (Tang et al. 2005). cis SATs may also have regulatory 
roles at the transcription level such as the  colliding transcriptional mechanisms called 
„transcriptional interference‟ proposed by Prescott and Proudfoot 2002, and later 
validated using atomic force microscopy (Crampton et al. 2006). Additionally, an 
expression analysis of cis SATs was observed to be consistent with the transcriptional 




SATs to be a result of RNA-dependent epigenetic modifications and not transcriptional 
interference (Camblong et al. 2007).  
 Antisense transcripts that bind to their sense complement in the nucleus may 
prevent an mRNA from being transported out of the nucleus and into the cytoplasm. This 
along with the tendency of SATs to be poly-A negative and nuclear localized, suggest 
that the primary regulatory role of SATs as regulators of gene expression may occur in 
the nucleus (Kiyosawa et al. 2005). The expression correlation of sense and antisense 
genes may provide some support for expression regulation of one transcript by the 
expression levels of another. A genome-wide analysis of cis SATs found that co-
expressed and inversely expressed patterns of SAT pairs are from a group of evolutionary 
conserved pairs (Chen et al. 2005).  
 
Transposable Elements 
 The insertion of a transposable element (TEs) in two different genes can create a 
SAT pair. TE activity has played a role in the formation of trans SATs such as the mouse 
B1 SINE copying itself into the coding region of one gene and into the template strand of 
an exon of another gene (Figure 2). This same transposon copied into various exons and 
template strands of exons of various genes can create a group of transcripts that have 
similar SABRs. The SABR of a single transcript matching various antisense transcripts 
supports the Class I transposon 'copy and paste' mechanisms for trans SAT formation.  
 Researchers found that TE insertions in exonic regions were less frequent in the 
coding and more frequent in the template strand at 47.3% and 52.7% respectively in the 
cow genome (Almeida et al. 2007). Other researcher also found TEs more likely to be 





 TE insertions can be advantageous resulting in new regulatory functions (Britten 
1996; Brosius 1999b; Jordan et al. 2003; van de Lagematt et al. 2003; Thornburg et al. 
2006) or they may be deleterious resulting in genetic diseases (Wallace et al. 1991; 
Tufarelli et al. 2003). Alignments of human and mouse sequences to protein domains 
from the PROSITE (Hulo et al. 2006) database revealed a small number of exonized TEs 
with the potential to either contribute to or not affect protein functionality (Sela et al. 
2007). Alignments of transposable element sequences to PDB entries found a small 




A. gene(A)   coding strand 
   5' GCCGGGCATGGTGGCGCACGCCTTTAATCCCAGCACTTGGGAGGCAGAGGCAGGCGGATTTCTGAGTTCGAG 3' 
   3' CGGCCCGTACCACCGCGTGCGGAAATTAGGGTCGTGAACCCTCCGTCTCCGTCCGCCTAAAGACTCAAGCTC 5' 
template strand   
 
 gene(A) mRNA: 
   5' GCCGGGCAUGGUGGCGCACGCCUUUAAUCCCAGCACUUGGGAGGCAGAGGCAGGCGGAUUUCUGAGUUCGAG 3' 
 
 
B. gene(B)   coding strand 
   5' CTCGAACTCAGAAATCCGCCTGCCTCTGCCTCCCAAGTGCTGGGATTAAAGGCGTGCGCCACCATGCCCGGC 3' 
   3' GAGCTTGAGTCTTTAGGCGGACGGAGACGGAGGGTTCACGACCCTAATTTCCGCACGCGGTGGTACGGGCCG 5' 
template strand   
 
 gene(B) mRNA: 
   5' CUCGAACUCAGAAAUCCGCCUGCCUCUGCCUCCCAAGUGCUGGGAUUAAAGGCGUGCGCCACCAUGCCCGGC 3' 
 
 
C.         gene(A) mRNA                           SATs 
   5' GCCGGGCAUGGUGGCGCACGCCUUUAAUCCCAGCACUUGGGAGGCAGAGGCAGGCGGAUUUCUGAGUUCGAG 3' 
   3' CGGCCCGUACCACCGCGUGCGGAAAUUAGGGUCGUGAACCCUCCGUCUCCGUCCGCCUAAAGACUCAAGCUC 5' 
  gene(B) mRNA 
 
 
Figure 2.     
Example of a trans SAT pair created by a transposable element inserted into two genes. Example 
of a portion of the mouse B1 SINE (underlined) integrated into an exon of one gene (A) and into the 





 Evidence suggests that TE activity has shaped various genomes (reviewed in 
Cordaux et al. 2006); however, TE insertion is usually detrimental when inserted into the 
coding or regulatory regions of genes. Some TE sequences in genes have withstood many 
years of purifying selection. Understanding past transposon activities may help us 
understand why some genes with TE insertions remain functional. Additionally SAT 
research can help the growing research interest in using artificial antisense 
oligonucleotides transcripts for therapeutic purposes (Dai et al. 2007).  
Transposable elements make up a large percentage of many genomes and have 
contributed to a number of protein coding sequences (Brosius 1999a; Nekrutenko and Li 
2001). TEs have been commonly labeled as „junk‟ DNA with the assumption that they 
served on purpose. Today, many researchers regard TEs as parasitic (Rouzic et al. 2007) 
while others argue that the relationship between TEs and their host are more symbiotic 
(Brosius 1999a) since there are some examples of TEs that have become functional non-
coding elements (Bejerano et al. 2006). 
 Transposable elements are relatively short sequences in the genome that can move 
around to different loci on the same or different chromosome within an organism. First 
discovered by Barbara McClintock in maize around 1950, TEs are categorized as Class I 
and Class II. Class I TEs use an mRNA intermediate for transposition. This results in two 
genomic loci containing the transposon sequence. Class II TEs have a DNA intermediate 
which is excised from its genomic location and moved to another region of the genome.
 Class I TEs are termed retroposons or retrotransposons because of their 
retrotransposition capabilities using an RNA intermediate. Most mammalian 
retrotransposons fall into three classes, short interspersed nuclear elements (SINEs), long 




SINEs and LINEs make up the largest proportion of interspersed repeats in human.  
 
LTR Retrotransposons 
 Retrotransposons that contain long terminal repeats (LTRs) at both ends are called 
LTR-transposons. Many LTRs have contributed to gene evolution (DeBarry et al. 2006) 
and the formation of various SATs.  
 
LINEs 
Retrotransposons that do not contain LTRs are called non-LTR retrotransposons 
and contain a polyadenylation sequence at the 3' terminus. These non-LTR 
retrotransposons include LINEs and SINEs. L1 is an example of a family of LINE 
elements found in mammalian genomes. A full length Line element can be anywhere 
from 4-6 kb in length and contain two coding regions, one for the nucleic acid binding 
protein and another for an endonuclease with reverse transcriptase. LINEs can be 
grouped into families based on their sequence divergence in their 3' end, which can be 
used as a temporal estimate of their insertion relative to other LINEs (Smit et al. 1995).   
  
SINEs 
 SINEs range from 100-400 base pairs (bp) and usually average around 300 bp and 
are the most abundant TE in human gene promoter regions (Thornburg et al. 2006). 
Unlike LINEs, SINEs do not code for any proteins, and rely on reverse transcriptase 
produced by LINEs for replication. By far the most abundant SINE in the human genome 
is the Alu element with over a million copies dispersed throughout the genome. Although 




(Mills et al. 2007).  
The origin of the primate specific Alu element dates back about 50 million years 
ago to the precursor sequence 7SL RNA. The abundance of Alu sequences in the human 
genome and not the chimp indicate that Alu proliferation was specific to the human 
genome (Hedges et al. 2004). The Alu elements do not code for their own reverse 
transcriptase but instead are mobilized in trans by utilizing reverse transcriptase produced 
by the L1 elements. TE sequences have been identified in thousands of human proteins 
and in some cases constitute greater than 80% of a gene sequence (Nekrutenko and Li 
2001; Britten 2004). B1 is an abundant SINE in the mouse genome and originated from 
an ancestral Alu sequence (Kriegs et al. 2007). SINEs have been used as phylogenetic 
markers showing the relationship between extant species (Nikaido et al. 1999).  
 
Retrovirus-like Elements 
 Retrovirus-like elements (RLEs) code for proteins similar to those in vertebrate 
retroviruses. They have long terminal repeats which can be used to estimate when the 
RLE insertion occurred and can be used as taxonomic markers (Cantrell et al. 2001). 
Vertebrate-specific endogenous retroviruses (ERVs) are the only RLEs that have been 
active in mammalian genomes (IHGSC 2001). RLEs have become such an integrated part 
of our genome that the presence or absence of specific ERV terminal repeats can be used 
as markers for disease risk in humans (Donner et al. 1999). RLEs can create SABRs 
similar to other transposable elements. 
 
DNA Transposons 




important for transposase recognition and can be either autonomous, containing an 
encoded transposase, or non-autonomous containing no transposase coding region. DNA 
transposons that do not code their own transposase rely on transposase produced by other 
transposons. DNA transposons move throughout the genome in a “cut and paste” manner 
and are suggested as playing a role in chromosomal rearrangement (Smit 1996).  
 
Effect of TEs on Alternative Splicing 
 TEs have generated many SATs and they can also affect gene regulation in other 
ways such as restructuring a gene through alternative splicing. Around 98.71% of splice 
sites in mammals contain the canonical dinucleotides GT as donor sites and AG as 
acceptor sites. An additional 0.56% of splice junctions contain the non-canonical 
dinucleotides GC – AG and the remaining 0.73% are small groups of different donor and 
acceptor dinucleotides (Burset et al. 2000). TEs have been implicated in gene evolution 
by exonization in which an exon is created due to a TE sequence containing canonical 
splice sites either in the sense or complimentary antisense sequence (Sorek et al. 2002; 
Lev-Maor et al. 2003; Kazazian 2004; Piriyapongsa et al. 2007; Wu and Sun 2007) and 
by intronization in which an Alu insertion into an exon creates an intron within that exon 
(Sela et al. 2007). These introduced splice sites can lead to transcript isoforms which may 
have premature stop codons and may be transcribed and translated into non-functional 
proteins. TE activity has also been found to increase the frequency of double stranded 
breaks, which can affect genome integrity (Gasior et al. 2006; Hedges and Deininger 
2007). They also provide potential genomic regions for homologous recombination that 
can enhance or disrupt chromosome integrity (Sen et al. 2006). Some TEs can integrate 




to diseases such as neurofibromatosis type 1 (NF1). This condition has been shown to be 
a result of an Alu element inserted into the intronic region of the NF1 gene (Wallace et al. 
1991).  
 TEs have been found in human promoter regions (Jordan et al. 2003) and have 
been shown to play important functional roles (Britten 1997; Jordan et al. 2003). Some 
genes are derived entirely from TE sequences (Britten 2004). Often a fraction of a TE 
sequence, called a TE cassette, is found in an exon due to introduced splice sites or a 
deletion after homologous recombination. TE cassettes tend to be alternatively spliced in 
the human genome (Wu et al. 2007).  
  
Gene Regulation 
 SATs may play a role in gene regulation. Genes are regulated both at the 
transcript and protein levels. Greater than 95% of mammalian RNA transcripts remain in 
the nucleus where they are broken down and eventually recycled (Jackson et al. 2000). 
Upon transcription, RNA transcripts form secondary structures such as stem-loops 
leading to a double-stranded RNA (dsRNA). The dsRNA molecules can lead to a number 
of RNA altering pathways such as adenosine deaminase that acts on RNA (ADAR) and 
RNA interference (RNAi).  
 
RNA Editing 
 Double-stranded RNAs can be edited by a class of enzymes known as ADAR 
(Bass 2002; DeCerbo and Carmichael 2005). These ADAR enzymes can act on dsRNA, 
such as the SABRs created by SATs, by transforming or „editing‟ adenosines to inosines 




alteration occurs because inosine is translated as if it were guanosine (Basilio et al. 1962). 
This RNA editing phenomenon was first discovered in the mitochondria of trypanosomes 
(Benne et al. 1986). ADAR2 is involved in the creation of the canonical splice junction 
AG by editing intronic AA to AI which mimics the conserved AG acceptor site (Reuter et 
al. 1999).  
 A-I editing plays a role in gene expression (Häsler and Strub 2007) and is 
necessary for an organism's survival (Higuchi et al. 2000; Hartner et al. 2004). The Alu 
transposable element has been identified to be prime sites for RNA editing (Kim et al. 
2004).   
Premature stop codons introduced by Alu sequences have been found to be edited 
out by an RNA-editing event (Lev-Maor et al. 2007). Editing of repetitive elements found 
in transcripts may be the predominant role for the RNA editing mechanism (Athanasiadis 
et al. 2004).   
 ADAR enzymes work on dsRNAs with a minimal length of 25-30 bp and are 
most efficient with duplexes of greater than 100 bp (DeCerbo and Carmichael 2005). Past 
studies in mice have shown that hyperedited RNAs, those with a double stranded region 
of greater than 50 bp and at least 20% A-to-I editing, tend to remain in the nucleus 
(DeCerbo and Carmichael 2005).  Long SAT SABRs could provide double stranded 
RNA precursors necessary for the ADAR enzyme to carry out RNA editing processes, 







 Duplexes of RNAs formed by two separate transcripts such as SATs may form 
dsRNA regions leading to the RNA interference (RNAi) pathway. The RNAi mechanism 
uses members of the RNase III enzyme family such as Dicer and Drosha to cleave 
dsRNA at specific positions on a transcript. Drosha generates pre-miRNA intermediates 
upon recognition and cleavage of the ~80 nucleotide RNA hairpin structures (Xuezhong 
et al. 2004). However, a study set of cis SATs in Arabidopsis thaliana did not find 
evidence for a role of small RNAs in the disproportionate regulation of gene expression 
(Henz et al. 2007). 
 
mRNA Masking 
 Nearly all eukaryotic mRNAs have poly-A tails which assist the transcript in 
transport, stability and translation (Hu et al. 2005). Translation generally occurs after 
poly-A elongation and in some cases in conjunction with other poly-A independent 
mechanisms (Vardy and Orr-Weaver 2007). There are specific hexamer poly-A signals 
near the end of mRNA sequences such as AAUAAA or a close variant. Many proteins 
and mRNAs are deposited maternally into the oocyte during oogenesis. These maternal 
mRNAs are subject to translation regulation by mRNA binding proteins that bind to 
specific sequences in the 3' UTR (Fu et al. 1999, Loning et al, 1999). This form of 
translational repression, also called mRNA masking, can occur in an organism by 
utilizing repressor proteins that recognize a short sequence in the 3' UTR of mRNA 
transcripts. However, it has been found that when a 3' UTR repressor site forms a dsRNA 
duplex with an antisense transcript or the repressor site is removed, the transcript can 




in gene activation upon binding over the repressor site of other transcripts. 
 
Nonsense-Mediated mRNA Decay (NMD) 
 NMD is a mechanism by which alternative transcripts with premature stop 
codons, such as those created by the activity of TEs, can be degraded preventing energy 
being expended in the synthesis of truncated proteins (Frischmeyer and Dietz 1999). 
Studies have shown that mouse embryos cannot develop if they lack the NMD protein 
Upf1; however, the loss of Upf1 is tolerated in lower eukaryotes (Medghalchi et al. 
2001). In NMD, a premature stop codon must be located more than 50 nucleotides 
upstream of the final intron position (Hillman et al. 2004). When introns are removed 
from a transcript, exon-junction complexes are deposited at the splice sites. The 
recognition of these complexes assists in transport from the nucleus (Hillman et al. 2004).  
As the ribosome moves along the transcript during translation, the exon-junction 
complexes are displaced. If one or more of the splicing junction complexes is located 
sufficiently downstream of the stop codon, the transcript is degraded. NMD may also 
serve to regulate the levels of mRNA production and degrade transcripts that can produce 
harmful proteins (Maquat 2005).  
 
Estimating Sequence Evolution 
 Some SAT SABRs have a high percent complementation indicating that they may 
be conserved for a biological purpose. Further investigation into this group can help 
understand the evolutionary history of these SABRs and provide clues as to why they 
have maintained a high level of conservation. 




nucleotide substitutions in orthologous sequences. Nucleotide substitutions in coding 
regions can be classified as one of two types of substitutions; transitions or tranversions. 
Transitions are mutation of a purine to a purine such as A to G or pyrimidine to 
pyrimidine such as T to C. Transversions are changes of a nucleotide from a purine to a 
pyrimidine or pyrimidine to a purine. Transitions occur more often than transversions 
since transitions do not result in a change in the number of chemical ring structures. 
Transversions result in the addition or loss of a ring in the chemical structure of the 
resulting substitution at the mutation site. The different rates of transition and 
transversions are important when estimating selection based on the type of replaced 
nucleotide. Nucleotide substitutions in coding regions can also be classified as 
synonymous or nonsynonymous.  
The genetic code is degenerate such that substitutions at certain codon position, 
especially at the third „wobble‟ position, result in a codon for the same amino acid. These 
mutations or substitutions are called silent or synonymous substitutions (KS) since the 
protein sequence is unchanged. However, if a mutation results in a codon change 
resulting in a change in the amino acid sequence it is called a nonsynonymous 
substitution (KA). Therefore, substitutions at the third position of a codon are thus more 
common than at the first two positions since there is a greater chance of a third codon 
position substitution resulting in the same amino acid. Substitutions in the first two codon 
positions are more likely to result in changes in the amino acid sequence which can be 
detrimental to the organism. 
 Determining synonymous and nonsynonymous rates is not trivial, because some 
amino acid changes have resulted from substitutions in multiple codon positions at 




difficult to determine which codon position substitution occurred first. Thus models of 
evolution are used to predict the rates of nonsynonymous and synonymous substitution.
 The Nei-Gojobori codon based method (Nei and Gojobori, 1986) determines the 
number of synonymous and nonsynonymous substitutions based on the number of 
potential synonymous and nonsynonymous sites respectively. The two rates are 
normalized by dividing by the number of each potential site respectively determining the 
p-distance. Additionally, the p-distance, which is defined as the proportion of nucleotide 
sites differences of two compared sequences, can be adjusted using the Jukes-Cantor 
correction (Jukes and Cantor, 1969) to adjust for multiple substitutions at the same site 
for synonymous and nonsynonymous sites and are often referred to as dS and dN 
respectively. This correction is useful when the time of divergence between two species 
is high since the probability of a second substitution at the same site as a previous 
substitution increases over time.  
The proportion of nonsynonymous to synonymous substitutions (KA / KS) can 
give an estimate of the relative type of selection that is occurring. Selection is considered 
neutral or no selection occurring when (KA = KS). Purifying or negative selection is 
inferred when (KA < KS) and positive or Darwinian selection is inferred when (KA > KS). 
 Estimating substitution rates in non-coding sequence such as UTRs is different 
than for coding sequences since the measurement of synonymous and nonsynonymous 
changes is reserved for protein coding sequences. Simply determining if there was a 
substitution is not sufficient to estimate the rate of sequence change. The probabilities of 
a transition or a transversion occurring are different and must be incorporated in the 
calculation methods. The Kimura two-parameter model was developed to account for the 




Determining percent GC content for regions of the 3' UTR can also supplement 
conservation studies of the SABR and the rest of the 3' UTR. Previous studies have 
identified a negative correlation between percent GC content and the level of 
conservation in mammalian 3' UTRs (Shabalina et al. 2003). If SABRs lie in regions of 
relatively high GC content, then conserved SABRs in regions of increased conservation 
may be due to GC content alone. 
 
Conservation of SATs 
 If SATs play a role in gene conservation, then the conservation of SAT pairs can 
give insight into which genes may be regulated by these mechanisms. The evaluation of 
the conservation of SATs depends on the definition of a SAT. Researchers usually set a 
high percent complementarity within the overlapping region which limits the number of 
overall SATs (Li et al. 2006). Lowering the percent complementarity in the SABR will 
increase the number of overall SATs, but SATs of low percent complementarity are 
unlikely to have a biological function due to reduced stability of dsRNA complexes. The 
number of conserved SAT pairs was generally low for a study of SATs in a population of 
three yeast, one fungi and one microsporidian species (Steigele and Nieselt 2005), and 
conservation was only about 20% for all human and mouse antisense genes in a different 
study (Veeramachaneni et al. 2004). The number of conserved cis and trans SATs using a 
HomoloGene search approach was 736 for human and mouse (Galante et al. 2007). Only 
a small percentage of identified human and mouse orthologous antisense transcripts are 
conserved across the two species (Veeramachaneni et al. 2004).  
 The antisense transcripts of two particular genes, thymidylate synthase (TS) and 




the nucleus than in the cytoplasm; however, the two gene sense strands had similar 
expression levels in the cytoplasm and nucleus, suggesting that the antisense transcripts 
for these two genes may not block transport into the cytoplasm and that antisense 
transcript binding activity may be most pronounced in the nucleus (Faghihi and 
Wahlestedt 2006). Additional support for this theory comes from the findings that only 
about 5% of mRNAs are exported to the cytoplasm for translation while the remaining 
95% are broken down in the nucleus (Jackson et al. 2000). 
 
Structure and Functional Annotation 
Genome sequencing is just an initial step in one approach to the identification of 
genes and the biological function of their products. Protein structure determination is 
done on a protein-by-protein basis. Solved structures are submitted to data repositories 
such as the Protein Data Bank (PDB) (http://www.rcsb.org/pdb). The PDB provides 
confirmed structure sequences in text format as well as 3-D images. With the growing 
number of databases storing functional data for various species, it is beneficial to have 
common terms or controlled vocabularies to describe functions across species. The Gene 
Ontology (GO) project is dedicated to using a controlled vocabulary set to describe 
functions, processes and components of genes and their products. 
 
Objectives of this Study 
 The goals of this project were to structurally characterize SATs that were 
identified in three different organisms; human, mouse and cow and investigate why the 
percent complementation of some sense-antisense binding regions (SABRs) are more 




mechanisms shared among organisms or mechanisms that are unique to each species. 
Structures in the PDB were used to determine potential effects of TE insertions on protein 
folding. 
 Sequence evolutionary rates were estimated to determine whether SABRs in the 3' 
UTR evolve at a different rate than the rest of the 3' UTR and the coding sequence. 
Finding significantly lower substitution rates in a 3' UTR SABR compared to the rest of 
the 3' UTR would suggest SABR functionality. However, a genome wide orthologous 
gene substitution rate could show that the 3' UTR localized SABR is no different than the 










 The integration of transposable elements (TEs) into the coding and template 
strands of the coding and UTRs may be an important contributor to the formation of 
sense-antisense transcripts (SATs). The goals of this project were to characterize the 
structure of SATs that were identified in three different organisms; human, mouse and 
cow and to investigate why the percent complementation of some sense-antisense binding 
regions (SABRs) are more conserved than others. The human, mouse and cow RefSeq 
datasets were individually analyzed for SATs. Unlike previous studies that filtered out 
sequences that aligned to TEs, the SAT datasets in this project were aligned to 
transposable elements sequences from their respective organisms. The data revealed a 
group of SATs that was created as the result of TEs integrating into opposing strands of 
coding regions of various genes creating a one-to-many relationship of sense to antisense 
transcripts within a particular genome. Although TEs have been often dismissed as „junk‟ 
DNA, the generation of SATs by TE integration could potentially have added to an 
organism‟s complex regulatory networks. However, the results of this project 
demonstrate that many SATs created by TEs have not remained conserved and others are 
the result of currently active TEs. It is difficult to distinguish whether recent TE 
insertions have contributed to species specific gene regulation or whether there has not 






 There is a growing interest in investigating potential gene regulatory mechanisms 
initiated by SATs as is demonstrated by many recent publications as well as public SAT 
databases on the Internet (Galante et al. 2007; Yin et al. 2007). The large percentage 
(>20%) of transcripts in the human genome that have the potential to form SATs (Chen et 
al. 2004) demonstrates the possibility of complex regulatory networks composed of many 
mRNA transcripts, including coding transcripts, that potentially bind to other mRNA 
transcripts and regulate their expression.  
 The public release of numerous sequenced genomes has created opportunities to 
apply a number of in silico techniques to identify SATs. Various methods and datasets 
have been used to search for SATs using expressed sequence tags (ESTs) and cDNAs, 
from repositories such as UniGene (Wheeler et al. 2003) and RefSeq, as well as clone 
datasets (Kiyosawa et al. 2003). Many researchers have concentrated specifically on 
identifying and classifying cis SATs within species (Chen et al. 2004; Chen et al. 2005; 
Knee and Murphy 1997; Shendure and Church 2002; Yelin et al. 2003; Wang et al. 2005; 
Zhang et al. 2006) while other researchers have studied the conservation of cis SATs 
across various species (Zhang et al. 2006). Each dataset and technique has identified 
many SATs both cis and trans, however, no common features have been identified which 
would allow scientists to categorize SATs with a general regulatory function. Some SATs 
may have gained a regulatory function while others may just be insignificant 
consequences of transposable element activity, segmental duplications, cross-over events 
or some other evolutionary event. Unlike previous studies, this project focuses on the 






The objectives of this project were to structurally characterize SATs using the 
locus of each SABR in transcripts of human, mouse and cow to determine whether SATs 
are more abundant in specific regions of a transcript.  
 
Materials and Methods 
 A goal of the RefSeq dataset is to provide accurate and full-length sequence data 
(Pruitt et al. 2005). It is composed of genomic, transcript and protein sequences retrieved 
from the public sequence repository GenBank (Benson et al. 2007). The RefSeq dataset 
was chosen for this project because it is a non-redundant, comprehensive set of gene 
transcript sequences for various model organisms.  
The human and mouse RefSeq datasets were downloaded from NCBI on April 2, 
2007. The cow RefSeq dataset was downloaded from NCBI on October 17, 2007. Only 
the NM_ prefixed RefSeq accessions were used because the XM_ prefixed RefSeq data 
set consists of computed gene models with little experimental evidence, whereas the 
NM_ prefixed accessions are either curated from full-length cDNA clones or created by 
aligning ESTs or cDNAs to a genome sequence. Alternative transcripts were maintained 
in the dataset. Each dataset was aligned in an all vs. all approach using the FASTA 
(Pearson 1988) alignment tool with an e-value of 1e-10 and the -i option to reverse 
complement one copy of each organism‟s dataset. This technique can also be 
accomplished using BLASTN (Li and Su 2006). A Perl script was used to remove 
reciprocal hits and parse the FASTA output to retrieve the alignment coordinates of SAT 
sequences containing ≥95% SABR complementation and an E-value of 1e-10. A 95% 




duplexes. The E-value was maintained at 1e-10 but the percent identity for the SABR 
was reduced to ≥80% for a second dataset of SATs. This would identify any SABRs that 
have accumulated mutations since their initiation. The genomic coordinates for the 
sequences involved in SATs were obtained from NCBI's GeneID coordinates. 
 A Perl script was used to parse the sequences of the SABR regions. These SABR 
sequences were aligned to transposable elements using CENSOR and the repeat libraries 
included with the CENSOR package. A Perl script was used to remove non-TE sequences 
such as satellite, simple and tandem repeat sequences, tRNA and rRNA sequences from 
the CENSOR repeat libraries. The libraries used were human (hum), primate (pri), 
mammal (mam), rodent (rod) and vertebrate (vrt). The human library was used first for 
human, the rodent library was used first for mouse and the mammal library was used first 
for cow. The CENSOR libraries were searched in the order as given on the command 
line: censor input_file.fasta -bprm „-filter=none‟ -s -nofilter -mode {sens} -lib hum -lib 
pri -lib mam -lib rod -lib vrt. For example, in the command above, each sequence was 
first aligned to the human repetitive sequence dataset. If there were no human repetitive 
sequences aligned, then the next repetitive element datasets in the order mammalian, 
vertebrate and rodent were used. If a part of a sequence aligned to a human repeat, it 
would be masked and no longer aligned to the sequential libraries; however, the rest of 
the unaligned sequence would be aligned to the libraries in the order given at the 
command line. 
 All individual SAT sequences were merged into groups based on the GeneIDs 
(unique identifiers for each gene locus) as provided by Entrez Gene (Maglott et al. 2007). 
This allowed the clustering of alternative transcripts to represent one gene locus when 




such as average SABR length and the percentage of the SABR consisting of a TE 
sequence.  
 The BioPerl Perl module was used in a Perl script to retrieve all protein sequences 
and gene symbols for each RefSeq accession of human and mouse that had ≥95% SABR 
complementation. FASTA alignments were conducted aligning all human to mouse, 
mouse to cow and human to cow protein sequences using an E-value of less than 0.001. 
The aligned sequences were scored as homologs if the alignment had greater than 30% 
identity across greater than 95% of both sequence lengths. 
The data from Table 6 was used as a population for the components involved in 
the trans SATs for the ≥95% complementation group. The cis SATs were not used since 
they generally overlap at the same genomic locus and thus have a high percent 
complementation due to being on opposite complementary DNA strands. The 
hypergeometric distribution (Figure 3) was used to test for any overrepresented 
components existing in the ≥95% SABR complementation dataset which is a subset of 
the 80% complementary dataset. 
 To investigate whether older Alu subfamilies were preserved in SATs the FASTA 
alignment tool was used for comparing all SABRs with the younger AluY subfamily 
















 The hypergeometric distribution can be used to identify overrepresented terms 
from a study sample within a population. The population is represented with n and the 
sample is represented by k. The number of SAT genes that have a particular component is 
represented by r. The proportion of genes in the population with a particular identity is p 
(Castillo-Davis and Hartl 2003).  
 
Results 
 A SAT pair consists of two distinct sequences a sense transcript and an antisense 
transcript. Therefore, it might be expected that 100 SAT pairs consist of 200 unique 
sequences if there is a one-to-one relationship among SAT sequences. However, of the 
1,030 sequences comprising the 515 human SAT pairs, there were only 745 unique 
sequences. This resulted because specific sense sequences can form a SAT pair with 
several different antisense transcripts in a one-to-many relationship. This is the case for 
all organisms in both levels of percent complementation (Table 1). As expected, there is a 
one-to-very-many relationship of sense to antisense transcripts in the ≥80% SABR 
complementation dataset as there are relatively few unique sequences making up the 




Table 1. Number of SATs and unique sequences identified in each organism for two different 
percent identity datasets. These include all alternative transcripts. 
 
                                                                                                                                                               
          ≥95% SABR complementation     ≥80% SABR complementation 
               unique      GeneID          unique    GeneID 
                               SATs        sequences      groups                SATs       sequences      groups         
       human     515            745       585                589,479         3,640      2,874 
       mouse     446            725       685                  42,777         1,787      1,688  






  A Perl script was used with the GeneID coordinates obtained from NCBI to 
determine the genomic locations of SATs and to cluster alternative transcripts of the 
same gene in order to differentiate between cis and trans SATs. The cis SATs were 
categorized into the three positional categories as defined in Chapter I (Figure 1) using 
the GeneID coordinates. All three organisms had a larger number of convergent cis SATs 
than the other two cis categories for both the ≥95% complementation and ≥80% 
complementation datasets (Table 2). The divergent category was the second most 
abundant category for all three organisms and both datasets. There was a larger number 
of cis than trans SATs in the ≥95% SABR complementation dataset for all organisms; 
however, there were significantly more trans SATs than cis SATs in the ≥80% SABR 
complementation datasets for each organism (Table 2). When a transposable element 
copies itself to another locus in the genome, it is at initially identical with its sequence of 
origin. If an important new function emerges from the transposition event, then is 
expected that the sequence would maintain a high level of conservation over evolutionary 
time. The lack of sequence conservation in the SABRs for trans SATs suggests that there 
these pairs do not confer a critical function such as gene regulation. However, trans SATs 
that have maintained high percent complementation and are the result of Alu sequences 
that proliferated more than 60 million year ago (MYA) would suggest a strongly 
conserved biological mechanism. The cis SATs, however, are the predominant category 
in the ≥95% SABR complementation dataset. The reason for a high level of conservation 
of cis SATs is not conservation, but the fact that these transcripts consist of opposing 






Table 2. Number of cis and trans SATs in human, mouse and cow for the ≥95%   
complementation and ≥80% complementation datasets for GeneID groups. Counts for all three 
organisms exclude alternative transcripts but demonstrate the one-to-many relationship between SATs 
for two levels of SABR complementation (comp.). 
 
                                                                                                                
                                            Human            Mouse                 Cow       
   ≥95% SABR comp.   
   Convergent (cis)        191       202       15  
   Divergent (cis)           50         51         0  
   Containment (cis)            9         12         0  
   Total cis SATs         250       265       15  
   Total trans SATs          84       130       52  
   Total SATs         334       395       67 
   Total SABRs with TE          74       137       19 
  
   ≥80% SABR comp.          
   Convergent (cis)        205             222       15 
   Divergent (cis)           60         57         2 
   Containment (cis)          12         14         0 
   Total cis SATs         277       293       17 
   Total trans SATs 390,386  37,232  5,391    
   Total SATs  390,639  37,525  5,408    




The average SABR lengths for the ≥80% SABR complementation dataset were 
shorter than those in the ≥95% SABR complementation dataset for all three organisms 
(Table 3) perhaps due to the increased number of short SINE sequences in the ≥80% 
SABR complementation dataset. 
 
 
Table 3. Statistics of SABR lengths for human, mouse and cow. 
                                                                                                                                                     
                                                              Average           Min                    Max            Median   
           human ≥95% complementation      344         60           3,561   213 
           human ≥80% complementation      274         60          3,561   299 
 
           mouse ≥95% complementation      330         62           2,304   192 
           mouse ≥80% complementation      167         62             2,304   163 
 
           cow ≥95% complementation 238         63        1,111               158 





 To access the extent of TEs in all sequences, the RefSeq sequences from each 
organism were aligned to the transposable element sequences provided in the CENSOR 
(Jurka 2005) repeat libraries. A Perl script was used to parse the results and calculate the 
percentage of TEs that aligned to the coding strand and the percentage of TEs that 
aligned to the template strand. These alignment results were also later used in the GO 
analysis section in Chapter II. There was a consistently higher percentage of TEs 
incorporated into the template strand than the coding strand for all three organisms (Table 
4). This agrees with the results from previous researchers (Makalowski et al. 1994; 
Lorenc and Makalowski 2003; Almeida et al. 2007) although the biological significance 
is not quite clear. However, it has been suggested that certain TE sequences are rich in 
canonical splice junctions that can alter the structure of the gene if it integrates into the 
coding strand (Sela et al. 2007). If the TE incorporates into the template strand, the 
number of introduced canonical splice junctions is reduced. 
 
 
Table 4. Percentage of transposable elements aligning to RefSeq sequences in the coding and 
template strands. 
 
                                                                                                                   
                             % Coding        % Template  
      human     46.0      54.0 
      mouse       46.9      53.1 
      cow                    45.6      54.4          
  
 
The SABRs were distributed across relatively the same regions of the transcripts 
in human and mouse, with the 3' UTR having the most localized SABRs (Table 5). 
Duplicate arrangements for each specific gene SABR were counted as a single 




the 3' UTR contained the most for the ≥95% SABR complementation dataset (Table 5). 
This is expected since the CDS displays more conservation across human and mouse than 
the UTRs (Makalowski et al. 1996). Additionally, the conservation of the coding 
sequence across species may indicate that it is less likely to contain a SABR due to a 
duplication or transposition event that would disrupt the coding portion of the transcript.  
 
Table 5. Localization of SABRs for human and mouse trans SATs. Total for all trans SATs having 
≥80% SABR complementation (≥80% comp) and ≥95% SABR complementation (≥95% comp). 
Duplicate arrangements for each specific gene SABR were counted as a single arrangement. 
                                                                                                                                                            
                     Human                                                  Mouse                    
              Arrangement       ≥80% comp      ≥95% comp            ≥80% comp      ≥95% comp     
 
  CDS – CDS      23    0        2      0  
  5' UTR - 5' UTR   132  14      19      4     
  5' UTR – START     41  10*        4      0 
 5' UTR – CDS    133    4*      20      2 
  5' UTR – STOP    417    3      42      0 
  5' UTR - 3' UTR            1,915  29    610    28 
  START – START       6    2        2      2 
  START - CDS      19    0        5      4* 
  START - STOP         20    0        0      0 
  START - 3' UTR   860    0      44      3 
  CDS - STOP      54    8*      11      0 
  CDS - 3' UTR              1,713    4    348      6 
  STOP – STOP       47    5*        8      2 
  STOP - 3' UTR              1,702  17    441    14 
               3' UTR - 3' UTR            2,123  62*              1,023  100*              
  TOTAL              9,205            158              2,579  165  
        
* p < 0.001 
 
Conserved SABR Components: Conserved Function or Recent TE Event? 
 The data reveal that there are a number of conserved 3' UTR SAT SABRs that 
may serve a biological function. However, since TE activity has played a role in the 
formation of many SATs, these conserved SABRs could be the result of not only TE 
activity but recent transposition events from active TEs that have not had much time for 




events of certain Alu elements. The AluJ family is known to have proliferated 60 million 
years ago; AluS proliferated between 60 and 20 million years ago; AluY began 
transposition activity approximately 20 million years ago. Some AluY subfamilies are 
even younger than 20 million years and include actively retrotransposed elements in the 
human population (Jurka et al. 2002). Other active elements in the human genome 
include L1 and SVA (Mills et al. 2007). The SABRs of trans SATs with a high percent 
complementation in the SABR may indicate either little evolutionary time for sequence 
divergence after a recent TE event, or a TE event that has resulted in a critical biological 
role. 
The hypergeometric distribution (Castillo-Davis and Hartl, 2003) was used to test 
for significant enrichment in the trans SATs for each component. The 3' UTR – 3' UTR 
SAT arrangement was overrepresented in both human and mouse datasets. Further 
investigation found that in the human dataset, the AluY transposable element which is 
currently an actively transposing element was significantly enriched in the ≥95% SABR 
complementation group using the hypergeometric distribution analysis (p < 0.01). There 
were no significant enrichments for a particular mouse transposable element in the ≥95% 
SABR complementation group when compared to the ≥80% SABR complementation 
dataset. 
  
Human SATs with ≥95% SABR Complementation 
 There were 515 SAT pairs in the dataset with ≥95% SABR complementation. 
There were only 745 unique sequences of the 1,028 sequences involved in the 514 SAT 
pairs indicating a one-to-many relationship between sense and antisense transcripts. 




45 of the 70 SABRs containing TEs from the 515 SAT SABRs. This is expected since 
Alu is the most abundant transposable element in the human genome, with over a million 
copies. The Alu sequence was also responsible for an average of 99% of the SABR 
alignment lengths with an average of only 45% of its sequence (Table 6). This suggests 
the potential of the Alu sequence to introduce canonical splice sites which would leave 
some of the Alu sequence in the intron regions. The Alu sequence in the CENSOR 
dataset was 334 nucleotides long, but generated an average SABR length of 141 
nucleotides. This is most likely due to alternative splice sites introduced by the Alu 
sequence or new exons created with only a portion of the Alu sequence. TEs such as 
MER85 averaged 100% of the TE sequence found in a fraction of the SABR sequence 
while other TEs such as THE1A covered an average of 100% of the SABR sequence with 
only a fraction of the TE sequence. 
 
Mouse SATs with ≥95% SABR Complementation 
 
 There were a total of 446 SAT pairs consisting of 725 unique sequences for the 
dataset with ≥95% SABR complementation. This resulted in a one-to-many relationship 
between sense and antisense transcripts similar to the human SAT results. As an example, 
the mouse trans SAT sense sequence NM_001081387.1 has five antisense transcripts 
each binding to the sense transcript at relatively the same coordinates (Table7). Although 
the B1_Mus2 SINE has a length of 147 nucleotides, the SABR length is only 105 
nucleotides. The B1_Mus2 SINE sequence spans the entire length of the SABR sequence, 
but only part of the B1 Mus2 SINE sequence is present in the SABR either due to 
alternative splice sites introduced by the B1_Mus2 sequence or due to mutations, 
insertions and deletions at the ends of the SABR that have accumulated since the 





Table 6. Average percent coverage of human SABRs (≥95% SABR complementation) by 
transposable elements. The transposable elements (TEs) are classified as SINEs (S), LINEs (L), 
DNA transposons (D)  and endogenous retroviruses (E).  
                                                                                                                                                                   
            Average          Average % SABR     Average % TE Number of 
 TE               SABR length      coverage by TE         found in SABR          SABRs              cis  trans 
 ALU  (S)     141                     99                          45                       45               0             45 
 ERV1-2-I_XT  (E) 1,981                       3                             1                          1                1              0 
 ERV2_MD_I  (E)        204                      42                            1                          1                1              0 
 HERV70_I  (E)           834                      23                            3                          1                1              0 
 L1  (L)                 96                         100                           2                          1              0              1 
 L1A_OC  (L)     1,136                       7                             1                          1                1              0 
 L1HS  (L)             244                      99                          27                         1                0              1 
 L1PA3  (L)           122                         100                         14                         1                0              1 
 L2A  (L)               788                      47                            3                          2                2              0 
 MER2  (D)    619                      28                          60                         1                0              1 
 MER2B  (D)             438                      21                          23                        4                0              4 
 MER30  (D)    593                        6                           15                         1                1              0 
 MER34B  (E)          1,545                     23                          66                         1                1              0 
 MER5A1  (E) 3,561                       2                           62                         1                1              0 
 MER85  (D)      1,461                       9                                      100                        1                1              0 
 MIR  (S)        1,721                     34                          54                         3                3              0 
 MIRb  (S)              360                      22                          29                         1                1              0 
 RNLTR17_I  (E)    238                      71                            2                            1                1              0 
 SVA  (S)         97                       99                            6                          1                0              1 
 THE1A   (E)          68                         100                                                   19                         1                0              1 
 Total                            392                           78                                                   39                             70                              15            55
           
 Total for each TE type 
 SINE     234  94     44  50  4            46 
 LINE     400  67       8    6  3              3 
 DNA transposon    631  19     41    7  2              5 







Table 7.  One-to-many relationship of trans mouse SATs. One sense transcript with five antisense 
transcripts having the sense-antisense binding region (SABR) region relatively in the same locus on 
the sense transcript aligning to the B1_Mus2 SINE (strand: c=coding, t=template, Chr=chromosome). 
                                                                                                                                                              
       Sense        SABR        SABR            SINE       Antisense            SINE 
       transcript                      start           end       Chr      strand      transcript        Chr     strand  
      NM_001081387.1      2521            2627 2 t NM_026282.2      9 c 
      NM_001081387.1      2521            2626 2 t NM_018804.3      3 c 
      NM_001081387.1      2521            2626 2 t NM_198107.1    10 c 
      NM_001081387.1      2521            2626 2 t NM_021534.2      2 c 




In many cases with the dataset having  ≥95% SABR complementation in the 




the most common TEs aligning to SABRs such as B1Mus1, B1_Mm and B2_Mm1. The 
TEs that cover 98 – 99% of the SABR could be due to mutations at the sequence ends 
after insertion or perhaps due to the difficulties sequence alignment programs have in 
aligning the ends of matches. Additionally, TEs covering a smaller percentage of the 
SABR suggest an introduction of a canonical splice sites by the TE sequence. The 
B1_Mus1 element is found in the highest number of SABRs and covers an average of 
99% of the entire SABR length (Table 8). 
 
Mouse SATs with ≥80% SABR Complementation 
 Although SABRs with lower than 95% complementarity are not likely to form 
RNA duplexes or confer a biological function, a dataset with a relaxed complementarity 
criterion would represent a set in which TE sequence divergence has occurred since the 
time of TE insertion. Differences between a set with a relaxed criterion and a 95% 
complementarity set could reveal biologically significant properties in the 95% 
complementarity set. To create a set for comparison, the percent complementation was 
relaxed to ≥80%. This resulted in 42,777 SAT pairs formed by 1,787 unique sequences. 
Of these SAT pairs, 42,545 had TE sequence in their SABR demonstrating the influence 
of TEs on the creation of SATs at this particular threshold. For the ≥80% SABR 
complementation dataset, the B1_Mus1 element was the most abundant TE in the SABRs 
with an average percentage of 89% of its sequence aligning in SABRs (Appendix C). 
This may indicate that mutations at the ends of the TE sequence caused misalignments 
that were not reported in the FASTA results or it may be due to the introduction of new 




Table 8. Average percent coverage of mouse SABRs (≥95% SABR complementation) by 
transposable elements. The transposable elements (TEs) are classified as SINEs (S), LINEs (L), 
DNA transposons (D) and endogenous retroviruses (E).  
                                                                                                                                                                   
            Average          Average % SABR     Average % TE Number of 
 TE               SABR length      coverage by TE         found in SABR  SABRs  cis  trans 
 B1  (S)                   243                        81                        61                         5                1              4 
 B1F  (S)                    727                        15                        71                         3                3              0 
 B1_Mm  (S)                  114                        98                        75                       13               0            13 
 B1_Mur1  (S)                602                        26                        94                         1                1              0 
 B1_Mur2  (S)             1,002                       12                        79                         1                1              0 
 B1_Mur4  (S)                367                        38                        94                         1                1              0 
 B1_Mus1  (S)                116                        99                        77                       35               0            35 
 B1_Mus2  (S)                144                        93                        80                       12               1            11 
 B1_Rn  (S)                  371                        69                        82                         3                1              2 
 B2  (S)                       67                      100                       32                         1                0              1 
 B2_Mm1a  (S)               145                        99                        74                       14               0            14 
 B2_Mm1t   (S)               280                        82                        99                         3                1              2 
 B2_Rat2  (S)                631                        26                        89                         1                0              1 
 B2_Rat4  (S)             1,534                       12                        99                         1                1              0 
 B2_Rn2  (S)                   77                        99                        41                        4                0              4 
 B3  (S)                     766                        22                        61                         2                2              0 
 B3A  (S)                    717                        31                        77                         2                2              0 
 BC1_Ma  (S)              2,304                         2                         29                         1                1              0 
 Harbinger-2_XT  (D)      249                        14                          1                          1                1              0 
 IAPEZI  (E)               136                      100                         2                          1                0              1 
 ID_Rn1  (S)                 938                          6                         55                         1                1              0 
 L1MC4  (L)                  270                        21                          2                          1                1              0 
 L1_MM  (L)                  250                        99                          4                          4                0              4 
 L2A  (L)                  105                        80                          3                          1                1              0 
 LTRX_ME  (E)          388                        12                         8                          1                1              0 
 LX  (L)                     94                      100                         9                          2                0              2 
 MEN  (S)                    441                        35                        55                         1                1              0 
 MER20  (D)             1,864                         5                         51                         1                1              0 
 MER21C  (E)               687                          7                           5                          1                1              0 
 MTA  (E)                  141                      100                       36                         2                0              2 
 MTAI  (E)                 106                      100                       10                         1                0              1 
 MTA_Mm_LTR  (E)      140                      100                       36                         1               0              1 
 MTEb_LTR  (E)             346                        25                        24                         1                1              0 
 MYS1_PL  (E)           126                        25                          1                          1                1              0 
 ORR1D1_LTR (E)          976                        35                       94                         1                1              0 
 PB1D10  (S)       2,038                         5                         85                         1                1              0 
 PB1D9  (S)          1,066                       10                        80                         2                2              0 
 RLTR10C  (E)       114                      100                       26                         1                0              1 
 RLTR16  (E)        2,304                         4                         18                         1                1              0 
 RSINE1  (S)               919                        13                        81                         1                1              0 
 
 Total                              309           79                                              66                   131                             32             99
           
 Total for each TE type 
 SINE       288    81   75                 109                 22            87  
 LINE       195    87     5    8  2              6 
 DNA transposon   1,057    10   26    2  2              0 




Cow SATs with ≥95% SABR Complementation 
 There were fewer SATs revealed in the analysis of cow SATs probably due to the 




Although the cow genome is not near the level of annotation as the human and mouse 
genomes, this study detected similar patterns in the number of SATs and unique 
sequences at different percent complementation in the SABRs. Cow SAT SABRs also 
contained more SINEs than any other transposable element for both complementation 
datasets (Table 9 and Appendix D). 
 
Table 9. Average percent coverage of cow SABRs (≥95% complementation) by transposable 
elements. The transposable elements (TEs) are classified as SINEs (S), LINEs (L) and endogenous 
retroviruses (E).  
                                                                                                                                                                   
            Average          Average % SABR     Average % TE Number of 
  TE              SABR length      coverage by TE         found in SABR          SABRs              cis  trans 
 ART2A  (S)            218                      100                       40                         2              0              2 
 BOVA2  (S)            134                        95                        48                         9               0              9 
 BOVB  (S)            131                        98                          4                          1                0              1 
 L1_BT  (L)            165                        99                        14                         3                0              3 
 L1P_MA2  (L)          124                        99                          2                          1                0              1 
 RNLTR17_I (E)          242                        33                          1                          1                0              1 
 
 Total                           153                             93                                                35                               17                                0            17  
         
 Total for each TE type 
 SINE     146    96   44  12  0            12       
 LINE     155    99   11      4  0              4 





Conserved SATs in Human, Mouse and Cow Orthologs 
 Conservation of SATs can provide a clue to understanding SAT function and 
whether conservation of specific SAT loci reflects functional importance of SATs. SATs 
that are maintained over evolutionary time demonstrate that they may be essential for the 
organism's survival and maintenance.  
 Only cis oriented SATs were found to be conserved across human, mouse and 
cow genomes (Table 10). This may demonstrate that if trans SATs have some function 
within a particular organism, it may not be shared across species. This concept is further 
investigated in Chapter III. The fewer conserved cow sequences reflect the lower level of 




Table 10. Conservation and arrangement of cis SATs with ≥95% SABR complementation for 
human, mouse and cow.  Mouse gene in parenthesis when the name differs  from human ortholog. 
                                                                                                                                              
        Species        Sense                                         Antisense                         cis orientation   
          Hs. Mm.          B3GAT2    SMAP1        convergent  
          Hs. Mm.          HTRA2    LOXL3        convergent 
          Hs. Mm.          DNAJC14    ORMDL2        convergent 
          Hs. Mm.          PRR3    GNL1        divergent 
          Hs. Mm.          PHYHIPL    FAM13C1            convergent 
          Hs. Mm.          SLC3A1    PREPL        convergent 
          Hs. Mm.          KRR1    GLIPR1        convergent 
          Hs. Mm.          C20orf132    RPN2        divergent 
          Hs. Mm.          DNAH11    CDCA7L        convergent 
          Hs. Mm.          TMEM140   C7orf49        convergent 
          Hs. Mm.          MGC4655    C16orf70        convergent 
          Hs. Mm.          C12orf48    PMCH        convergent 
          Hs. Mm.          DKFZp667G2110   (BC043118)  MINA        convergent 
          Hs. Mm.          ATP5F1    WDR77        divergent 
          Hs. Mm.          COG1    FAM104A  (D11Wsu99e)      convergent 
          Hs. Mm.          VRK2    FANCL        convergent 
          Hs. Mm. Bt.    POLR3H    ACO2        convergent  
          Hs. Mm.          DMTF1    C7orf23        convergent 
          Hs. Mm.          C20orf132 (4922505G16Rik)  RPN2        divergent 
          Hs. Mm.          YPEL1    PPIL2        convergent 
          Hs. Mm.          RPE    FLJ23861  (LOC273425)      convergent 
          Hs. Mm.          LRRC59    EME1        convergent 
          Hs. Mm.          MORG1    DHPS        convergent 
          Hs. Mm.          CRBN    TRNT1        convergent 
          Hs. Mm.          PKMYT1    PAQR4        convergent 
          Hs. Mm.          THOC6    HCFC1R1            divergent 
          Hs. Mm.          RBM13    C8orf41  (BC019943)          convergent 
          Hs. Mm.          DTX3L    PARP9        divergent 
          Hs. Mm.          KRI1    ATG4D        convergent 
          Hs. Mm.          ANGPTL6   FLJ11286  (A230050P20Rik)      convergent 
          Hs. Mm.          FAM151A (BC026682)  ACOT11        containment 
          Hs. Mm.          CNTD1    BECN1        convergent 
          Hs. Mm.          TMEM85    SLC12A6        convergent 
          Hs. Mm.          CCDC111    MLF1IP        convergent 
          Hs. Mm.          LRRC39    CCDC76        convergent 
          Hs. Mm.          C16orf58    SLC5A2        convergent 
          Hs. Mm.          PIGF    RHOQ        convergent 
          Hs. Mm.          RAF1    MKRN2        convergent 
          Hs. Mm.          NOL3    LOC653319  (4931428F04Rik)      convergent 
          Hs. Mm.          WDR6    DALRD3        convergent 
          Hs. Mm.          POLR2B    IGFBP7        convergent 
          Hs. Mm.          GBA2    CREB3        convergent 
          Hs. Mm.          CTSA    NEURL2        divergent 
          Hs. Mm.          FANCI    POLG        convergent 
          Hs. Mm.          ABI1    PDSS1        convergent 
          Hs. Mm.          PPP1CA    RAD9A        convergent 
          Hs. Mm.          LRIG1    SLC25A26       convergent 
          Hs. Mm.          TSR1    SRR        convergent 
          Hs. Mm.          FCHSD1    RELL2        convergent 
          Hs. Mm. Bt.    RAD9A     PPP1CA        convergent 
          Hs. Mm.          C14orf45  (2900006K08Rik)  ALDH6A1       convergent 







 The dataset of ≥80% SABR complementation in all three genomes having 
thousands of SATs composed of relatively few unique sequences shows the one-to-many 
relationship of sense to antisense transcripts. However, the detection of so many SATs at 
this threshold may show that the reduction in complementation over time may be due to 
the SABRs of these SATs having no conserved function. The relatively similar 
coordinates of the SABR in each transcript involved in multiple SAT relationships points 
to a similar mechanism of origin. One of these events is the process of TEs integrating 
into the exons on the coding strand of some genes and the template strand of the exons of 
other genes creating a one-to-many relationship of sense to antisense transcripts. There 
are more SABRs localized in the 3' UTR of the transcripts for all three organisms. This 
suggests the ability of the 3' UTR to extend by addition of TE sequence while still 
maintaining transcript coding functionality. The CDS has fewer SABRs since transposon 
insertions in the CDS often disrupt coding sequence, which leads to non-functioning 
proteins. The 5' UTR has more SABRs localized than the CDS but not as many as the 3' 
UTR. Perhaps this is because the 5' UTR is generally much shorter than the 3' UTR and 
the possibility of 5' UTR regulatory region disruption. 
 If there were a conserved regulatory relationship between trans SATs, the 
sequence conservation in the SABR would most likely have been higher and many trans 
SATs would have been identified in the dataset of ≥95% SABR complementation. While 
the relatively few trans SATs in the ≥95% SABR complementation group may have a 
biological function in individual species, the search for homologous trans SATs across 




identified across species. 
 
TEs 
 Using the two datasets with ≥80 and ≥95% SABR complementation thresholds 
allowed a better assessment of the evolutionary fate of SATs created through 
transposition or other duplication events. Transposable elements were found in various 
sequences of all three genomes. The fact that the majority of trans SATs were found in 
the ≥80% SABR complementation dataset, but not the ≥95%  dataset suggests that the 
majority of trans SATs do not have a biological function. For a transposable element 
involved in SAT SABRs to create or become part of a regulatory process, the 
transposition events in each gene would have had to occurred at a relatively close 
temporal interval. Conservation in the SABRs of a few trans SATs may be due to either 
the necessity to form a RNA duplex as part of a critical biological function or due to 
recently created SATs that have not had enough time to diverge. The high numbers of 
trans SATs that have TE sequence in the SABRs (Table 2) and the biased localization of 
the SABR to the 3' UTR (Appendix A) demonstrate the influence TEs have on the origin 
of the majority of the SATs in the ≥80% SABR complementation dataset and also 
suggest that TEs may contribute to the observation that 3' UTRs are on average longer 
than 5' UTRs. 
 
RNA Editing: An Overlooked Gene Regulation Mechanisms of SATs? 
SATs have been demonstrated as having gene regulatory properties both for trans 
(Smith et al. 1988) and cis (Prescott and Proudfoot 2002; Crampton et al. 2006) 




that produce a RNA duplex in the coding region of a transcript are targets for RNA 
editing. SAT duplexes of the 4f-rnp and a transcriptional read-through of sas-10 genes in 
Drosophila melanogaster were suggested in providing the dsRNA region for RNA 
editing enzymes that edit A-I which lead to the observed down-regulation of 4f-rnp by 
sas-10 (Peters et al. 2003).  
 This research project demonstrated that transposable elements have played a role 
in the origin of SATs. The average SABR length exceeded 100 bp which can lead to an 
increased occurrence of A-I editing events called hyper-editing which occurs more 
frequently in duplexes longer than 100 bp (DeCerbo and Carmichael 2005). Hyper-
editing can edit up to 50% of adenosines to inosines (Nishikura et al. 1991) as was found 
in a sense-antisense region of two RNA transcripts of Xenopus oocytes (Kimelman and 
Kirschner 1989).  
Another result of A-I editing is the removal of premature stop codons as was 
demonstrated in vitro (Woolf et al. 1995). If premature stop codons are not removed 
through A-I editing, the transcripts are prime candidates for degradation by the NMD 
regulatory mechanism since the splice junction complexes remain on the transcript after 
the pioneering round of translation.  
The creation of stop codons is not possible through an A-I editing process since 
the only way to edit a codon to a stop codon is to begin with a stop codon. However, 
premature stop codons could be created after a less common C-U editing process by 
altering codons such as the codon for glutamine (CAA) but this process was found to be 
dependent on specific genes and is not as widespread as A-I editing. An example of C-U 
editing is apolipoprotein B (apoB) in which a glutamine (CAA) is changed to a stop 




apoB (Bostrom et al. 1989). Additional editing events of T-C were observed in cDNA 
clones; however, the A-I and T-C conversions were not observed in the same clone.  
 
Component Analysis of trans-SATs 
The cis SATs are expected to be conserved since they overlap at the same locus. 
There is little difference between the numbers of conserved cis SATs in the ≥95% SABR 
complementation group compared to the ≥80% SABR complementation group. The few 
cis SATs in the ≥80% SABR complementation group but not in the ≥95% group may be 
due to sequencing errors or polymorphisms.  
The fact that 13/15 of the TEs found in the 3' UTR of the conserved human trans 
SATs were the younger AluY group indicates that these were the result of recent 
transposition events (<20 million years) that have not had time to diverge below the 
≥95% SABR complementation threshold. There were no significant alignments between 
trans SATs and two older Alu families (AluSp and AluJo) indicating that AluSp and 
AluJo proliferation in the human genome did not have a significant impact on conserved 







IN SILICO FUNCTIONAL ANALYSIS OF SENSE-ANTISENSE TRANSCRIPTS 
 
Overview 
 The general function of sense-antisense transcripts (SATs) is still under 
investigation. A functional Gene Ontology (GO) analysis of the gene products of SATs 
may provide insights into the general function of SATs or the effects of sense-antisense 
binding regions (SABRs) on protein folding properties. The goals of this project were to 
perform a computational functional analysis of groups of SATs in human, mouse and 
cow and to use confirmed structural sequences to determine whether the SABRs of SATs 
created by transposable elements disrupt the ability of a protein to properly fold. RNA 
editing in SABRs was also investigated to determine if these double stranded RNA 
complexes have a significant effect on protein folding capacities. The GO analysis 
showed enrichments for the functional category of „DNA repair‟ and the component 
category „cytoplasm‟. A GO Slim analysis showed enrichments for „catalytic activity‟ 
which is the parent ontology of „DNA repair‟. A GO analysis can give insights to 
possible enrichments of molecular functions, biological processes or cellular components 
for a specific set of genes; however, the results can often be broadly interpreted even if 
there are no highly significant enrichments. 
 
Introduction 
 GO analysis is an in silico approach to investigating functional significance of 
groups of genes, and will be more informative as total genome annotations improve. 




over-represented groups for a number of GO attributes such as transferase activity, 
protein binding, and protein modification (Wang et al. 2006). GO Slim terms are terms 
that are mapped to upper level terms of specific lower level Gene Ontology categories 
using maps such as the one provided by the European Bioinformatics Institute (EBI; see 
Appendix E). A GO Slim functional analysis of five fungal species, Saccharomyces 
cerevisiae, Ashbya gossypii, Saccharomyces pombe, Neurospora crassa and Neurospora 
cuniculi SATs using the GO Slim terms provided by the Saccharomyces Genome 
Database found the common GO Slim term „nucleobase, nucleoside, nucleotide and 
nucleic acid metabolism‟ in S. cerevisiae, S. pombe and N. crassa (Steigele and Nieselt 
2005). Additionally they found that a high number of SAT transcripts have nuclear 
localization in four of the five fungal species studied. 
 
Objectives 
A goal of this project was to investigate functional categories of protein products 
encoded by the sense strand of SATs using the GO. Tests were performed to identify 
significant enrichments of specific GO terms within SATs and between SAT and non-
SAT sequences. Another goal was to investigate the effect SABRs and TEs on the 
production of folded proteins. The protein-coding portions of SAT sequences were 
compared to nucleotide sequences of proteins with known structures to determine 
whether the SABRs of SATs potentially affect the folding properties of proteins as a 
result of processes that change the nucleotide sequence such as TE insertions and RNA 
editing. If the SABR or TE portion of the protein is found in a homolog in a protein 





Materials and Methods 
Gene Ontology Analysis 
The Gene Ontology is organized into three principle ontologies: molecular 
function (F), biological process (P) and cellular component (C). The molecular function 
ontology describes activities occurring at the molecular level such as catalytic and 
binding (The Gene Ontology Consortium 2000). The biological process describes the 
contribution of the gene product to a biological objective, and the cellular component 
describes where a gene product is found in the cell (The Gene Ontology Consortium 
2000). A gene product may be annotated with one or more terms from one or more of the 
three principle ontologies.   
 GO terms available from Ensembl Biomart (http://www.biomart.org/ 
biomart/martview/) were used in conjunction with GeneMerge to identify 
overrepresented GO Slim terms among the ≥95% SABR complementation group of 
SATs. A BioPerl Perl module was used to retrieve protein sequences for the list of 
RefSeq nucleotide accessions from the RefSeq repository. Since the Ensembl GO terms 
are more current than RefSeq, the RefSeq protein sequences were aligned using FASTA 
to the Ensembl protein. GO terms were assigned to each RefSeq sequence that aligned 
with 100% identity to an Ensembl protein sequences annotated with at least one GO term. 
After the GO terms were assigned to the RefSeq sequences, the July 24, 2007 version of 
the GO Slim map file (Appendix E) provided by EBI was used to map each full GO term 
to its corresponding GO Slim term. This step is necessary because the full GO terms do 
not report all upper level GO terms for each accession and some over-represented upper-
level GO term may be identified using this approach. Some full GO terms had multiple 




 Perl scripts were used to divide GO Slim terms into the appropriate GO category 
(F, P or C) using the August 8, 2007 version of the Gene Ontology (Appendix F) and to 
remove redundancy of GO Slim terms for individual sequences. Each accession could 
have multiple GO Slim terms for each category as well as terms from any combination of 
the three categories. The final GO Slim enrichment analysis was done using GeneMerge 
on each of the three GO category files which was more sensitive than performing the 
analysis on all three ontology groups together. The RefSeq sequences that had no 
alignments to the Ensembl dataset or aligned but had no GO term assigned were not used 
in this analysis. 
 In order to determine which SABRs had TE sequence, the full set of RefSeq 
sequences and the specific SABR sequences were aligned to a repetitive element database 
provided by RepBase using the CENSOR repeat screening software. 
 The Gene Ontology in conjunction with GeneMerge was used to identify any 
overrepresented GO terms within the ≥95% SABR complementation dataset in various 
analyses using the RefSeq sequences for each organism as a population and various study 
datasets as explained in Table 11. 
 
Table 11. Population and study datasets for the Full GO and GO Slim analyses of the ≥95% 
SABR complementation dataset. 
 
       Population   Study Dataset    Results     
               Full GO                                                                        
        All RefSeq sequences  a) All SATs    Table 14 
b) All RefSeq aligning to TE  Table 15 
 
               GO Slim                                                                             
        All RefSeq sequences   a) All SATs       Table 16 
b) All SATs with TE in SABR   Table 17 
c) All SATs without TE in SABR   Table 18 
d) All RefSeq aligning to TE   Table 19 





 The population used in all tests was all the NM prefixed RefSeq mRNAs that 
aligned to GO defined Ensembl transcripts. Study samples were always a subset of the 
population. Tests were performed to determine whether each study set has a different 
distribution of GO terms compared to the population set. The first analysis compared all 
SATs to RefSeq sequences to determine if SATs in general were enriched for specific 
Full GO terms. Another Full GO analysis was to investigate if RefSeq sequences 
containing TEs were enriched for specific GO terms compared to all RefSeq sequences. 
 GO Slim tests were done to increase the level of statistical power. The first GO 
slim test compared all SATs to all RefSeq sequences. The second GO Slim analysis 
compared just SATs with TEs in the SABRs to all SATs which would demonstrate that 
any enrichment in this group could be contributed to SABRs formed by TEs. A third GO 
Slim study compared SATs without TEs in the SABR to all SATs. The final GO Slim 
analysis compared RefSeq sequences that aligned to TEs to all RefSeq sequences in order 
to understand if TEs were found in genes with particular functions. 
GeneMerge uses the hypergeometric distribution to identify any overrepresented 
GO terms in the population and incorporates Bonferroni correction for testing more than 
one hypothesis with a single dataset. For n independent hypotheses, the significance level 
that should be used is 1/n times as compared to a single hypothesis test. The Bonferroni 
values of less than 0.5 were recorded since the Bonferroni adjustment may not maintain 
statistical power for small populations (Leon 2004). 
 
 
Effects of SABRs on the Production of a Folded Protein 
 
 Often sequences that align to TEs are assumed non functional and dismissed from 
gene predictions and subsequently gene annotations and functional analysis (Curwen et 




produce functional proteins, all the structurally defined proteins sequences that also have 
a defined function were downloaded from the PDB website on November 28, 2007. The 
PDB structure sequence dataset contains both protein sequences of proteins with solved 
structures as well as nucleotide sequences of ribosomal and other RNAs. Only the 
103,538 confirmed protein structure sequences from the PDB dataset were used, although 
the sequences were somewhat redundant. The PDB sequences were compared to the 
RefSeq nucleotide dataset using BLASTX with an e-value of 1e-100. The alignments 
were reviewed best significant hits were used since the e-value cutoff was stringent and 
the PDB sequence consistently was annotated with the same function as the RefSeq 
accession even though some of the alignments were as low as 70% identity. The 
functional descriptions for the RefSeq accessions and PDB accessions for all significant 
alignments were manually reviewed to confirm the match. A Perl script was used to 
evaluate sequence alignment coordinates to determine if any portion of the PDB structure 
aligned to any part of the RefSeq sequence that either formed the SABR or aligned to a 
transposable element using coordinates from the SAT FASTA alignment search and the 
CENSOR TE alignment. A SABR or TE region aligning to a PDB protein structure 
sequence will provide support that the SABR or TE did not adversely affect the protein 
structure or function at least for that particular gene transcript. However, this analysis 
method cannot provide support that a SABR or TE sequence has adversely affected the 
functionality of a folded protein. 
 The population dataset for these tests were all RefSeq sequences aligning to a 
PDB confirmed protein structure sequence and the study datasets were 1) the SATs from 
the population that have a SABR overlapping a CDS that aligns to a PDB structure 







Gene Ontology Analysis Results 
 An initial GO term enrichment analysis was conducted using GeneMerge on the 
full GO terms as provided by the Ensembl BioMart project. There were 9,285 and 10,288 
human and mouse sequences respectively that contained GO terms. Both human and 
mouse analyses indicated enrichments for „DNA repair‟ in the full GO term analyses. 
Additionally in the full GO analyses, the human study set was enriched for „nuclease 
activity‟ and mouse study set was enriched for „response to DNA damage stimulus‟ and 
„citrate metabolic process‟ (Table 12). Three of the 11 study fraction sequences with the 
„DNA repair‟ GO identifier in human and the 14 study fraction sequences in mouse are 
homologs of the two species. A GO analysis conducted by previous researchers for cis 
SATs in human also found the GO term „DNA repair‟ enriched in the sample dataset 
(Lehner et al. 2002). GO analysis results of SATs such as the significant e-score for 
„citrate metabolic process‟ found in mouse could be misrepresented since an estimated 
>20% of all human transcripts have the potential to form SATs and all three genes that 




Table 12.  Full GO term enrichment analysis for human and mouse SATs with ≥95% SABR 
complementation. 
                                                                                                                                                                  
      Population    Study   Bonferroni  
  Species  GO identifier    fraction         fraction    e-score          GO term                                          
   human  GO:0004518         11/9285      5/261           0             nuclease activity 
   human  GO:0006281         91/9285    11/261           0.03        DNA repair          
 
   mouse   GO:0006974     103/10288    14/333          0              response to DNA damage stimulus 
   mouse   GO:0006281     115/10288    14/333          0.01         DNA repair 




 The Full GO term enrichment for all RefSeq sequences aligning to some portion 
of a transposable element sequence revealed various GO enrichments (Table 13). The 
gene products of these transcripts were localized in the nucleus which also increased the 
significance level of „intracellular‟ of which „nucleus‟ is a lower level component. Also 
there was an overrepresented set of gene products that functioned in „metal ion binding‟ 
and its lower level molecular function „zinc ion binding‟. There was also a significant 
enrichment for gene products involved in transcription and its lower level process 
„regulation of transcription, DNA-dependent‟.  
 
 
Table 13.  Full GO term enrichment analysis for human and mouse RefSeq sequences 
containing transposable element sequence in any part of the RefSeq sequence. 
                                                                                                                                                              
           Population    Study           Bonferroni  
      Species  GO identifier     fraction         fraction        e-score               GO term                        
 
       human  GO:0003676        235/7165        125/2895   0.078           nucleic acid binding 
       human  GO:0005634      1712/7165        785/2895   1.852e-04    nucleus 
       human  GO:0008270        937/7165        476/2895   6.819e-09    zinc ion binding 
       human  GO:0005622        793/7165        404/2895   2.618e-07    intracellular 
       human  GO:0046872        907/7165        444/2895   3.120e-05    metal ion binding 
       human  GO:0006350        581/7165        291/2895   0.001           transcription 
 
       mouse  GO:0003676        367/6750        157/2263   0.160           nucleic acid binding 
       mouse  GO:0006355        620/6750        267/2263          2.314e-04    regulation of transcription,  
                  DNA-dependent 
       mouse  GO:0008270        635/6750        287/2263         1.617e-07     zinc ion binding 
       mouse  GO:0005634      1221/6750        494/2263         2.187e-05     nucleus 
       mouse  GO:0005622        567/6750        237/2263         0.019            intracellular 






 From the original 23,663, 19,724 and 9,538 RefSeq sequences in the human, 
mouse and cow datasets respectively, there were 7,165, 6,735 and 1,757 sequences 




Slim terms assigned in the GO Slim map file (Appendix E). These were used as the 
overall population for the analysis from which the sample datasets were derived after 
dividing into the three GO categories. Although there are fewer Bos taurus sequences 
with GO terms as compared to the more annotated human and mouse genomes, the 
significant enrichment categories in Bos taurus were similar to mouse and human.  
 
GO Slim: All SAT Sequences: F: Molecular Function 
 
 The most significant enriched molecular function (F) GO Slim terms shared by 
human and mouse SATs were „catalytic activity‟ and „hydrolase activity‟ (Table 14). 
Cow did not have sufficient data to complete a GeneMerge analysis for the molecular 
function and cellular component GO categories. Hydrolase is defined as “the catalysis of 
the hydrolysis of various bonds” (http://geneontology.org). Although reverse 
transcriptase which is encoded by an open reading frame in autonomous LINEs is 
considered a catalytic process, it is unlikely that the catalytic activity enrichment is a 
result of transposons since the majority of TEs in SAT SABRs are SINEs which lack 
coding potential for transposition enzymes. 
 
P: Biological Process 
 The most significant biological process was identified as „metabolic process‟. 
Other significant biological processes such as „macromolecule molecular process‟ and 
„nucleobase, nucleoside, nucleotide and nucleic acid metabolic process‟ are lower level 
terms of „metabolic process‟. „DNA repair‟ which was a significantly enriched category 
found in the full GO term analysis is one of the lower level components of the „metabolic 




transformation but also macromolecular processes such as DNA repair and replication as 
well as protein synthesis and degradation ultimately resulting in cell growth. However, 
metabolic process does not involve protein-protein interaction or protein-nucleic acids 
interactions (http://www.geneontology.org). 
 
C: Cellular Component 
 The GO Slim analysis showed enrichment of SATs for localization in the 
„cytoplasm‟ and „intracellular‟ (Table 14). The GO Slim term „intracellular‟ is an upper 
level cellular component term of „cytoplasm‟ and „nucleus‟ GO terms so enrichment in 
either of these two should show enrichment for „intracellular‟. Other researchers have 
identified SATs as being nuclear localized using Northern hybridization (Kiyosawa et al. 
2005). This could be possible when describing the localization of the mRNA transcripts 
since the majority of transcripts remain in the nucleus where they are eventually broken 
down into their components. However, the GO Slim terms „intracellular‟ and „cytoplasm‟ 
describe the functional location of the gene products not the transcripts. These 
„intracellular‟ gene products are located in the cytoplasm as opposed to other locations 
such as „membrane‟ or „cell surface‟.  
 
 GO Slim: All SATs with TE in SABR and all SATs without TE in SABR 
 There were no specific GO Slim term differences between the group of SATs that 
had TE sequence in the SABR (Table 15) and the group of SATs that did not have TE 
sequence in the SABR (Table 16). Both are beginning to reflect enrichments for the GO 
Slim terms that are enriched for the dataset containing all SATs but neither dataset 




Table 14.  GO Slim analysis for all SAT sequences. Three species (Sp.), human (Hs), mouse (Mm) 
and cow (Bt), are divided into the three principle Gene Ontology categories using the population 
dataset of all RefSeq sequences and study set of all unique sequences involved in a SAT pair with 
≥95% SABR complementation. 
                                                                                                                                                                   
    Population Study       Bonferroni  
 Sp.         GO  identifier  fraction            fraction      e-score           GO term                                       
   F: molecular function 
 Hs GO:0003824      2273/6356         77/175            0.318     catalytic activity 
 Hs GO:0005215        498/6356         22/175             0.407     transporter activity 
 Hs GO:0016787        959/6356         37/175             0.422     hydrolase activity 
 Mm GO:0003824 2043/6018         99/194      1.098e-05   catalytic activity 
 Mm GO:0016787        866/6018         46/194             0.007  hydrolase activity  
 Mm GO:0005488 3854/6018       143/194             0.053 binding 
 Mm GO:0016740        698/6018         34/194             0.194 transferase activity 
 
   P: biological process 
 Hs GO:0006810      1014/5817         41/161             0.113   transport 
 Mm GO:0008152 2734/5397       112/166           0.001  metabolic process 
 Mm GO:0043170      2145/5397         90/166           0.002 macromolecule metabolic process 
 Mm GO:0009058   474/5397         26/166           0.046  biosynthetic process 
 Mm GO:0006810        938/5397         42/166            0.109 transport 
 Mm GO:0006139      1099/5397         46/166           0.248 nucleobase, nucleoside, nucleotide  
        and nucleic acid metabolic process 
 Bt GO:0008152        765/1231          10/11              0.405   metabolic process 
 
   C: cellular component 
 Hs GO:0005737      1767/5750         63/167              0.301    cytoplasm 
 Mm GO:0005622      2873/5539       132/178      5.099e-09  intracellular 







Table 15. GO Slim analysis for sequences with SABR containing TE sequence. Three species 
(Sp.), human (Hs), mouse (Mm) and cow (Bt), are divided into the three principle Gene Ontology 
categories using the population dataset of all RefSeq sequences and study set of all unique sequences 
involved in a SAT pair with ≥95% SABR complementation and aligning to a TE sequence. 
                                                                                                                                                                   
    Population Study       Bonferroni  
 Sp.         GO identifier   fraction            fraction      e-score           GO term                                       
   F: molecular function 
 none 
   P: biological process 
 Hs none 
 Mm GO:0008152      2734/5397        30/41         0.0353 metabolic process 
 Bt none 
 
   C: cellular component 
 Hs none 
 Mm GO:0005622      2873/5539        38/50         0.0031 intracellular 
 Mm GO:0005737      1474/5539        25/50         0.0026 cytoplasm 




Table 16. GO Slim analysis for sequences with no TE sequence in the SABR. Three species (Sp.), 
human (Hs), mouse (Mm) and cow (Bt), are divided into the three principle Gene Ontology categories 
using the population dataset of all RefSeq sequences and study set of all unique sequences involved in 
a SAT pair with ≥95% SABR complementation and not aligning to a transposable element sequence. 
                                                                                                                                                                   
    Population Study       Bonferroni  
 Sp.         GO identifier   fraction            fraction      e-score           GO term                                       
   F: molecular function 
 Hs GO:0016787        959/6356         33/145         0.1976 hydrolase activity 
 Hs GO:0003824      2273/6356         67/145         0.1304 catalytic activity 
 Mm GO:0016787        866/6018         37/149         0.0103 hydrolase activity 
 Mm GO:0003824      2043/6018         79/149  2.2776e-05   catalytic activity 
 Mm GO:0005488      3854/6018       111/149         0.0890 binding 
 Bt none 
 
   P: biological process 
 Hs none 
 Mm GO:0009058        474/5397         20/126         0.1205 biosynthetic process 
 Mm GO:0008152      2734/5397         83/126         0.0066 metabolic process 
 Mm GO:0043170      2145/5397         66/126         0.0468 macromolecule metabolic process 
 Bt none 
 
   C: cellular component 
 Hs GO:0005737      1767/5750         55/138         0.1324 cytoplasm 
 Mm GO:0005622      2873/5539         95/130  4.2190e-06 intracellular 





GO Slim: All RefSeq Sequences Aligning to a TE Sequence 
 
 The GO Slim analysis showed enrichment of human and mouse RefSeq 
transcripts that aligned to any transposable element sequence for localization in the 
nucleus and its upper level component „intracellular‟ (Table 17). The GO Slim and full 
GO term mouse analyses found significant enrichments for „nucleic acid binding‟ in 
addition to „catalytic activity‟. The principle category „biological process' showed 
enrichment for the GO Slim terms „metabolic process‟ which is an upper level process of 
„transcription‟ and „regulation of transcription, DNA-dependent‟ terms which were found 
significant in the full GO term analysis for all RefSeq sequences aligning to a TE 
sequence. Additional GO Slim enrichments in this dataset included „nucleobase, 




metabolic process‟ both of which are lower level processes of „metabolic process‟ which 
was also found as significant in the GO Slim analysis. The GO Slim term „regulation of 
biological process‟ also had a high level of significance in mouse and a significant but 
higher e-score in human and was the only significant GO Slim term found in cow for this 
dataset (Table 17). A summary of all of these GO analyses is listed in Table 18. 
 
Table 17.  GO Slim analysis for all RefSeq sequences aligning to a TE sequence. Three species 
(Sp.), human (Hs), mouse (Mm) and cow (Bt), are divided into the three principle Gene Ontology 
categories using the population dataset of all RefSeq sequences and study set of all RefSeq sequences 
containing an alignment to a known transposable element sequence. 
                                                                                                                                                                   
    Population Study       Bonferroni  
 Sp.         GO identifier   fraction            fraction      e-score           GO term                                       
   F: molecular function 
 Hs GO:0030528        642/6356        284/2541           0.277 transcription regulator activity 
 Hs GO:0004386          76/6356  42/2541           0.115 helicase activity 
 Mm GO:0030528        465/6018        177/1988           0.238   transcription regulator activity 
 Mm GO:0004386          54/6018  27/1988           0.169   helicase activity 
 Mm GO:0016829          53/6018  26/1988           0.263   lyase activity 
 Mm GO:0016787        866/6018        322/1988           0.072   hydrolase activity 
 Mm GO:0003824      2043/6018        776/1988    8.244e-08   catalytic activity 
 Mm GO:0003676      1026/6018        425/1988    9.247e-09   nucleic acid binding 
 Mm GO:0016740        698/6018        268/1988           0.021 transferase activity 
 Bt none 
   P: biological process 
 Hs GO:0050789      1875/5817        806/2293           0.002   regulation of biological process 
 Hs GO:0006139      1509/5817        709/2293    4.732e-11   nucleobase, nucleoside, nucleotide  
        and nucleic acid metabolic process 
 Mm GO:0009058        474/5397         185/1741          0.014   biosynthetic process 
 Mm GO:0006810        938/5397         340/1741          0.051   transport 
 Mm GO:0007610        131/5397           56/1741          0.146   behavior 
 Mm GO:0008152      2734/5397       1067/1741   4.284e-26   metabolic process 
 Mm GO:0030154        561/5397         222/1741          0.001   cell differentiation 
 Mm GO:0050789      1381/5397         545/1741   6.526e-10   regulation of biological process 
 Mm GO:0006139      1099/5397         464/1741   9.152e-14   nucleobase, nucleoside, nucleotide 
        and nucleic acid metabolic process 
 Mm GO:0008219        223/5397           99/1741          0.002   cell death 
 Mm GO:0043170      2145/5397         842/1741   8.325e-18   macromolecule metabolic process 
 Bt GO:0050789        281/1231             98/346          0.055 regulation of biological process 
 
   C: cellular component 
 Hs GO:0005634      1786/5750         818/2295   7.063e-09   nucleus 
 Hs GO:0005622      3717/5750       1572/2295   3.704e-06   intracellular 
 Mm GO:0005634      1283/5539         523/1815   4.162e-11    nucleus 
 Mm GO:0005622      2873/5539       1105/1815   3.856e-20 intracellular 
 Mm GO:0005694          99/5539   49/1815           0.004 chromosome 
 Mm GO:0005737      1474/5539         545/1815           0.001 cytoplasm 




Table 18. Summary of significant GO enrichments for the ≥95% SABR complementation 
dataset analyses. All results for human (Hs) and mouse (Mm) species (Sp) are significant to p < 
0.001. 
             
GO analysis Study Set   Sp Results Table GO term     
Full GO All SATs   Hs Table 14 nuclease activity   
Full GO All SATs   Mm Table 14 response to DNA damage stimulus 
Full GO RefSeq w/ TE   Hs Table 15 nucleus     
Full GO RefSeq w/ TE   Hs Table 15 zinc ion binding     
Full GO RefSeq w/ TE   Hs Table 15 intracellular     
Full GO RefSeq w/ TE   Hs Table 15 metal ion binding    
Full GO RefSeq w/ TE   Hs Table 15 transcription     
Full GO RefSeq w/ TE   Mm Table 15 regulation of transcription, 
             DNA-dependent    
Full GO RefSeq w/ TE   Mm Table 15 zinc ion binding     
Full GO RefSeq w/ TE   Mm Table 15  nucleus      
Full GO RefSeq w/ TE   Mm Table 15 metal ion binding   
  
GO Slim All SATs   Mm Table 16 catalytic activity   
GO Slim All SATs   Mm Table 16 metabolic process 
GO Slim All SATs   Mm Table 16 intracellular  
GO Slim All SATs   Mm Table 16 cytoplasm   
 
GO Slim SABRs w/o TE   Mm Table 18 catalytic activity    
GO Slim SABRs w/o TE   Mm Table 18 intracellular     
 
GO Slim RefSeq w/ TE   Mm Table 19 catalytic activity    
GO Slim RefSeq w/ TE   Mm Table 19 nucleic acid binding   
GO Slim RefSeq w/ TE   Hs Table 19 nucleobase, nucleoside, nucleotide 
            and nucleic acid metabolic process 
GO Slim RefSeq w/ TE   Mm Table 19 metabolic process 
GO Slim RefSeq w/ TE   Mm Table 19 cell differentiation 
GO Slim RefSeq w/ TE   Mm Table 19 regulation of biological process 
GO Slim RefSeq w/ TE   Mm Table 19 nucleobase, nucleoside, nucleotide 
            and nucleic acid metabolic process 
GO Slim RefSeq w/ TE   Mm Table 19 macromolecule metabolic process 
GO Slim RefSeq w/ TE   Hs Table 19 nucleus 
GO Slim RefSeq w/ TE   Hs Table 19 intracellular 
GO Slim RefSeq w/ TE   Mm Table 19 nucleus 
GO Slim RefSeq w/ TE   Mm Table 19 intracellular 
GO Slim RefSeq w/ TE   Mm Table 19 cytoplasm 
             
w/ = with 





The Effects of SABRs on Protein Folding Properties 
 The alignment of PDB structures sequences can give an insight to the affect of 
SABRs and TEs on the functionality of gene products. As with the GO analysis, the 
analysis is only as accurate as the current state of annotations for the gene products of an 
organism. There were some alignments of the PDB structure sequences to the regions of 
transcripts that aligned to a transposable element sequence for all three organisms. 
Additionally, there were alignments of the PDB structure sequences to the SABRs for the 
≥80% SABR complementation dataset for each organism. There may be some level of 
the dsRNA regions of SABRs affecting the protein folding potential, however, the results 
show that there are some SABRs that align to PDB confirmed structure sequences for 
human and mouse (Table 19). Additionally, there were some alignments to the regions of 




Table 19. Population and study dataset numbers for the functional inhibition of SABRs study. 
Population includes all RefSeq sequences that align to a PDB structure sequence. Number of 
sequences in the ≥95% SABR complementation dataset that have a PDB structure sequence aligning 
to a SABR that overlaps a CDS (PDB in SABR) and number of sequences in the RefSeq dataset 
where a transposable element overlap a PDB structure sequence (TE in PDB). 
 
                                                                                                                                                    
              Population       PDB in SABR       TE in PDB          
    
  Human 3,268/23,663       4/37   79/9950 
    Mouse  2,406/19,724     21/21   47/7044 




 Using GO Slim terms to perform a GO analysis provides insight to possible 
enrichments for particular GO categories for selected study samples. However, a GO 




products. A GO analysis will become more useful and precise as future research provides 
additional genes that are annotated with GO terms. The human and mouse had more 
significant results than cow due to the higher number of annotations that include GO 
terms. The most significant e-values were found in mouse for most of the enriched GO 
Slim terms. Patterns of GO Slim term enrichment similar to human and mouse began to 
emerge in Bos taurus perhaps since the most studied and conserved sequences are prime 
candidates for gene annotation using comparative genomics.  
 The GO Slim analysis gives insights into general upper level GO categories 
enrichments while the full GO term analysis gave more specific processes. The full GO 
term analysis didn't find the enrichments for cellular component terms „nucleus‟ and 
„cytoplasm‟ which were found with the GO Slim analysis. However, the GO Slim did 
identify enrichments in upper level terms for „nuclease activity‟, „DNA repair‟, 
„Response to DNA damage stimulus‟ and „citrate metabolic process‟ which were 
identified by the full GO term analysis. The full GO term analysis of SATs found „DNA 
repair‟ and „citrate metabolic process‟ enrichments which are both lower level terms of 
the GO Slim enriched term „metabolic process‟. The full GO term analysis coupled with 
the GO Slim analysis better defines enrichments in the study sets.   
 There was no observable difference in the GO Slim analysis for all SATs 
containing a transposable element in the SABR and SATs that did not contain a 
transposable element in the SABR. There was also no significantly enriched category in 
either of these two subsamples when compared to the study sample of all RefSeq 
sequences involved in a SAT pair. Based on these findings, there is no support showing 
that SATs containing TE sequence have any specific specialized function when compared 




 Although other researchers found SAT gene transcripts to be nuclear localized, 
the results of this GO Slim study suggest that the gene products of SATs are mostly 
localized within the cytoplasm. RefSeq sequences containing transposable element 
sequence were enriched for the cellular component GO Slim terms „nucleus‟ and 
„intracellular‟.  
The alignments of the PDB structure sequences to SABRs and TEs demonstrated 
that there are some transcripts in which these two characteristics do not alter the 
properties of a folding protein. This analysis was challenging since many SABRs are 
located within UTRs which will not align to PDB structure sequences. Moreover, 
aligning PDB structure sequences to the entire transcript whose length can be thousands 
of nucleotides long is somewhat biased when attempting to align PDB structures to small 






DETECTING EVOLUTIONARY RATE VARIATION  
IN SENSE-ANTISENSE TRANSCRIPTS 
 
Overview 
 Substitution rates across orthologous genes can give insights to specific conserved 
regions of gene sequences. Lower substitution rates may be interpreted as increased 
conservation but other characteristics of these genomic regions should be added to the 
analysis. The goals of this project were to investigate the conservation level across the 3' 
UTRs of a set of sense-antisense transcripts (SATs) with sense-antisense binding regions 
(SABRs) residing primarily in the 3' UTR sequence and to possibly identify reasons for 
increased conservation levels in different areas of the 3' UTRs. The substitution rate was 
used as a measurement of conservation in the 3' UTRs of a set of 8,384 orthologous 
human and mouse genes. A subset of human and mouse cis-oriented SATs was compared 
to the conservation of the 3' UTRs of the 8,384 orthologous human and mouse genes to 
determine if there were significant differences in specific regions in the 3' UTRs of the 
subset of SAT genes. The data indicated that the SABRs of a set of SATs lie in a region 
of increased conservation when compared to the rest of the 3' UTR indicating that the 
SABRs may be conserved and serve a biological purpose. However, these SABRs lie in 
regions of low %GC which may account for increased conservation levels at the 3' end of 
the 3' UTRs in human and mouse genes involved in the cis-oriented SATs. 
 
Introduction 




in either coding or non-coding DNA sequences. Selective pressure can be estimated by 
comparing the number of substitutions or nucleotide mutations that have occurred in the 
sequences of orthologous genes between two or more species. A set of conserved human 
and mouse SATs was evaluated in this study to determine substitution rates across the 
orthologous transcripts. Differences in substitution rates across the 3' UTR can give 
insight to the possibilities of conserved functionality in conserved orthologous 3' UTR 
SABRs. The substitution rate for the 3' UTR preSABR (the region from the stop codon to 
the beginning of the SABR) was compared with the substitution rate of the SABR for 
each of a set of 13 SAT pairs to identify the substitution rates of these two regions of the 
UTR which may indicate possible function for a conserved SABR. The Wilcoxon test 
was used to test for significant differences between the substitution ratios between KA/KS, 
K3UPS/KS and K3USABR/KS.  
 
Objectives 
 The objective of this study was to search for significant differences in substitution 
rates of the 3' UTRs of human and mouse orthologous genes and identify possible factors 
contributing to sequence divergence in different regions of the UTRs. This study can 
provide a better understanding of sequence divergence in the 3' UTRs of human and 
mouse genes containing SABRs in their 3' UTRs. Conserved 3' UTR SABRs may 
indicate a conserved function of the SABR sequence; however, other factors contributing 
to sequence conservation such as %GC are explored. 
 
Materials and Methods 




human and mouse for the comparisons of the CDS and SABR, and further selected based 
on sufficient lengths of preSABR (>25 nucleotides) for the comparison of preSABRs (the 
3' UTR sequence located upstream of the SABR) to SABRs. Additionally, these SATs 
were selected because their overlapping regions are purely UTR sequence. The conserved 
SAT set was derived from the conserved genes calculated earlier using the best FASTA 
alignments finding genes with conserved SATs. The SATs were all cis-oriented with 
SABRs overlapping only in the 3' UTRs. This is a good representative set of SATs since 
a majority of the SABRs are in the 3' UTR convergently arranged genes. The coding 
sequence, preSABR and SABR sequences were parsed using a Perl script and the CDS 
and SABR coordinates. The human and mouse corresponding gene sequences were 
aligned using MUSCLE (Edgar, 2004). The MUSCLE alignment was then translated 
using EBI translation tool (http://www.expasy.ch/tools/dna.html) and then aligned using 
NCBI's blast2seq application (Tatusova and Madden, 1999) to verify that the MUSCLE 
alignment conserved the amino acid sequence for each gene. Once verified, the MUSCLE 
alignment was used as input for the SNAP web program (Korber, 2000) provided by the 
HIV database website (www.hiv.lanl.gov) which calculated the synonymous and 
nonsynonymous rates. The SNAP program uses the Nei-Gojobori codon based method 
incorporating the Jukes-Cantor correction for multiple substitutions at the same site for 
protein coding sequences. 
 The human and mouse orthologous SABRs were aligned using MUSCLE. The 
chi-square test was used to test for significant divergence from the null hypothesis that 
the substitution rate in the preSABR was equal to that of the SABR using the Kimura 
two-parameter model (Figure 4) for both regions. The values used were the number of 




alignment could be the addition of sequence in one organism or the deletion of that 
sequence region in the other showing lack of conservation for the gapped region. 
Therefore, gaps were removed from the alignment and not used in the computations. 
Poly-A tails were also removed since they may be present in the sequence submitted to 
public databases but not present in the genomic sequence and they can alter the 
calculations of substitution rates. 
 
K = - (½) ln{(1 – 2P – Q) sqrt(1 – 2Q)} 
 
Figure 4.  
Kimura two-parameter model equation. P = the number of transition sites divided by the total 
number of compared sites and Q = the number of transversion sites divided by the total number of 




The Wilcoxon test was used to test for significant differences between the 
substitution ratios KA/KS, K3UPS and K3USABR.  The Wilcoxon rank-sum test is used when 
the two populations tested are not normal and returns a p-value to test that the two 
population distributions are the same. Since different regions of a coding sequence can 
have different KA/KS ratios (Liang et al. 2006), the substitution rate of the 3' UTRs was 
further investigated by using a window of 100 bases sliding every 25 across the length of 
the 3' UTR. A local installed version of the sequence alignment tool MUSCLE (Edgar, 
2004) was used to make the alignments of the regions of interest. The Kimura two-
parameter model test was applied to each window and the results were graphed and 
analyzed.  
The 3' UTRs from 8,384 human and mouse orthologous genes were retrieved 
from the BioMart database (http://www.biomart.org/biomart/martview) in order to 




approach for determining orthologous sequences. Each 3' UTR of each orthologous gene 
were aligned using the MUSCLE application. A Perl script was used to remove gaps and 
poly-A tails from both sequences. Only sequences longer than 300 nucleotides were used. 
The aligned sequence was then divided into 10 equal sized windows of varying length 
depending on the length of the 3' UTR. This 10-window approach allowed comparisons 
of all the 3' UTRs for all the orthologous pairs. The Kimura two-parameter test was then 
used to calculate the substitution rate within each of the 10 windows for all the 
alignments and the results were graphed and analyzed. Additionally, the percent GC 
content for each window for the alignments were calculated. The Tukey-HSD test is used 
to test all pairwise comparisons among means. In this study, the Tukey-HSD test was 
performed to test for significant differences for each pair of means for the substitution 
rates for each of the 10 windows. The Tukey-HSD was also used to test for significant 
differences in the mean percent GC for each of the 10 windows across the 3' UTRs of 
human and mouse orthologous genes. 
 
Results 
CDS vs. UTR Substitution Rates 
 Deviations from neutral evolution among coding sequences can be estimated 
using the KA/KS ratio. The ratio of nonsynonymous to synonymous (KA/KS = 0.12) 
substitutions in the human and mouse orthologous gene set was similar to rates found in a 
study of 52 human genes with mouse orthologs (KA/KS = 0.16) (Li and Su, 2006). 
Neutral evolution can be estimated using similar logic when comparing coding sequence 
to non-coding sequence substitution rates. When the ratio   K3UPS / KS = 1 then neutral 




selective constraint can be inferred. Additionally, positive, or diversifying, selection is 
inferred when K3UPS / KS > 1. This logic has been used in previous sequence comparisons 
of coding and non-coding regions (Li and Su, 2006). The average ratio of K3UPS / KS for 
12 of the 13 SAT gene pairs (one was removed because the preSABR was < 10 nt) was 
0.811 indicating neutral evolution of the preSABR with the corresponding coding 
sequence. However, the ratio of K3USABR/Ks for the 13 SAT pairs was 0.448 indicating 
selective constraint. The null hypotheses of KA/KS = K3UPS/KS and KA/KS = K3USABR/KS 
were rejected, p < 0.001 and p < 0.001 respectively, using the two-tailed Wilcoxon test. 
In both cases, the substitution ratio for the CDS was lower than the UTR ratios. 
 
Substitution Rates: preSABR vs. SABR  
 The estimation of the average sequence substitution rates in the preSABR (K3UPS) 
for 12 of the 13 SAT pairs (one was dropped because the preSABR sequence was < 10 
nt) was 0.325 which was similar to the previous study of the substitution rate of the full 
3‟ UTR of 52 human/mouse genes (K3U = 0.318) (Li and Su, 2006). The average SABR 
length for the 13 SAT pairs was 253 and the average preSABR length was 600. The 
average substitution rate for the SABRs (K3USABR = .202) was lower than the preSABR 
UTR sequences (K3UPS = 0.325) indicating conservation of sequence in this region. A chi-
square test of the observed and expected rates in the preSABR vs. the SABR resulted in 
17 of the 26 tests with significant p-values (p < 0.05) allowing rejection of the null 
hypothesis of K3UPS = K3USABR. All significant preSABR substitution rates were higher 
than their corresponding SABR substitution rates (Table 20). The null hypothesis of 
K3UPS/KS = K3USABR/KS was rejected (p < 0.001) and the two-tailed Wilcoxon test 




their corresponding pre-SABRs (KU3PS).  
 
Table 20. Substitution rates for coding sequences (KS, KA and KA/KS), 3' UTR preSABR (K3UPS) 
and the SABR (K3US) sequences for 26 human and mouse genes forming cis SATs. Chi-square p-
values are shown for substitution rate comparisons between preSABR and SABR sequences. 
 
                                                                                                                                                                                            
  Human  Mouse  KS KA KA/KS  K3UPS K3US p-value   
  PHYHIPL Phyhipl  0.495 0.011 0.023  0.161 0.195 0.166 
  FAM13C1 1200015N20Rik 0.668 0.080 0.119  0.293 0.195 0.006 
 
  ABI1  Abi1  0.374 0.009 0.024  0.183 0.098 0.013  
  PDSS1  Pdss1  0.478 0.076 0.158  0.169 0.098 7.48e-11 
 
  DMTF1  Dmtf1  0.361 0.024 0.065  0.263 0.126 0.010 
  C7orf23  4930420K17Rik 0.265 0.011 0.041  0.330 0.126 0.002 
 
  EME1  Eme1  0.533 0.177 0.332  0.378 0.171 0.001 
  LRRC59  Lrrc59  0.510 0.021 0.041  0.263 0.171 0.033 
 
  GBA2  Gba2  0.479 0.065 0.136  0.259 0.347 0.307 
  CREB3  Creb3  0.658 0.191 0.290  0.414 0.347 0.551 
 
  PPP1CA  Ppp1ca  0.647 0.003 0.004  0.230 0.159 0.222 
  RAD9A  Rad9a  0.444 0.101 0.229  0.475 0.159 1.74e-08 
 
  SLC12A6 Slc12a6  0.061 0.133 2.171  0.311 0.135 0.001 
  TMEM85 Tmem85  0/350 0.002 0.007  0.401 0.135 3.13e-04 
 
  LRIG1  Lrig1  0.609 0.083 0.136  0.282 0.040 3.04e-07 
  SLC25A26 Slc25a26  0.645 0.062 0.097  0.399 0.040 2.91e-10 
 
  BECN1  Becn1  0.470 0.008 0.016  0.146 0.225 0.143 
  CNTD1  Cntd1  0.461 0.084 0.183  0.389 0.225 1.72e-04 
 
  YPEL1  Ypel1  0.687 0.004 0.005  0.351 0.438 0.736 
  PPIL2  Ppil2  0.763 0.049 0.064  0.510 0.438 0.996 
 
  CACNA1H Cacna1h  0.661 0.076 0.115  0.506 0.191 4.40e-05 
  TPSG1  Tpsg1  0.676 0.164 0.243  0.297 0.191 0.456 
 
  DHPS  Dhps  0.588 0.047 0.080   +++ 0.366  +++ 
  MORG1  1500041N16Rik 0.533 0.035 0.065  0.976 0.366 0.004 
 
  MGC4655 C76566  0.897 0.086 0.096  0.533 0.130 7.79e-11 
  C16orf70  D230025D16Rik 0.386 0.015 0.040  0.245 0.130 2.13e-04 
 
  AVERAGES:   0.532 0.006 0.012  0.325 0.202   
 




 A sliding window of 100 bases moved in 25 base intervals across the length of the 
3' UTR revealed that the substitution rate was higher in the initial portion of the 3' UTR 
and was lowest at the end for the RAD9A and Rad9a orthologous human and mouse 
genes (Figure 5) presenting evidence that K3UPS ≠ K3USABR for these genes. This indicates 
that in these transcripts, there is some conservation of sequence between human and 




Figure 5.  
Substitution rate change across the 3' UTR for the human gene RAD9A and homologous mouse 
gene Rad9A. A sliding window of 100 bases was moved across the 3' UTR every 25 bases and the 
Kimura two-parameter test was performed on each window. The SABR is shown as the region 




 The gene PPP1CA, which is the other member of the SAT pair with RAD9A and 
an antisense transcript to RAD9A, also demonstrated significantly lower substitution 








Figure 6.  
Substitution rate change across the 3' UTR for the human gene PPP1CA and the homologous 
mouse gene Ppp1ca. A sliding window of 100 bases was moved across the UTR every 25 bases and 
the Kimura two-parameter test was performed on each window. The SABR is shown as the region 





 Using the 10-window approach, the substitution rates for each 3' UTR showed a 
general trend of lower substitution rates indicating sequence conservation towards the 3' 
end of the 3' UTR where the SABRs are located (Figure 7). The 5' end of the 3' UTR 
which is represented by the first window comprising the first 10% of the 3' UTR was 







Figure 7.  
Substitution rate change across the 3' UTR for the 26 human and mouse genes comprising 13 
SAT pairs. The 3' UTR for the alignments of each orthologous human-mouse pair was divided into 
ten equal sized windows and the substitution rate was calculated for each window. Gaps and poly-A 




 Using the 10-window approach, the percent GC was calculated for each of the 10 
windows across the 3' UTRs for the 26 human genes (Figure 8). The first window which 
is the 5' end of the 3' UTR was significantly higher than the last window located at the 3' 
end of the 3' UTR (p < 0.001). Additionally, the percent GC was significantly higher in 
the first window than the last (p < 0.001). The same results were observed for the 26 








Figure 8.  
Percent GC content across the 3' UTRs for the 26 human genes comprising 13 SAT pairs. The 3' 
UTR for each human gene was divided into ten equal sized windows and the percent GC was 
calculated for each window. The same windows were used as the K3UTR alignments in which gaps 
and poly-A tails were removed from the alignments prior to calculating percent GC content. 
 
 
Figure 9.  
Percent GC content across the 3' UTRs for the 26 mouse genes comprising 13 SAT pairs. The 3' 
UTR of each mouse gene was divided into ten equal sized windows and the percent GC was 
calculated for each window. The same windows were used as the K3UTR alignments in which gaps 




The substitution rate and percent GC was calculated for 8,384 3' UTRs of 
orthologous human and mouse genes. Each 3' UTR was divided into the windows to 
facilitate comparisons of UTRs of varying lengths. The average length of the 3' UTR 
after removing gaps and poly-A tails was 1,041 nucleotides. The distribution of lengths, 
rounded down to the nearest hundred, for these alignments is shown in Figure 10. 
Decreasing substitution rates were found from the 5' to the 3' regions of the 3' UTRs for 
the set of 8,384 orthologous human and mouse genes (Figure 11). The last window 
(win10) which comprised the last 10% of sequence for each alignment had a significantly 
lower mean substitution than the first window (win1) which comprises the first 10% of 
the sequence alignments (p < 0.001). Win10 is the region of the 3' UTR where conserved 
poly-A signal(s) generally reside and may be a significant factor in the resulting lower 
substitution rate for win10. 
 
 
Figure 10.  
Distribution of alignment lengths for the 3' UTRs of 8,384 human and mouse orthologous genes. 






Figure 11.  
Substitution rate change (K3UTR) across the 3' UTR for 8,384 human and mouse orthologous 
genes. The 3' UTRs for the alignments of each orthologous human-mouse pair was divided into ten 
windows and the substitution rate was calculated for each window. Gaps and poly-A tails were 





 Additionally, the percent GC for human and mouse was calculated separately for 
each of the ten windows used in the substitution rate analysis. Both human and mouse 
had significantly higher means, p < 0.001 and p < 0.001 respectively, in the first window 





Figure 12.  
Percent GC content across the 3' UTRs for 8,384 human genes. The 3' UTR for each human gene 
was divided into ten equal sized windows and the percent GC was calculated for each window. The 
same windows as the K3UTR alignments were used in which gaps and poly-A tails were removed 





Figure 13.  
Percent GC content across the 3' UTRs for 8,384 mouse genes. The 3' UTR for each mouse gene 
was divided into ten equal sized windows and the percent GC was calculated for each window. The 
same windows as the K3UTR alignments were used in which gaps and poly-A tails were removed 






 The same ten-window algorithm was applied to the region 2,000 bases upstream 
of the 3' UTR. There were 13,035 alignments after removing gaps. The distribution of the 
substitution rates, rounded down to the nearest hundred, is shown in Figure 14.  
 
 
Figure 14.  
Distribution of alignment lengths for the 2,000 bases upstream of the 3' UTR of 13,035 human 
and mouse orthologous genes. The alignment lengths were each rounded down to the nearest 
hundred. 
 
The substitution rate (Ks) was lowest at window ten where the final exon of a 
gene would typically reside (Figure 15). Windows one through nine may have higher Ks 
values due to being located in intronic regions. The percent GC for each of the ten 
windows was also calculated on the same 13,035 alignment dataset. Window ten (win10) 
had a significantly higher (p < 0.001) GC content than the previous nine windows for 





Figure 15.  
Substitution rate (Ks) across the 2,000 bases upstream of the 3' UTR for 13,035 human and 
mouse orthologous genes. The region 2,000 bases upstream of the 3' UTR for the alignments of each 
orthologous human-mouse pair was divided into ten windows and the substitution rate was calculated 






Figure 16.  
Percent GC content across the region 2,000 bases upstream of the 3' UTR for 13,035 human 
genes. The region 2,000 bases upstream of the 3' UTR for each mouse gene was divided into ten equal 
sized windows and the percent GC was calculated for each window. Gaps and poly-A tails were 








Figure 17.  
Percent GC content across the region 2,000 bases upstream of the 3' UTR for 13,035 mouse 
genes. The region 2,000 bases upstream of the 3' UTR for each mouse gene was divided into ten equal 
sized windows and the percent GC was calculated for each window. Gaps and poly-A tails were 
removed from the alignments prior to calculating percent GC content. 
 
 
The 2,000 bases downstream of the 3' UTR were also analyzed using the ten-
window algorithm. There were 13,024 alignments after gaps were removed. The 
distribution of the alignment lengths, rounded down to the nearest hundred, of this dataset 
is given in Figure 18. The substitution rates are lowest near the end of the 3' UTR (win1) 
and increase slightly and then plateau traveling farther downstream from the 3' UTR 
(Figure 19). This suggests that the intragenic region closest to the 3' UTR of a gene 







Figure 18.  
Distribution of alignment lengths for the 2,000 bases downstream of the 3' UTR of 13,024 






Figure 19.  
Substitution rate (Ks) across the 2,000 bases downstream of the 3' UTR for 13,024 human and 
mouse orthologous genes. The region 2,000 bases downstream of the 3' UTR for the alignments of 
each orthologous human-mouse pair was divided into ten windows and the substitution rate was 
calculated for each window. Gaps and poly-A tails were removed from the alignments prior to 






The percent GC for each of the ten windows was also calculated on the same 
13,024 alignment dataset downstream of the 3' UTR. Window one (win1) had a 
significantly lower GC content than the previous nine windows for both human (Figure 
20) and mouse (Figure 21) datasets. This is the window closest to the 3' end of the 3' 





Figure 20.  
Percent GC content across the region 2,000 bases downstream of the 3' UTR for 13,024 human 
genes. The region 2,000 bases downstream of the 3' UTR for each human gene was divided into ten 
equal sized windows and the percent GC was calculated for each window. Gaps and poly-A tails were 








Figure 21.  
Percent GC content across the region 2,000 bases downstream of the 3' UTR for 13,024 mouse 
genes. The region 2,000 bases downstream of the 3' UTR for each human gene was divided into ten 
equal sized windows and the percent GC was calculated for each window. Gaps and poly-A tails were 








The chi-square test results indicated that K3UPS ≠ K3USABR in 17 of the 26 tests 
performed suggesting that some SABRs may be under selective constraint while others 
are not. However, there may be other conserved motifs across the preSABR that lead to 
the insignificant differences between the two UTR regions. The two cis-oriented SAT 
genes CREB3 and GBA2 have an overlapping region of 122 nucleotides. There are two 
poly-A signals at each end of the SABR on opposite strands that conserve the SABR 
boundaries, one is the conserved antisense hexamer of AAUAAA at the beginning of the 
SABR and the other contains the hexamer AAUAAA within a 16 nucleotide sequence 
AAGAAAUAAAUAAGUG at the end of the SABR. The 16 nucleotide sequence may be 




poly-A tail is essential for translation initiation. A repressor protein recognizing and 
binding to this site may prevent poly-A polymerase from binding the poly-A site 
hindering poly-A extension and translation; this would need to be tested using a wet lab 
approach. These two regions make up 67% of the 33 identical conserved nucleotide sites 
located in the alignment between the human and mouse SABRs.  
 The substitution rate (K3U) across the entire 3' UTR for the human gene, RAD9A, 
and mouse gene, Rad9a, was lower at the end of the 3' UTR which is the location of the 
SABR, indicating that the SABR may be under greater selective constraint than the rest 
of the UTR. This is supported with a significant chi-square test comparing the preSABR 
sequence substitution rate with the SABR substitution rate and the significant substitution 
ratio differences using the Wilcoxon test. However, the 3' UTR substitution rates for a 
dataset of 8,384 human and mouse orthologous gene pairs showed that there were 
significantly lower substitution rates and percent GC in the final window comprising the 
last 10% of the UTRs when compared to the other nine windows comprising the first 
90% of the UTRs. Therefore, the conservation in the SABRs may be due to the 
coincidental presence of one or more conserved poly-A signals in the region rather than 
the need for binding of complementary SATs. Previous studies finding a negative 
correlation between 3' UTR overall sequence conservation and percent GC in mammalian 
3' UTRs (Shabalina et al. 2003) may be a direct result of the poly-A conserved region at 





SUMMARY AND CONCLUSIONS 
 Sense-antisense transcripts have been shown to be abundant in many prokaryotic 
as well as eukaryotic organisms. The characterization of SATs in human, mouse and cow 
provide a detailed look into past transposable element activities leading to the formation 
of SATs and especially trans localized SATs. Each organism evaluated has its own 
unique set of transposable elements involved in the formation of SATs. The human 
genome has been shaped by the Alu repetitive sequence, which has played a significant 
role in the formation of trans SATs resulting from TE activity. The mouse trans SATs 
are mostly derived from B1_Mus transposable elements. Although the annotation of the 
Bos taurus genome is an ongoing effort, patterns similar to the human and mouse 
characterized SATs emerged in the SAT analysis such as various SABRs with a large 
percentage of the SABR sequence being composed of transposable element sequence. 
Additionally, this demonstrates the influence transposable element activity on the lengths 
of the 3' UTRs, 5' UTRs and coding regions. Overall there was a many-to-many 
relationship among SATs for all three organisms. 
 Although the proportion of all SABRs that contained TE sequence in the ≥95% 
SABR complementation dataset was not very high, the percent in the ≥80% SABR 
complementation group was significant. A significant proportion of trans SATs found in 
the ≥80% SABR complementation group originated from transposable elements or had 
transposable element cassettes in their sequence. A one-to-many relationship of sense to 
antisense transcripts in the ≥80% SABR group is expected due to the high level of 
activity of TEs in the evolution of mammalian genomes, and is a result of the insertion of 




of the exons of many other genes.  
 The goals of this project were structural, functional and evolutionary 
characterization of SATs in human, mouse and cow. While previous research has focused 
on the cis regulatory mechanisms of cis positioned SATs, there may be some regulation 
of gene expression by trans SATs, but this is expected to be limited to the trans SATs 
that have maintained a high percent conservation in the SABR shared with other SATs 
allowing binding of complementary transcripts in vivo. However, this group of trans 
SATs may just be the result of young currently active transposable elements such as the 
human AluY subfamily that may have resulted in a biological function or created a 
SABR that has not had enough time for sequence divergence. There were not any 
conserved trans SATs identified across species suggesting that a prominent trans 
regulatory process for SATs with ≥95% SABR complementation may not be conserved 
across species and if there are some trans regulation of SATs, it may be unique to each 
species. However, this could be a result of the parameters set for detecting conserved 
SATs across organisms such as a high percent complementation in the SABR. The cis 
SATs seem to have greater potential for transcript regulation via transcriptional 
mechanisms colliding and stalling as explained by other researchers since some 
conserved cis SATs were identified. While trans SATs still have the potential to serve as 
a regulatory element, as is evidenced by the commercial use of antisense 
polygalactouronase gene expression regulation in the FlavrSavr tomato, SAT gene 
regulation created by TEs would have to be verified using expression data on a case by 
case basis. 
 A GO and PDB structure analysis provided insight into the functional 




RefSeq sequences with transposable element sequences. The GO Slim analysis revealed 
significant enrichment for GO Slim terms in select sets of SATs and all RefSeq 
sequences containing a TE anywhere in the sequence. A full GO term analysis facilitates 
a better understanding of the functions and processes of these study sets, however, the 
full GO term analysis did not find enrichments such as localization of SATs gene 
products in the cytoplasm which was found using the GO Slim analysis. The enrichment 
for „DNA repair‟ found in human and mouse in this research is supported by other 
researchers finding the same enrichment from a full GO term analysis of SATs. An 
additional full GO term enrichment for „nuclease activity‟ was found in human SATs 
which describes genes that break the ester bond linkages within nucleic acids which may 
be a supporting process for „DNA repair‟. Additionally the full GO term „response to 
DNA damage stimulus‟ was also found enriched in all SATs which may also be a process 
occurring in conjunction with „DNA repair‟. 
 The GO Slim analysis of all transcripts involved in SAT pairs supported and 
enhanced the full GO term analysis. The enrichment of broader GO terms reflected the 
full GO term analysis results of enrichment for „DNA repair‟. The enrichment of the GO 
Slim term „metabolic process‟ is an upper level category of „DNA repair‟ and „citrate 
metabolic process‟. Additionally, the GO Slim analysis revealed enrichment of terms in 
the molecular function category such as „catalytic activity‟. The full GO term analysis of 
SATs identified enrichment for „catalytic activity‟ which is an upper level term for the 
GO Slim enrichment of SATs for „nuclease activity‟ which is defined as “catalysis of the 
hydrolysis of ester linkages within nucleic acids” (http://geneontology.org) which is a 
lower level process of „DNA repair‟. Although reverse transcriptase which is encoded by 




unlikely that this catalytic activity enrichment is a result of transposons since the majority 
of TEs in SAT SABRs are SINEs which lack the coding potential for transposition 
enzymes. The GO Slim analysis did however find enrichments of terms for SATs not 
identified by the full GO term analysis. In the cellular component GO category. The GO 
Slim term „cytoplasm‟ was identified as an enriched term for all SATs. Although 
previous researchers identified SATs as being nuclear localized, their analysis may have 
been based on a different percent complementarity criterion for SATs. Our GO Slim 
analysis finding SATs are localized in the cytoplasm does not agree with the enrichment 
„DNA repair‟ since this process would be limited to nuclear localized DNA. This may be 
a result of incomplete GO terms for the current annotations which will improve as 
annotators continue to update genomes. 
 The effects of SATs on the production of a folded protein using PDB structure 
sequences showed that there are few sequences aligning to PDB structure sequences that 
also align to TE sequences or are part of SABRs for that same sequence. Although this 
analysis cannot confirm or deny that TE sequence or SABRs inhibit the folding 
properties of the protein of any individual transcript, it does show that there are few 
transcript regions occupied by TE sequence or SABRs that do overlap to a defined PDB 
structure sequence. Whether SABRs affect the folding properties of a protein is difficult 
to infer since most of the SABRs are located in the UTRs where the PDB structure 
sequences will not be found. 
 Transposable elements have been demonstrated to disrupt splicing patterns and 
create premature stop codons as well as introducing introns into the 3' end of a transcript. 
Premature stop codons leave some downstream splice junction complexes after the 




as a target to breakdown the transcript into its components. SATs contribute to transcript 
regulation by providing the long mRNA duplex which is susceptible to hyper-editing of 
RNA by the ADAR enzymes. This long duplex region recruits the ADAR enzymes that 
have the potential to transform premature stop codons to tryptophan. More studies may 
reveal that the SABRs provide the dsRNA regions necessary to recruit the ADAR 
enzymes and edit premature stop codons into tryptophan in the SAT SABRs, however, 
there are not many opportunities for this since there are very few SAT pairs that have 
their SABRs in the coding sequence (CDS) region of the gene. Additionally, a read-
through translation of a transcript could result if the SABR overlaps the transcripts stop 
codon and RNA editing alters it to a tryptophan if SATs do indeed play a role in creating 
dsRNAs precursors leading to RNA editing. 
 The estimation of evolutionary conservation in the 3' UTRs of human and mouse 
orthologous genes found increased conservation in the SABR when compared to the rest 
of the 3' UTR, which may suggest a functional constraint on the SABR. Additionally, the 
substitution rate in the coding sequence was lower than the rate found in the UTR. The 
last 10% of the 3' UTRs of human and mouse orthologous genes also demonstrated 
decreased substitution rates along the 5' end of the 3' UTRs where the SABRs of a small 
dataset of SATs reside. However, the percent GC was lower at the 5' ends of the 3' UTRs 
suggesting that the low substitution rates may be due to the low percent GC content 
rather than the actual conservation of SABR functionality since percent GC was found to 
be negatively correlated with sequence conservation in mammalian 3' UTRs. 
 The regions 2,000 bases upstream and 2,000 bases downstream of the 3' UTR 
suggest that the regions closest to the 3' UTR are more conserved that the regions father 




closest to the 3' UTR where the final exon for a gene generally resides. This suggests that 
GC percentage is highest where substitution rate is lowest in coding regions. However, in 
the 3' UTR, the region with the lowest substitution rate was also the region of lowest GC 
percentage. This may be due to the 3' end of the 3' UTR contains one or more conserved 
regulatory poly-A signals or protein suppressor regions which make this particular 







Alfano, G., Vitiello, C., Caccioppoli, C., Caramico, T., Carola, A., Szego, M., McInnes, 
 R., Auricchio, A., and Banfi, S. 2005. Natural antisense transcripts associated  
 with genes involved in eye development. Hum. Mol. Genet. 14: 913-923. 
 
Almeida, L., Silva, I., Silva Jr., W., Castro, J., Riggs, P., Carareto, C., and Amaral, M.  
 2007. The contribution of transposable elements to Bos taurus gene structure.  
 Gene 390: 180-189. 
 
Athanasiadis, A., Rich, A., and Maas, S. 2004. Widespread A-to-I RNA editing of Alu- 
 containing mRNAs in the human transcriptome. PLoS Biology 2: e391. 
 
Basilio, C., Wahba, A.J., Lengyel, P., Speyer, J.F., and Ochoa, S. 1962. Synthetic  
 polynucleotides and the amino acid code. Proc. Natl. Acad. Sci. 48: 613-616. 
 
Bass, B. 2002. RNA editing by adenosine deaminases that act on RNA. Annu. Rev.  
 Biochem. 71: 817-846. 
 
Bejerano, G. Lowe, C.B., Ahituv, N., King, B., Siepel, A., Salama, S.R., Rubin, E.M.,  
Kent, J.K., and Haussler, D. 2006. A distal enhancer and an ultraconserved exon 
are derived from a novel retroposon. Nature 441: 87-90. 
 
Benne, R., Van den Burg, J., Brakenhoff, J., Sloof, P., Van Boom, J., and Tromp, M.  
 1986. Major transcript of the frameshifted coxII gene from trypanosome  
 mitochondria contains four nucleotides that are not encoded in the DNA. Cell 46: 
 819-826. 
 
Benson, D., Karsch-Mizrachi, I., Lipman, D., Ostell, J., and Wheeler, D. 2007. GenBank. 
 Nucleic Acids Res. 35: D21-D25. 
 
Blin-Wakkach, C., Lezon, F., Ghoul-Mazgar, S., Hotton, D., Montiero, S., Teilluaud, C., 
 Pibouin, L., Orestes-Cardoso, S., Papagerakis, P., Macdougall, M., Robert, B.,  
and Berdal, A. 2001. Endogenous Msx1 antisense transcript: In vivo and in vitro  
 evidences, structure, and potential involvement in skeleton development in  
 mammals. Proc. Natl. Acad. Sci. 98: 7336-7341. 
 
Bostrom, K., Lauer, S.J., Poksay, K.S., Garcia, Z., Taylor, J.M., and Innerarity, T.L.  
 1989. Apolipoprotein B48 RNA editing in chimeric apolipoprotein EB mRNA.  
 J. Biol. Chem. 264: 15701-15708. 
 
Britten, R. 1996. Cases of ancient mobile element DNA insertions that now affect gene  
 regulation. Mol. Phylogenet. Evol. 5: 13-17. 
 
Britten, R. 1997. Mobile elements inserted in the distant past have taken on important  





Britten, R. 2004. Coding sequences of functioning human genes derived entirely from 
 mobile element sequences. Proc. Natl. Acad. Sci. 101: 16825-16830. 
 
Brosius, J. 1999a. Genomes were forged by massive bombardments with retroelements 
 and retrosequences. Genetica 107: 209-238. 
 
Brosius, J. 1999b. RNAs from all categories generate retrosequences that may be exapted
 as novel genes or regulatory elements. Gene 238: 115-134. 
 
Burset, M., Seledtsov. I.A., and Solovyev, V.V. 2000. Analysis of canonical and non- 
 canonical splice sites in mammalian genomes. Nucleic Acids Res. 28: 364-4375. 
 
Camblong, J., Iglesias, N., Fickentscher, C., Dieppois, G., and Stutz, F. 2007. Antisense 
 RNA stabilization induces transcriptional gene silencing via histone deacetylation 
 in S. cerevisiae. Cell 131: 706-17. 
 
Cantrell, M.A., Filanoski, B.J., Ingermann, A.R., Olsson, K., DiLuglio, N., Lister, A., and 
 Wichman, H.A. 2001. An ancient retrovirus-like element contains hot spots for  
 SINE insertions. Genetics 158: 769-777. 
 
Castillo-Davis, C.I., and Hartl, D.L. 2003. GeneMerge – post-genomic analysis, data  
mining, and hypothesis testing. Bioinformatics 7: 891-892 
 
Chao, H., Spicer, A.P. 2005. Natural antisense mRNAs to hyaluronan synthase 2 inhibit 
 hyaluronan biosynthesis and cell proliferation. J. Biol. Chem. 280: 27513-27522. 
 
Chen, J., Sun, M., Kent, W., Huang, X., Xie, H., Wang, W., Zhou, G., Shi, R., and  
 Rowley, J. 2004. Over 20% of human transcripts might form sense-antisense  
 pairs. Nucleic Acids Res. 32: 4812-4820. 
 
Chen, J., Sun, M., Hurst, L., Carmichael, G., and Rowley, J. 2005. Genome-wide  
 analysis of coordinate expression and evolution of human cis-encoded sense- 
 antisense transcripts. Trends Genet. 21: 326-329. 
 
Cordaux, R., Udit, S., Batzer, M., and Feschotte, C. 2006. Birth of a chimeric primate  
 gene by capture of the transposase gene from a mobile element. Proc. Natl. Acad. 
 Sci. 103: 8101-8106. 
 
Crampton, N., Bonass, W., Kirkham, J., Rivetti, C., and Thomson, N. 2006. Collision  
 events between RNA polymerases in convergent transcription studied by atomic 
 force microscopy. Nucleic Acids Res. 34: 5416-5425. 
 
Curwen, V., Eyras, E., Andrews, T.D., Clarke, L., Mongin, E., Searle, S.M.J., and Clamp, 








Dai, L., Wang, X., Yao, X., Lu, Y., Ping, J., and He, J. 2007. Enhanced therapeutic  
 effects of combined chemotherapeutic drugs and midkine antisense   
 oligonucleotides for hepatocellular carcinoma. World J. Gastroenterology 13:  
 1989-1994. 
 
DeBarry, J., Ganki, E., McCarthy, E., and McDonald, J. 2006. The contribution of LTR 
 retrotransposon sequences to gene evolution in Mus musculus. Mol. Biol. Evol.  
 23: 479-481. 
 
DeCerbo, J., and Carmichael, G. 2005. Retention and repression: fates of hyperedited  
 RNAs in the nucleus. Curr. Opin. Cell Biol. 17: 302-308. 
 
Donner, H., Tönjes, R.R., Van der Auwera, B., Siegmund, T., Braun, J., Weets, I.,  
 Herwig, J., Kurth, R., Usadel, K.H., and Badenhoop, K. 1999. The presence or  
 absence of a retroviral long terminal repeat influences the genetic risk for type 1 
 diabetes conferred by human leukocyte antigen DQ haplotypes.  J. Clin.   
 Endocrinol. Metab. 84: 1404-1408. 
 
Edgar, R.C. 2004. MUSCLE: a multiple sequence alignment method with reduced time  
 and space complexity. BMC Bioinformatics 5: doi:10.1186/1471-2105-5-113. 
 
Faghihi, M., and Wahlestedt, C. 2006. RNA interference is not involved in natural  
antisense mediated regulation of gene expression in mammals. Genome Biol. 7:  
doi: 10.1186/gb-2006-7-5-r38. 
 
Frischmeyer, P.A., and Dietz, H.C. 1999. Nonsense-mediated mRNA decay in health in 
 disease. Hum. Mol. Genet. 8: 1893-1900. 
 
Fu, L., Ma, W., and Benchimol, S. 1999. A translation repressor element resides in the 3' 
 untranslated region of human p53 mRNA. Oncogene 18: 6419-6424. 
 
Galante, P., Vidal, D., de Souza, J., Camargo, A., and de Souza, S. 2007. Sense-antisense
 pairs in mammals: functional and evolutionary considerations. Genome Biol. 8:  
 doi:10.1186/gb-2007-8-3-r40. 
 
Gasior, S., Wakeman, T., Xu, B., and Deininger, P. 2006. The human LINE-1   
 retrotransposon creates DNA double-strand breaks. J. Mol. Biol. 357: 1383-1393. 
 
The Gene Ontology Consortium. 2000. Gene Ontology: tool for the unification of  
biology. Nature Gene. 25: 25-29. 
 
Gotea, V., and W. Makałowski, W. 2006. Do transposable elements really contribute to  
proteomes? Trends  Gene. 22: 260-267. 
 







Hartner, J., Schmittwolf, C., Kispert, A., Muller, M., Higuchi, M., and Seeburg, P. 2004. 
 Liver disintegration in the mouse embryo caused by deficiency in the RNA- 
 editing enzyme ADAR1. J. Biol. Chem. 279: 4894-4902. 
 
Häsler, J., and Strub, K. 2006. Alu elements as regulators of gene expression. Nucleic  
 Acids Res. 34: 5491-5497. 
 
Hedges, D., and Deininger, P. 2007. Inviting instability: transposable elements, double- 
 stranded breaks, and the maintenance of genome integrity. Mutation Res. 616: 46-
 59. 
 
Hedges, D.J., Callinan, P.A., Cordaux, R., Xing, J., Barnes, E., and Batzer, M.A. 2004.  
 Differential Alu mobilization and polymorphism among the human and   
 chimpanzee lineages. Genome Res. 14: 1068-1075. 
 
Henz, S.R., Cumbie, J.S., Kasschau, K.D., Lohmann, J.U., Carrington, J.C., Weigel, D., 
 and Schmid, M. 2007. Distinct expression patterns of natural antisense transcripts 
 in Arabidopsis. Plant Physiol. 144: 1247-1255. 
 
Higuchi, M., Maas, S., Single, F., Hartner, J., Rozov, A., Burnashev, N., Feldmeyer, D., 
 Sprengel, R., and Seeburg, P. 2000. Point mutation in an AMPA receptor gene  
 rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature 
 406: 78-81. 
 
Hillman, R.T., Green, R.E., and Brenner, S.E. 2004. An unappreciated role for RNA  
 surveillance. Genome Biol. 5: doi:10.1186/gb-2004-5-2-r8. 
 
Hu, J., Lutz, C., Wilusz, J., and Tian, B. 2005. Bioinformatic identification of candidate 
 cis-regulatory elements involved in human mRNA polyadenylation. RNA 11: 001-
 009. 
 
Hulo, N., Bairoch, A., Bulliard, V., Cerutti, L., De Castro, E., Langendijk-Genevaux, P., 
 Pagni, M., and Sigrist, C. 2006. The PROSITE database. Nucleic Acids Res. 34:  
 D227-D230. 
 
IHGSC, International Human Genome Sequencing Consortium. 2001. Initial sequencing 
 and analysis of the human genome. Nature 409: 860-921. 
 
Jackson, D., Pombo, A., and Iborra, F. 2000. The balance sheet for transcription: an  
 analysis of nuclear RNA metabolism in mammalian cells. The FASEB Journal 14: 
 242-254. 
 
Jen, C., Michalopoulos, I., Westhead, D., and Meyer, P. 2005. Natural antisense   
 transcripts with coding capacity in Arabidopsis may have a regulatory role that is 







Jordan, I., Rogozin, I., Glazko, G., and Koonin, E. 2003. Origin of a substantial fraction 
 of human regulatory sequences from transposable elements. Trends Genet. 19:  
68-72. 
 
Jukes, T.H., and Cantor, C.R. 1969. Evolution of protein molecules. Pp. 21-123 in H. N. 
 Munro, ed. Mammalian protein metabolism. Academic Press, New York. 
 
Jurka, J. Krnjajic, M., Kapitonov, V.V., Stenger, J.E., and Kokhanyy, O. 2002. Active  
Alu elements are passed primarily through paternal germlines. Theoretical Pop.  
Biol. 61: 519-530. 
 
Jurka, J., Kapitonov, V.V., Pavlicek, A., Klonowski, P., Kohany, O., and Walichiewicz,  
J. 2005. Repbase Update, a database of eukaryotic repetitive elements. Cytogenet. 
 Genome Res. 110: 462-467. 
 
Kazazian, H. 2004. Mobile elements: Drivers of genome evolution. Science 303: 1626- 
 1632. 
 
Kim, D., Kim, T., Walsh, T., Kobayashi, Y., Matise, T., Buyske, S., and Gabriel, A.  
 2004. Widespread RNA editing of embedded Alu elements in the human   
 transcriptome. Genome Res. 14: 1719-1725. 
 
Kimelman, D., and Kirschner, M.W. 1989. An antisense mRNA directs the covalent  
 modification of the transcript encoding fibroblast growth factor in Xenopus  
 oocytes. Cell 59: 687-696.  
 
Kimura, M. 1980. A simple method for estimating evolutionary rates of base   
 substitutions through comparative studies of nucleotide sequences. J. Mol. Evol. 
 16: 111-120. 
 
Kiyosawa, H., Yamanaka, I., Osato, N., and Kondo, S. RIKEN GER Group,   
 GSL Members,   Hayashizaki, Y., 2003. Antisense transcripts with FANTOM2  
 clone set and their implications for gene regulation. Genome Res. 13: 1324-1334. 
 
Kiyosawa, H., Mise, N., Iwase, S., Hayashizaki, Y., and Abe, K. 2005. Disclosing hidden 
 transcripts: Mouse natural sense-antisense transcripts tend to be poly(A) negative 
 and nuclear localized. Genome Res. 15: 463-474. 
 
Knee, R., and Murphy, P. 1997. Regulation of gene expression by natural antisense  
 RNA transcripts. Neurochem. Int. 31: 379-392. 
 
Korber B. 2000. HIV Signature and sequence variation analysis. Computational  
 analysis of HIV molecular sequences, Pp. 55-72. in A. G. Rodrigo and   
G. H. Learn, eds. Kluwer Academic Publishers, Dordrecht, Netherlands. 
 
Kramer, C., Loros, J., Dunlap, J., and Crosthwaite, K. 2003. Role for antisense RNA in  





Kreigs, L., Churakov, G., Jurka, J., Brosius, L., and Schmitz, J. 2007. Evolutionary  
 history of 7SL RNA-derived SINEs in supraprimates. Trends Genet. 23: 158-161. 
 
Kumar, M., and Carmichael, G. 1998. Antisense RNA: Function and fate of duplex  
 RNA in cells of higher eukaryotes. Microbiol. and Mol. Biol. Rev. 62: 1415- 
 1434. 
 
Lehner, B., Williams, G., Campbell, D., and Sanderson, D. 2002. Antisense transcripts in 
 the human genome. Trends Genet. 18: 63-64. 
 
Leon, A. 2004. Multiplicity-adjusted sample size requirements: a strategy to maintain  
 statistical power with Bonferroni adjustments. J. Clin. Psychiatry 64: 1511-1514. 
 
Lev-Maor, G., Sorek, R., Levanon, E.Y., Paz, N., Eisenberg, E., and Ast, G. 2007. RNA-
 editing-mediated exon evolution. Genome Biol. 8: doi:10.1186/gb-2007-8-2-r29. 
 
Liang, H. Zhou, W. and Landweber, L.F. 2006. SWAKK: a web server for detecting  
 positive selection in proteins using a sliding window substitution rate analysis.  
 Nucleic Acids Res. 34: W381-W384; doi:10.1093/nar/gk1272. 
 
Li, Y., and Su, B. 2006. No accelerated evolution of 3' UTR region in human for brain- 
 expressed genes. Gene 383: 38-42. 
 
Li, Y., Qin, L., Guo, Z., Liu, L., Xu, H., Hao, P., Su, J., Shi, Y., He, W., and Li, Y. 2006. 
 In silico discovery of human natural antisense transcripts. BMC Bioinformatics 7: 
 10.1186/1471-2105-7-18. 
 
Lipman, D. 1997. Making (anti)sense of non-coding sequence conservation. Nucleic  
 Acids Res. 25: 3580-3583. 
 
Loning, F., Ma, W., and Benchimol, S. 1999. A translation repressor element resides in  
 the 3' untranslated region of human p53 mRNA. Oncogene 18: 6419-6424. 
 
Lorenc, A., and Makalowski, W. 2003. Transposable elements and vertebrate diversity.  
 Genetica 118: 183-191. 
 
Maglott, D., Ostell, J., Pruitt, K., and Tatusova, T. 2007. Entrez Gene: gene-centered  
 information at NCBI. Nucleic Acids Res. 35: D26-D31. 
 
Makalowski, W., Mitchell, G., and Labuda, D. 1994. Alu sequences in the coding regions 
 of mRNA: a source of protein variability. Trends Genet. 10: 188-193. 
 
Makalowski, W., Zhang, J., and Boguski, M.S. 1996. Comparative analysis of 1196  
 orthologous mouse and human full-length mRNA and protein sequences.  
 Genome Res. 6: 846-857. 
 





Medghalchi, S.M., Frischmeyer, P.A., Mendell, J.T., Kelly, A.G., Lawler, A.M., and  
 Dietz, H.C. 2001. Rent1, a trans-effector of nonsense-mediated mRNA decay, is 
 essential for mammalian embryonic viability. Hum. Mol. Genet. 10: 99-105. 
 
Mills, R.E., Bennett, E.A., Iskow, R.C., and Devine, S.E. 2007. Which transposable  
 elements are active in the human genome? Trends Genet. 23: 183-191. 
 
Nei, M. and Gojobori, T. 1986. Simple methods for estimating the numbers of   
 synonymous and nonsynonymous nucleotide substitutions. Mol. Biol. and Evol.  
 3: 418-426.  
 
Nekrutenko, A., and Li, W. 2001. Transposable elements are found in a large number of 
 human protein-coding genes. Trends Genet. 17: 619-621. 
 
Nikaido, M., Rooney, A.P., and Okada, N. 1999. Phylogenetic relationships among  
 cetartiodactyls based on insertions of short and long interspersed elements:  
 hippopotamuses are the closest extant relatives of whales. Proc. Natl. Acad. Sci.  
 18: 10261-10266. 
 
Nishikura, K., Yoo, C., Kim, U., Murray, J.M., Estes, P.A., Cash, F.E., and Liebhaber,  
 S.A. 1991. Substrate specificity of the dsRNA unwinding/modifying activity.  
 EMBO J. 10: 3523-3532. 
 
Ohhata, T., Hoki, Y., Sasaki, H., and Sado, T. 2008. Crucial role of antisense   
 transcription across the Xist promoter in Tsix-mediated Xist chromatin   
 modification.  Development 135: 227-235. 
 
Osato, N., Suzuki, Y., Ikeo, K., and Gojobori, T. 2007. Transcriptional interference in cis 
 natural antisense transcripts of human and mice. Genetics 176: 1299-1306. 
 
Pearson, W.R., and Lipman, D.J. 1988. Improved tools for biological sequence  
comparison. Proc. Natl. Acad. Sci. 85: 2444-2448. 
 
Peters, N.T., Rohrbach, J.A., Zalewski, B.A., Byrkett, C.M., and Vaughn, J.C. 2003.  
 RNA editing and regulation of Drosophila 4f-rnp expression by sas-10 antisense 
 readthrough mRNA transcripts. RNA 9: 698-710. 
 
Piriyapongsa, J., Polavarapu, N., Borodovsky, M., and McDonald, J. 2007. Exonization  
of the LTR transposable elements in the human genome. BMC Bioinformatics 8: 
doi:10.1186/1471-2164-8-291. 
 
Prescott, E., and Proudfoot, N. 2002. Transcriptional collision between convergent genes 
 in budding yeast. Proc. Natl. Acad. Sci. 99: 8796-8801.  
 
Pruitt, K., Tatusova, T., and Maglott, D. 2005. NCBI Reference Sequence (RefSeq): a  
 curated non-redundant sequence database of genomes, transcripts and proteins.  





Reuter, S.M., Dawson, T.R., and Emerson, R.B. 1999. Regulation of alternative splicing 
 by RNA editing. Nature 399: 75-80. 
 
RIKEN Genome Exploration Research Group and Genome Science Group (Genome  
 Network Project Core Group) and the FANTOM Consortium. 2005. Antisense  
 transcription in the mammalian transcriptome. Science 309: 1564-1556. 
 
Rouzic, A., Boutin, T., and Capy, P. 2007. Long-term evolution of transposable elements 
 Proc. Natl. Acad. Sci. 104: 19375-19380. 
 
Sela, N., Mersch, B., Gal-Mark, N., Lev-Maor, G., Hotz-Wagenblatt, A., and Ast, G.  
 2007. Comparative analysis of transposed element insertion within human and  
 mouse genomes reveals Alu's unique role in shaping the human transcriptome.  
 Genome Biol. 8: doi:10.1186/gb-2007-8-6-r127. 
 
Sen, L., Han, K., Wang, J., Lee, J., Wang, H., Callinan, P., Dyer, M., Cordaux, R., Liang, 
 P., and Batzer, M. 2006. Human genomic deletions mediated by recombination  
 between Alu elements. Am. J. Hum. Genet. 79: 41-53. 
 
Shabalina, S. A., Ogurtsov, A.Y., Lipman, D.J., and Kondrashov, A.S. 2003. Patterns in  
interspecies similarity correlate with nucleotide composition in mammalian  
3' UTRs. Nucleic Acids Res. 31: 5433-5439. 
 
Shendure, J., and Church, G. 2002. Computational discovery of sense-antisense   
 transcription in the human and mouse genomes. Genome Biol. 3: 0044.1-0044.14. 
 
Simons, R.W. 1988. Naturally occurring antisense RNA control – a brief review. Gene  
 72: 35-44. 
 
Sleutels, F., Zwart, R., and Barlow, D. 2002. The non-coding Air RNA is required for  
 silencing autosomal imprinted genes. Nature 415: 810-813. 
 
Smit, A. 1996. The origin of interspersed repeats in the human genome. Curr. Opin.  
 Genet. Dev. 6: 743-748. 
 
Smit. A.F., Tóth, G., Riggs, A.D., and Jurka, J. 1995. Ancestral, mammalian-wide  
 subfamilies of LINE-1 repetitive elements. J. Mol. Biol. 246: 401-417. 
 
Smith, C., Watson, C., Ray, J., Bird, C., Morris, P., Schuch, W., and Grierson, D. 1988. 
 Antisense RNA inhibition of polygalactouronase gene expression in transgenic  
 tomatoes. Nature 334: 724-726. 
 
Sorek, R., Ast, G., and Graur, G. 2002. Alu-containing exons are alternatively spliced.  
 Genome Res. 12: 1060-1067. 
 
Standart, N., Dale, M., Stewart, E., and Hunt, T. 1990. Maternal mRNA from clam  
 oocytes can be specifically unmasked in vitro by antisense RNA complementary 




Steigele, S., and Neiselt, K. 2005. Open reading frames provide a rich pool of potential  
 natural antisense transcripts in fungal genomes. Nucleic Acids Res. 33: 5034- 
 5044. 
 
Tang, W., Kinken, K., and Newton, R.J. 2005. Inducible antisense-mediated post- 
transcriptional gene silencing in transgenic pine cells using green fluorescence  
protein as a visual marker. Plant and Cell Physiology 46: 1255-1263. 
 
Tatusova, T.A., and Madden, T.L. 1999. Blast 2 sequences - a new tool for comparing  
 protein and nucleotide sequences. FEMS 174: 247-250. 
 
Terryn, N., and Rouze, P. 2000. The sense of naturally transcribed antisense RNAs in  
 plants. Trends Plant Sci. 5: 394-396. 
 
Thornburg, B., Gotea, V., and Makalowski, W. 2006. Transposable elements as a  
 significant source of transcription regulating signals. Gene 365: 104-110. 
 
Tufarelli, C., Stanley, J.A., Garrick, D., Sharpe, J.A., Ayyub, H., Wood, W.G., and Higgs 
 D.R. 2003. Transcription of antisense RNA leading to gene silencing and  
 methylation as a novel cause of human genetic disease. Nat. Genet. 34: 157-165. 
 
van de Lagemaat, L., Landry, J., Mager, D., and Medstrand, P. 2003. Transposable  
 elements in mammals promote regulatory variation and diversification of genes  
 with specialized functions. Trends Genet. 19: 530-536. 
 
Vanhee-Brossollet, C., and Vaquero, C. 1998. Do natural antisense transcripts make  
 sense in eukaryotes? Gene 211: doi:10.1016/S0378-1119(98)00093-6 . 
 
Vardy, L., and Orr-Weaver, T.L. 2007. Regulating translation of maternal messages:  
 multiple repression mechanisms. Trends Biol. 17: 547-554. 
 
Veeramachaneni, V., Makalowski, W., Galdzicki, M., Sood, R., and Makalowska, I.  
 2004. Mammalian Overlapping Genes: The Comparative Perspective. Genome  
 Res. 14: 280-286. 
 
Wacheck, V., and Zangemeister-Wittke, U. 2006. Antisense molecules for targeted  
 cancer therapy. Oncology Hematology 59: 65-73. 
 
Wagner, E.G., and Simons, R.W. 1994. Antisense RNA control in bacteria, phages, and 
 plasmids. Annu. Rev. Microbiol. 48: 713-742. 
 
Wallace, M.R., Anderson, L.B., Saulino, A.M., Gregory, P.E., Glover, T.W., and Collins, 
 F.S. 1991. A de novo Alu insertion results in neurofibromatosis type 1. Nature  
 353: 864-866. 
 
Wang, H., Chua, N., and Wang, X. 2006. Prediction of trans-antisense transcripts in  





Wang, X., Gaasterland, T., and Chua, N. 2005. Genome-wide prediction and   
 identification of cis-natural antisense transcripts in Arabidopsis thaliana. Genome 
 Biol. 6: doi:10.1186/gb-2005-6-4-r30. 
 
Wheeler, D., Church, C., Federhen, S., Lash, A., Madden, T., Pontius, J., Schuler, G.,  
 Schrimi, L., Sequeira, E., Tatusova, T., and Wagner, L. 2003. Database resources 
 of the National Center for Biotechnology. Nucleic Acids Res. 31: 28-33. 
 
Woolf, T.M., Chase, J.M., and Stinchcomb, D.T. 1995. Towards the therapeutic editing 
 of mutated RNA sequences. Proc. Natl. Acad. Sci. 92: 8298-8302. 
 
Wu, M., Li, L., and Sun, Z. 2007. Transposable element fragments in protein-coding  
 regions and their contribution to human functional proteins. Gene 401: 165-171. 
 
Xuezhong, C., Hagedorn, C.H., and Cullen B.R. 2004. Human microRNAs are processed 
 from capped, polyadenylated transcripts that can also function as mRNAs. RNA  
 10: 1957-1966. 
 
Yelin, R., Dahary, D., Sorek, R., Levanon, E., Goldstein, O., Shoshan, A., Diber, A.,  
 Biton, S., Tamir, Y., Khosravi, R., Nemzer, S., Pinner, E., Walach, S., Bernstein, 
 J., Savitsky, K., and Rotman, G. 2003. Widespread occurrence of antisense  
 transcription in the human genome. Nature 21: 379-386. 
 
Yin, Y., Zhao, Y., Wang, J., Liu, C., Chen, S., Chen, R., and Zhao, H. 2007. antiCODE: a 
 natural sense-antisense transcripts database. BMC Bioinformatics 8:   
 doi:10.1186/1471-2105-8-319. 
 
Zhang, Y., Liu, S., Liu, Q., and Wei, L. 2006. Genome-wide in silico identification and  
 analysis of cis natural antisense transcripts (cis-NATs) in ten species. Nucleic  








AVERAGE PERCENT COVERAGE OF HUMAN SABRS BY INCLUDING ALL  
 
ALTERNATIVE TRANSCRIPTS TRANSPOSABLE ELEMENTS (TEs)  
 
(≥80% SABR COMPLEMENTATION) 
 
                                                                                                                                                                   
            Average          Average % SABR     Average % TE Number of 
 TE               SABR length      coverage by TE         found in SABR  SABRs  cis  trans 
 ALU  (S)              273              97                          84                           369,230           1    369,230 
 CAM1_GG  (L)    388                        9                            5                                  3                1               2 
 CHARLIE1  (D)      384                        19                            3                                  1                0               1 
 CHARLIE1A  (D)     368                        14                            4                                  2                0               2 
 CHARLIE1B  (D)      353                        15                          10                                 1                0               1 
 CHARLIE26a  (D)     372                        14                          16                                 2                0               2 
 CHARLIE3  (D)         140                      100                           5                                  2                0               2 
 CHARLIE4  (D)         424                        18                            4                                  1                0               1 
 CHARLIE5  (D)        364                        11                            1                                  2                0               2 
 CHARLIE8A  (D)      371                          9                           10                                 2                0               2 
 CHESHIRE_A  (D)    228                        15                          12                                 2                0               2 
 CHESHIRE_B  (D)    374                        20                          22                                 1         0               1 
 ERV11_MD_I  (E)   1,246                       10                            1                                  1                1               0 
 ERV33_MD_I  (E)    580                        16                            1                                  1                1               0 
 ERV36_MD_LTR(E)1,003                       10                          15                                 1                0               1 
 GGERVK1  (E)      569                        15                            1                                  1                1               0 
 GGLTR8A_LTR  (E)  949                          7                             7                                  1                1               0 
 GOLEM_B  (D)   336                          8                             2                                  2                0               2 
 HARLEQUIN  (E)     592                          9                             1                                  1                0               1 
 HERV49I  (E)    358                        13                            1                                  2                0               2 
 HERV70_I  (E)         203                        92                            2                                61               1             61 
 HERVIP10FH  (E)     592                        29                           3                                  1                0               1 
 HERVK14CI  (E)      381                        18                            1                                  1                0               1 
 HERVL  (E)   656                      100                         12                                 1                0               1 
 L1  (L)        141                        90                           2                                10               0             10 
 L1-2a_MD  (L)          401                        11                            2                                  1                1               0 
 L1A_OC  (L)           1,136                           7                             1                                  1                1               0 
 L1HS  (L)            269                        98                          29                               12               0             12 
 L1M2_5  (L)        323                          9                             1                                  1                0               1 
 L1M3C_5  (L)          3,561                         2                             4                                  1                1               0 
 L1M4B  (L)           355                        11                            1                                  1                0               1 
 L1MA10  (L)      374                        17                            7                                  3                0               3 
 L1MA1  (L)          344                        12                            4                                  6                0               6 
 L1MA2  (L)         343                        13                            4                                  1                0               1 
 L1MA3  (L)         350                          9                             3                                  1                0               1 
 L1MA4A  (L)        370                        15                            5                                  2                0               2 
 L1MA5A  (L)       339                        10                            3                                  4                0               4 
 L1MA7  (L)              354                        12                            4                                  1                0               1 
 L1MB1  (L)              346                        10                            4                                  5                0               5 
 L1MB2  (L)              297                        17                            6                                  4                0               4 
 L1MB3  (L)              341                        15                            6                                  3                0               3 
 L1MB5  (L)              356                        10                            4                                  2                0               2 
 L1MB8  (L)              344                        10                            4                                  3                0               3 
 L1MC4  (L)              356                        11                            1                                  5                0               5 
 L1MD1  (L)             351                        10                            4                                  2                0               2 
 L1MD2  (L)              354                        14                            4                                  1                0               1 
 L1MDA_5  (L)          339                        12                            1                                15              0             15 
 L1MDB_5  (L)           366                        13                            3                                  1                0               1 
 L1ME4A  (L)             382                        16                            7                                  2                0               2 
 L1ME5  (L)              386                        13                            9                                  4                0               4 
 L1MEC_5  (L)           398                        15                            2                                  1                0               1 
 L1ME_ORF2  (L)      360                        13                            1                                19              0             19 
 L1PA10  (L)             228                        99                          25                               11               0             11 
 L1PA11  (L)             104                      100                         11                                 1                0               1 
 L1PA13  (L)             307                        30                           9                                11               0             11 
 L1PA15  (L)             409                        99                          44                                 3                0               3 




              Average          Average % SABR     Average % TE Number of 
 TE               SABR length      coverage by TE         found in SABR  SABRs  cis  trans 
 L1PA3  (L)              297                        94                          30                               10               0             10 
 L1PA4  (L)              237                        92                          24                               20               0             20 
 L1PA5  (L)              162                        93                          16                                 5                0               5 
 L1PA7  (L)              329                        96                          35                               17               0             17 
 L1PA7_5  (L)            788                      100                         46                                 1                0               1 
 L1PA8  (L)              345                          9                             3                                  3                0               3 
 L1PB1  (L)              159                        85                          15                                 1                0               1 
 L1PB2  (L)              348                          9                             3                                  1                0               1 
 L1PB4  (L)              330                        12                            5                                  9                0               9 
 L1P_MA2  (L)           389                        15                            1                                  3                0               2 
 L1PREC1  (L)            288                        99                            4                                  4                0               4 
 L1PREC2  (L)           272                        29                            1                                  8                0               8 
 L2A  (L)                531                        27                            2                                  5      2               3 
 L2B_ME  (L)             400                        14                          16                                 1                0               1 
 LTR12  (E)              207                        99                          31                                 1                0               1 
 LTR13  (E)              334                      100                         33                                 1                0               1 
 LTR14B  (E)             390                      100                         66                                 2                0               2 
 LTR14C  (E)             370                         9                             6                                  2                0               2 
 LTR17  (E)              326                      100                         42                                 1                0               1 
 LTR19B  (E)             583                        99                        100                                1                0               1 
 LTR2B  (E)              326                        14                            9                                35               0             35 
 LTR3  (E)               125                        98                          28                                 1                0               1 
 LTR35_MD  (E)        440                        20                          11                                1                1               0 
 LTR38C  (E)             242                        19                            7                                  2                0               2 
 LTR5  (E)               281                      100                        29                                 1                0               1 
 LTR66  (E)              367                        11                            7                                  6                0               6 
 LTR7B  (E)              271                       47                          17                               10               0             10 
 LTRIS_Mm_LTR (E) 106                        31                            7                                 1                1               0 
 MADE1  (D)            340                        10                          42                                 2                0               2 
 MER11B  (D)          1,090                       99                        100                                1                0               1 
 MER11D  (D)            632                      100                         73                                 1                0               1 
 MER1A  (D)              459                        62                          53                                 2                0               2 
 MER1B  (D)              186                        96                          53                                 1                0               1 
 MER2  (D)               355                        20                          18                               29               0             29 
 MER2B  (D)              357                        12                          12                               21               0             21 
 MER30  (D)              327                        66                          61                                 3                1               2 
 MER31I  (D)             330                        13                            1                                  2                0               2 
 MER3  (D)            357                        10                          16                                 7                0               7 
 MER34B  (D)           1,545                       23                          66                                 1                1               0 
 MER34B_I  (D)         390                       19                           1                                  2                0               2 
 MER41A  (D)            362                        15                          10                                 1                0               1 
 MER44B  (D)             373                        14                          10                                 2                0               2 
 MER44D  (D)            129                      100                         19                                 1                0               1 
 MER45R  (D)             162                        31                            3                                  1                1               0 
 MER51I  (D)             348                        13                            1                                  6                0               6 
 MER5A1  (D)      356                         2                           62                                 1                1               0 
 MER5B  (D)        367                        12                          24                                 2                0               2 
 MER63B  (D)          395                        22                          20                                 1                0               1 
 MER65I  (D)             360                        14                            1                                  2                0               2 
 MER66C   (D)           344                          8                             5                                  4                0               4 
 MER77  (D)              363                        10                           6                                  1      0               1 
 MER85  (D)              284                        76                          91                                 9                1               8 
 MER9  (D)               498                        95                          92                                 2                0               2 
 MER96B  (D)             324                        11                            9                                  3                0               3 
 MIR3  (S)            366                        17                          32                                 2                0               2 
 MIR  (S)              756                        21                          30                               10               3               7 
 MIRb  (S)             346                        12                          16                               11               1             10 
 MLT1A1  (E)           351                        11                            9                                  5                0               5 
 MLT1A  (E)              333                        14                          12                                 1                0               1 
 MLT1B  (E)              369                        15                          14                                 3                0               3 
 MLT1C1  (E)             383                        14                          12                                 1                0               1 
 MLT1C  (E)              348                        13                          10                                 1      0               1 
 MLT1E  (E)              210                        30                          10                                1                0               1 
 MLT1F  (E)              358                        18                          11                                 6                0               6 
 MLT1H1  (E)             935                          4                             8                                  1       0               1 
 MLT1H  (E)              348                        13                            8                                  1                0               1 
 MLT1K  (E)              352                        14                            8                                  1                0               1 
 MLT1L  (E)              354                        10                            6                                  1                0               1 
 MLT2B2  (E)             318                        11                            7                                  2                0               2 




             Average          Average % SABR     Average % TE Number of 
 TE               SABR length      coverage by TE         found in SABR  SABRs  cis  trans 
 MSTA  (E)             263                        48                          21                                 7                0               7 
 MSTB1  (E)            182                        96                          41                                 1                0               1 
 MSTC  (E)             380                        14                          12                                2                0               2 
 PABL_AI  (E)        279                        14                            1                                  3                0               3 
 PB1  (S)            336                        10                          25                                 1                0               1 
 RLTR11A2_LTR (E)164                        47                          14                                 1                1               0 
 RLTR24_MM  (E)   234                        16                            6                                  1                0               1 
 RNLTR17_I  (E)    238                        71                            2                                  1                1               0 
 SVA2  (S)           236                        92                          99                                 2                0               2 
 SVA  (S)            223                        76                           8                              118              0           118 
 THE1A  (E)          338                        76                          54                                 9               0               9 
 THE1B  (E)          183                      100                         51                                 3                0               3 
 THE1BR  (E)         453                        43                          16                                 6                0               6 
 THE1C  (E)          342                        12                          11                                 7                0               7 
 THE1D  (E)          293                        23                          13                                 5                0               5 
 TIGGER7  (D)          340                                14                                                   2                                10                       0              10 
 




DNA transposon (D) 






AVERAGE PERCENT COVERAGE OF MOUSE SABRS INCLUDING ALL  
 
ALTERNATIVE TRANSCRIPTS BY TRANSPOSABLE ELEMENTS (TEs)  
 
(≥80% SABR COMPLEMENTATION) 
 
                                                                                                                                                                   
            Average          Average % SABR     Average % TE Number of 
 TE               SABR length      coverage by TE         found in SABR  SABRs  cis  trans 
 B1  (S)                         137                      95                       92           179        1           178 
 B1F  (S)                        181                      84                       97             201       3           198 
 B1_Mm  (S)                        158                      88                        93                              4,822             0        4,822 
 B1_Mur1  (S)                      166                      94                        94                           44              1             43 
 B1_Mur2  (S)                      154                      93                        92                          96              1             95 
 B1_Mur3  (S)                      151                      91                        91                         187              0           187 
 B1_Mur4  (S)                      148                      94                       92                         711             1           710 
 B1_Mus1  (S)                      160                      89                        94                            11,806            0      11,806 
 B1_Mus2  (S)                      164                      88                        96                              8,029             1        8,028 
 B1_Rn  (S)                        154                      90                        92                              2,602             1        2,601 
 B2  (S)                           187                      94                        84                         173             0           173 
 B2_Mm1a  (S)                     190                      94                        91                         744              0           744 
 B2_Mm1t  (S)                      189                      94                        91                         411             1           410 
 B2_Mm2  (S)                       178                      95                        85                         857              0           857 
 B2_Rat1  (S)                      180                      95                        90                         287              0           287 
 B2_Rat2  (S)                      182                      94                        90                              1,599            0        1,599 
 B2_Rat3  (S)                      171                      95                        86                         233             0           233 
 B2_Rat4  (S)                      179                      95                        89                         701              1           700 
 B2_Rn2  (S)                       128                      94                        64                         123              0           123 
 B2_Rn  (S)                        221                      17                        22                             1               0               1 
 B3  (S)                           306                      75                        55                             6                2               4 
 B3A  (S)                          717                      35                        86                             2                2               0 
 BC1_Ma  (S)                      2,304                       2                         29                             1                1               0 
 BGLII_A_LTR  (E)             186                      21                          8                              1                0               1 
 CR1-G  (L)                         2,170                       2                           1                              1                1               0 
 ERV24_MD_I  (E)              222              23                          1                              1                1               0 
 ERV46_MD_I  (E)          1,401                 3                           1                              1                1               0 
 ERVB1_3-I_RN  (E)            246                      20                          1                              1                0               1 
 ERVB2_1-I_MM (E)        1,028             13                          1                              2                1               1 
 ERVB4_1-LTR_MM (E)     424             99                        80                             1                0               1 
 ERVB5_1-I_MM  (E)          183      17                         1                              1                0               1 
 GGERVK10  (E)               1,150            3                           1                              1                1               0 
 Harbinger-2_XT  (D)           249           14                          1                              1                1               0 
 HERVR  (E)                         323             37                          2                              1                0               1 
 HITCHCOCK2_LTR(E)      383              17                        10                             1                1               0 
 IAPEZI  (E)                    136       100                         2                              1                0               1 
 IAPLTR1a_MM  (E)            141           88                        35                             1                0               1 
 IAPLTR1_Mm_LTR(E)      284             96                        72                             5                0               5 
 IAPLTR2b_LTR  (E)           284              84                        72                             2                0               2 
 ID_Rn1  (S)                      938             6                         55                             1                1               0 
 L1MC4  (L)                     270             21                          2                              1                1               0 
 L1_MM  (L)                       246           96                          4                          163              0           163 
 L1PA14_5  (L)                    546           12                          3                              3               0               3 
 L1R2_RN  (L)                     104             91                        13                             1               0               1 
 L2-2_ME  (L)                     195             36                          3                              1                1               0 
 L2A  (L)                         105             80                          3                              1                1               0 
 LTR12E  (E)                    590              7                           4                              1                1               0 
 LTR16A1  (E)                   1,234           12                        34                             1                0               1 
 LTR6_MD  (E)                 1,150                 5                           7                              1                1               0 
 LTRIS3  (E)                    144                      99                        27                             2                0               2 
 LX  (L)                          198                      94                        18                           39               0             39 
 LX3  (L)                       173         98                        17                             1                0               1 
 MEN  (S)                         187            85                        54                         798              1           798 
 MER106B  (D)                    273            44                        12                             1                1               0 
 MER20  (D)                      1,864             5                         51                             1                1               0 
 MER21C  (E)                    687            8                           6                              1                1               0 




             Average          Average % SABR     Average % TE Number of 
TE               SABR length      coverage by TE         found in SABR  SABRs  cis  trans                
 MERVL_LTR  (D)            144        99                        29                             7                0               7 
 MLT2F  (E)                      1,485           5                         10                             1                1               0 
 MT2B  (E)                    202           58                        18                             6                0               6 
 MT2B2_LTR  (E)              130                      97                        24                             3                0               3 
 MT2C  (E)                       127                      92                        31                           19               0             19 
 MTA  (E)                        335                      98                        82                           29               0             29 
 MTAI  (E)                       106                    100                       10                             3                0               3 
 MTA_Mm_LTR  (E)          225                      98                        55                           51               0             51 
 MTB_Mm_LTR  (E)          170                      86                        35                             7                0               7 
 MTB_Rn_LTR  (E)           240                      98                        58                           45               0             45 
 MTC  (E)                        185                    100                       44                             1                0               1 
 MTEb_LTR  (E)               346                      25                        24                             1                1               0 
 ORR1A0  (E)                     122                    100                       35                             5                0               5 
 ORR1A2_LTR  (E)           183                      99                        55                           18               0             18 
 ORR1A3_LTR  (E)            140                      99                        42                             2                0               2 
 ORR1A4_LTR  (E)           144                      95                        41                             8                0               8 
 ORR1AI  (E)                     189                      93                          9                              1                0               1 
 ORR1A_Rn_LTR (E)         222                      98                       66                           17               0             17 
 ORR1B1  (E)                     128                    100                       33                             1                0               1 
 ORR1B2  (E)                       88                      98                        23                             1                0               1 
 ORR1BI  (E)                     186                      76                        10                         218              0           218 
 ORR1D1_LTR  (E)            976                      35                        94                             1                1               0 
 ORR1D  (E)                      201                      20                        10                             1                0               1 
 PB1D10   (S)                    521                      17                        44                             6                1               5 
 PB1D9  (S)                      599                      49                        88                             4                2               2 
 RLTR10C  (E)                  114                    100                       26                             1                0               1 
 RLTR10E  (E)                    101                      95                        30                             1                0               1 
 RLTR13D  (E)                   114                      96                        11                             1                0               1 
 RLTR13D3  (E)                119                    100                       11                             1                0               1 
 RLTR16  (E)                    2,304                        4                         18                             1                1               0 
 RLTR17_MM  (E)             218                      17                          4                              5               0               5 
 RLTR25_MM  (E)             180                      22                          5                              4                0               4 
 RLTR35_MM  (E)             196                      30                        12                             6                0               6 
 RLTR44C_LTR  (E)           523                      98                        95                             1                0               1 
 RLTR6I_MM  (E)               232                      21                          1                              1               0               1 
 RLTR9E  (E)                   304                    100                       73                             1                0               1 
 RLTRETN_MM  (E)          221                      99                        63                             1                0               1 
 RMER17D2_MM (E)         196                      21                          5                              1                0               1 
 RMER19  (E)                   226                      19                          6                              2                0               2 
 RMER19A_LTR  (E)          119            66                        10                             1                0               1 
 RNLTR7_I  (E)                198                      21                          1                              8                0               8 
 RSINE1  (S)                     919                      14                        85                             1                1               0 
 RSINE2  (S)                   181                      90                        45                         569              0           569 
 RSINE2A  (S)                  187                      88                        49                         208              1           208 
 SINEB1_MU  (S)              160                      81                        95                             8                0               8 
 Tigger2f  (D)                      323                      14                          1                              1                0               1 
 URR1  (D)           144                      96                        57                           36                            0            36 
 URR1B  (D)                        126                      98                                               55                                     5                            0              5 
 




DNA transposon (D) 






AVERAGE PERCENT COVERAGE OF COW SABRS BY INCLUDING ALL  
 
ALTERNATIVE TRANSCRIPTS TRANSPOSABLE ELEMENTS (TEs)  
 
(≥80% SABR COMPLEMENTATION) 
 
                                                                                                                                                                   
            Average          Average % SABR     Average % TE Number of 
 TE               SABR length      coverage by TE         found in SABR  SABRs  cis  trans 
 ARMER1 (Repeat)   140                        94                        42                           13              0             13 
 ART2A  (S)          268                        98                        48                           56               0             56 
 ART2B_BT  (S)         99                       100                       20                             1                0               1 
 BCS  (S)            118                        92                        36                           26               0             26 
 BDDF2 (L)           620                        33                          5                            37               0             37 
 BOV2  (S)           306                        95                        50                         460              0           460 
 BOVA2  (S)          161                        96                        56                              1,777             1        1,777 
 BOVB  (S)           370                        89                          9                            41              0             41 
 Bov-tA1  (S)        146                        98                        62                         270              0           270 
 BOVTA  (S)          146                        97                        67                              1,313             0        1,313 
 Bov-tA2  (S)       137                        97                        62                         589             0           589 
 Bov-tA3  (S)       151                        96                        68                         427              0           427 
 BTALUL1  (S)        179                        97                        54                           77               0             77 
 BTCS  (S)           304                        92                       93                         80               0             80 
 L1_BT  (L)          225                       90                        17                           23               0             23 
 L1_Felid  (L)           312                          9                           3                              1                0               1 
 L1MB7  (L)            344                        15                          6                              2                0               2 
 L1MC4  (L)            358                        16                          2                              1                0               1 
 L1MC5  (L)            359                        18                          3                              1                0               1 
 L1P_MA2  (L)         124                        99                         2                              1                0               1 
 LINE_CH  (L)          172                        64                          6                              2                0               2 
 MAR1b_MD  (S)     157                        92                        53                            2                0               2 
 MER2  (D)           165                        19                          9                              1                0               1 
 RNLTR17_I  (E)     242                        33                          1                              1                0               1 
 RNLTR21_I  (E)      445                        13                          1                              1                1               0 
 RTE1_LA (L)            326                               99                                         10                                     1                           0                1 
 





DNA transposon (D) 






EXCERPTS FROM THE GO SLIM MAP FILE FROM THE EBI WEBSITE 
! Mapping of GO terms to GO Slim Terms 24-JUL-2007 
! Slim Term Source: GOA Database @ EBI 
! Version: $ 
! Date: $Date: $ 
! Format: GO_id <tab> GO_slim_id 
GO:0000049      GO:0003676 
GO:0000182      GO:0003676 
GO:0000217      GO:0003676 
GO:0000339      GO:0003676 
GO:0000340      GO:0003676 
GO:0000341      GO:0003676 
GO:0000342      GO:0003676 
GO:0000400      GO:0003676 
GO:0000401      GO:0003676 
GO:0000402      GO:0003676 
GO:0000403      GO:0003676 
GO:0000404      GO:0003676 
GO:0000405      GO:0003676 
GO:0000406      GO:0003676 
GO:0000739      GO:0003676 
GO:0000900      GO:0003676 
GO:0003676      GO:0003676 
GO:0003677      GO:0003676 
GO:0003680      GO:0003676 
GO:0003681      GO:0003676 
GO:0003684      GO:0003676 
GO:0003688      GO:0003676 
GO:0000146      GO:0003774 
GO:0003774      GO:0003774 
GO:0003777      GO:0003774 
GO:0008569      GO:0003774 
GO:0008574      GO:0003774 
GO:0060001      GO:0003774 
GO:0060002      GO:0003774 
GO:0000009      GO:0003824 
GO:0000010      GO:0003824 
GO:0000014      GO:0003824 
GO:0000016      GO:0003824 
GO:0000026      GO:0003824 






EXCERPT FROM THE GO.terms_and_ids FILE  
 
PROVIDED BY THE GENE ONTOLOGY 
 
!version: $Revision: 1.521 $ 
!date: $Date: 2007/08/15 10:47:59 $ 
! 
! GO IDs (primary only) and text strings 
! GO:0000000 [tab] text string  [tab] F|P|C 
! where F = molecular function, P = biological process, C = cellular component 
! 
GO:0000001 mitochondrion inheritance       P 
GO:0000002 mitochondrial genome maintenance        P 
GO:0000003 reproduction    P 
GO:0000005  ribosomal chaperone activity    F 
GO:0000006 high affinity zinc uptake transmembrane transporter activity  F 
GO:0000007 low-affinity zinc ion transmembrane transporter activity   F 
GO:0000008 thioredoxin     F 
GO:0000009 alpha-1,6-mannosyltransferase activity  F 
GO:0000010 trans-hexaprenyltranstransferase activity       F 
GO:0000011 vacuole inheritance     P 
GO:0000012 single strand break repair      P 
GO:0000014 single-stranded DNA specific endodeoxyribonuclease activity     F 
GO:0000015 phosphopyruvate hydratase complex       C 
GO:0000016 lactase activity        F 
GO:0000017 alpha-glucoside transport       P 
GO:0000018 regulation of DNA recombination P 
GO:0000019 regulation of mitotic recombination     P 
GO:0000020 negative regulation of recombination within rDNA repeats   P 
GO:0000022 mitotic spindle elongation      P 
GO:0000023 maltose metabolic process       P 
GO:0000024 maltose biosynthetic process    P 
GO:0000025 maltose catabolic process       P 
GO:0000026 alpha-1,2-mannosyltransferase activity  F 
GO:0000027 ribosomal large subunit assembly and maintenance      P 
GO:0000028 ribosomal small subunit assembly and maintenance      P 
GO:0000030 mannosyltransferase activity    F 
GO:0000031 mannosylphosphate transferase activity  F 
GO:0000032 cell wall mannoprotein biosynthetic process     P 
GO:0000033 alpha-1,3-mannosyltransferase activity  F 
GO:0000034 adenine deaminase activity      F 
GO:0000035 acyl binding    F 
GO:0000036 acyl carrier activity   F 







SEQUENCE ALIGNMENTS OF SELECTED HUMAN AND MOUSE  
 

























MUSCLE (3.6) multiple sequence alignment 
 
 
ABI1      -TTTTTTTTTTTCTTTTGAAGTAGATTCTTATTACTCAGTCATACTGTGGGACTATTATG 
Abi1      TTTTTCTTTTTTCTTTTCATGTAGG---TTATTACTCCGTCATACTGTGGGATTA-TATG 
           **** *********** * ****    ********* ************** ** **** 
 
ABI1      GTTAACAGAACTGTCTTAATATGTTTTAAAATGTGCCCATATTTTC-AGAACATGCTGTT 
Abi1      GTTAACAGAATTGTTTTAATG---TTTAAAATGTGCCCATATTTTCAAGGACA---TGTT 
          ********** *** *****    ********************** ** ***   **** 
 
ABI1      TTATTGGTA-AATTGAATGTCTACCTGTAAGCATAAATCTTTGAGGCAGTTTATGTATTG 
Abi1      TTATTGGTATATTTGGATGTCTACCTGTAAGCATAAATTTTGGAGGCAGTTCAAACATTG 
          ********* * *** ********************** ** ********* *   **** 
 
ABI1      CTGAATAGCAATTTATACAAGAAGCTGTCCATAACTGATTATGCTTATGTACTTACTTAC 
Abi1      CTGAGCAGCAGTTTATA--------TGCCTATAATTGATTATGCATATG----TACTCAC 
          ****  **** ******        ** * **** ********* ****    **** ** 
 
ABI1      ACATTTTTAACTTTATGACCAGCCTAAATATTCTGGGGGAAGTGGGGTATAATATTTAAC 
Abi1      ACCTTGCTAAGTTTATGACCAGCCTAAAACTTCTGGGG---ATTGGGTATTATGTTTAAC 
          ** **  *** *****************  ********    * ****** ** ****** 
 
ABI1      GAATCATGATTCAGATTGTACCATTACATGTTTCAGTGCAGCATGGTTACTAACGCTATG 
Abi1      AAATCATGGTTCAGAATGCACCATTACATGTTTCAGTGCAGCATGGTCACTAACATTGTG 
           ******* ****** ** **************************** ******  * ** 
 
ABI1      TCAGACTAATATT-AAAATCAGAAAATTTAAATGCTGGTGCTGGTCAGACTTTTTTTGTT 
Abi1      TCAGACTAATAGGAAAAAACAGAAAACGTCAATGCTGGTGCTGGTCATACTTTTGGT-TT 





ABI1      AGATTCTCTCATTTAAAAAAAATACTGTTTGTTTAAAGCATGCATAAAAATTTATGTATT 
Abi1      CAATTCTCAT-TTTTAAAAAAATACTG--TGTTTAAAGCATGCATAAATTTTTATGTATT 
            ******   *** ************  *******************  ********** 
ABI1      GAAATATACTTAAAAATTCAAGATGCTTCCCATTTGTGTAATATTTACCTGGAGGACTCG 
Abi1      GAAATATACTTAACAATTCAAGATGCTTCCAATTTGTGTAACGATTATCTGGAGTACTCA 
          ************* **************** **********   *** ****** **** 
 
ABI1      TACTTAGGTGTCTTAACGTGAATTGAGTCTCC-AAGGTCTCCATGTGAAACAAGCAAAAA 
Abi1      TAC-------------------TTGAGTCTCCTAAGCTCTCCATGTGAAATGA------- 
          ***                   ********** *** *************  * 
 
ABI1      GAGAATTATCTGTAATGTTGTAATTTGTACCTAAGTTTTTTAATGAGTGAAATTTGCATT 
Abi1      -AAGACTATCTGTAATGTTGTAATTTGTATCTAAGTTTTTTAATGAGTGAAATTTGCATT 
           *  * *********************** ****************************** 
 
ABI1      ATAAACTTTTTCCATTCATAAATACATAAGTGAACCAAAGGTTTTTGTCCTTTCCTTCAC 
Abi1      ATAAA-TTTTTCCATTCATAAATACATAAGTGAACCAAAGGATTTTGGCCTCTCCTTTAC 
          ***** *********************************** ***** *** ***** ** 
 
ABI1      TGATTTGCTTTAAAAA-------------AAATAAAAG--------------------AT 
Abi1      TGGTTTGCTTTAATTATGTATGCTAGTGCATATGCATGCACACCCTCCCACCCCTTTAAG 
          ** **********  *             * **  * *                    * 
 
ABI1      AATGATTTATTGCAGAATTATGATTCTATTTTCTCAATATGTTAACTTGGAAAAAAATTT 
Abi1      AAAGATTTATTGCAGAATTATGGTTCTATTTTCTCAATGCATCAGTTTTGAAAATATTTT 
          ** ******************* ***************   * *  ** ***** * *** 
 
ABI1      TAGCCTTATCTTAATCTGTCCCAACAG-CAATGTGACGGATTTTTGCAGATTCAAAATCT 
Abi1      TAGCTTAATCTTAATGTGTCCAAACAGTCAATGTGACAGAATTTTGCAGA---------- 
          **** * ******** ***** ***** ********* ** ********* 
 
ABI1      GCAATGGTTATTTACAAGTCAATCTACTGAATTCCTTTTTTAAATAATCTTTTGAAACTA 
Abi1      -------------------------------------------------TTTTGGAGCT- 
                                                           ***** * ** 
 
ABI1      AGAAAATGTGTCAAATTGTGTGCATT-CATTCTGTAGGTAAAATTCTTA--AGGATTGCC 
Abi1      --AGACTGTGTCAGAGTAAGCACATGATATTCTGGGGGCAACATCTGAAGGAGGAGTGCC 
            * * ******* * *  *  ***   ******  ** ** **    *  **** **** 
 
ABI1      ATGTCAGTCCTTCAGTTGTACAGTGAACTG-TTGTACACTGGTTCAATGAAAGGAAGTTA 
Abi1      ACACCGGTCCTTTGGATTTTAATGAAACTGAATTTACATTGACTCAGTGAAAGGAAA--- 
          *   * ******  * * *  *   *****  * **** **  *** ********* 
 
ABI1      AAAGTACCTTTTACATATTGTAAAAGTGGATACAGTTGATTTGTGAGTAGGCACTCTTTA 
Abi1      -----ATCCTTTACATATTGTAAAGATGGATGCAGTTCATTTGTGGATAGGCA-TATTTA 
               * * ***************  ***** ***** *******  ****** * **** 
 
ABI1      ATCCATTACCTGGCACTAGCAACATTAGAATTTTAAAATAAAATAATTGGGAAAGAAGGT 
Abi1      ATCCATTCCCTGGCACTAGAAACA-TAAAATTT-----TACAATAATTTTGAAAGAAACT 
          ******* *********** **** ** *****     ** *******  *******  * 
 
ABI1      GGGTCATGTATTAATCAGTGAACAGAGATTTACCTAACCAACAGACTTGGATTGTCTTTT 
Abi1      AGGCCATGTATTAATCTGTAAACAGG--------TAATAAGCAGGTTTGTATTG------ 
           ** ************ ** *****         ***  * ***  *** **** 
 
ABI1      GACATAATCAAAATGCAACACATGCACTTTGTGTGTCTCCTCTTAATTGAAGGGAGGGC- 
Abi1      ----TAACTTTGATGCAACACATGCACTTTGTGTGTCTC--CTTGATTCAAGGGAGGGTG 
              ***     ***************************  *** *** ********* 
 
ABI1      TGAGGGATGTTTTCTCTTCTTGTCTTGTGTATAATTCTCTATTGCTTAGGATATTAAAGT 
Abi1      TGAGGGATA---------CTTCTCTTGTATATAAGACTGTACTGCTTAGGATATTAAAGT 





ABI1      AGAGCACTCAAGTGTGGGTTTCTGTGTTATTGAGGATTTGTTTGGAATTCAAATTACAGT 
Abi1      AGATCACACAAGTGTGGGTTTC-------------------------------------- 
          *** *** ************** 
 
ABI1      TATGTACTGGATGCTACAGACTTATAACAGCATAGTGAATGGTAAGACTAGTGCAAAACA 
Abi1      TATGTACTGAGGGTTGCAGATTTATGACAGCATAGTGA----TGAGAGCAGTGCAAAA-- 
          *********   * * **** **** ************    * ***  ********* 
 
ABI1      GTTATTTCTGAAAATTAAAGACCATTATTGCTACCAAATCAATGTGACTATTTCATATGC 
Abi1      --TATTTCTGAAAATTAAAGACCATTGTTCCTACCAAATCAATG-----ATTCCATATAT 
            ************************ ** **************     *** ***** 
 
ABI1      ATTTT-GCCTTTGTTAATTTTAAACAAACAAAGTATCATTAGTGATCAGCTAGCTACC-- 
Abi1      ATTTTAACCTTTGTTATTTTTGAAGTACTA---TGTCATTAGCAATCAGATAGCTTTTTA 
          *****  ********* **** **  *  *   * *******  ***** ***** 
 
ABI1      TTCTACTTTCCATTTTTCAAGTGGATTGTTCTCTTAATTTGTATATAACCTGTTGTCTAA 
Abi1      TTATGCATTTCCTTTTTGAAGCAAAATGTTTTCTTCATTTGTAAATAACCTGTTGTCTAA 
          ** * * ** * ***** ***   * **** **** ******* **************** 
 
ABI1      ATTTTATGTACAGTCTTTTATAATAAACCATTCTCCTATATG-AAATTTTGGATACTGTT 
Abi1      ATTTTATCT--AGTCTTTTATAATAAACTATGCTCCTATATGAAAAATTTGGATATTGTT 
          ******* *  ***************** ** ********** *** ******** **** 
 
ABI1      AAAATATAACTCATGTGGACTTCAA---TGCAGACTTCACATTTTTCTGACCTTTACTCC 
Abi1      AAAGTATAACTAATGTGGATTTAAATAGTACAGACTTCAAAATTCTCTGACCTTTAATCC 
          *** ******* ******* ** **   * ********* * ** *********** *** 
 
ABI1      TACGGT-AAATCAAGACAAACCATTTGAATTTTAACATTGGTTATTTATTTGTGTAATGG 
Abi1      TATGGTGAAACAAAGACAAACCACTTGAATTTTAACGTTGATTATTTATTTGTGTAATGG 
          ** *** ***  *********** ************ *** ******************* 
 
ABI1      CCTTACATGTGGATATTAACAGTGTAAACAATACCACATATAACCATCAAGATACCTTGA 
Abi1      CTTTACATGTGGGCATTAACAGTGTAAACAATACCACATATAACCATCAGGATACCTCGA 
          * **********  *********************************** ******* ** 
 
ABI1      TTATAATTTATAGGACTAGAATGACAGATTCAGGTGGTTTATTAATTACATTTAAAAAGT 
Abi1      TTAGAATTTATAGGACTATAATGACA----CTGGT------TTAATTACATTTAAAAAGT 
          *** ************** *******    * ***      ******************* 
 
ABI1      TTTCTGAAAAAACTTTTGCAATAAAAA-------------------------------AA 
Abi1      TTTCCG-AAAAACTTTGCCAATAAAAATTGCCCATCAATAAGGTTGAAATTATTTCTTAA 
          **** * *********  *********                               ** 
 
ABI1      AATAAAT----------TGCCCATCAA--------------------------------- 
Abi1      AATGATTTTTGGTTTTCTGCACATGAAGCAAATAGTGTTTCACAAAATCATTAGGCACAG 
          *** * *          *** *** ** 
 
ABI1      ------------- 











































(3.6) multiple sequence alignment 
 
 
BECN1      CTTTTTTCCTTAGGGGGAGGTTTGCCTTAAAGGCTTTTAATTTTGTTTTGTTTGCAAACA 
Becn1      -CTTGCTCCTTA-GGGGATGTTTGCCTTTAAGGTTTTATACTTTGTTTGGTTTGGAAAGA 
             **  ****** ***** ********* **** ***  * ******* ***** *** * 
 
BECN1      TGTTTTAAATTAAATTCGGGTAATATTAAACAGTACATGTTTACAATACCAAAAAAGAAA 
Becn1      TGCTTTAAATTAAATTTGGGTAATATTAAAC--CACATGTTTACAATACC---------A 
           ** ************* **************   ****************         * 
 
BECN1      AAATCCACAAAAGCCACTTTATTTTAAAATATCATGTGACAGATACTTTCCAGAGCTACA 
Becn1      AAATCCACAAAAGCTACTTTATTTTCAAATA-----TGACAGATAGTTTCCAGAG----- 
           ************** ********** *****     ********* ********* 
 
BECN1      ACATGCCATCTATAGTTGCCAGCCCTGGT-CAGTTTTGATTCTTAACCCCATGGACTCCT 
Becn1      -TACGCCATGTATAGCAAAGAACCCTGCCATAGTTTTGA--CTCAGCCCCATGCA-TCCT 
             * ***** *****     * *****    ********  ** * ******* * **** 
 
BECN1      TTCCCTTTCTTCTCTGAAAAAAACTAATTTAAATTTGCTTTTCTTTTTTTTAACTGAGTT 
Becn1      TTCCC--TCTTTCCTGAAAACAACTAATTTAAATTTGCTTTGTTTTCTTTT--TTAAGTT 
           *****  ****  ******* ********************  *** ****   * **** 
 
BECN1      GAATTGAGATTGATGTGTTTTCACTGGATTTTTATCTCTCTCAACTTCCTGCACTTAACA 
Becn1      GAATTGACGTTAATGTGTTTTCACTGGA-TTTTATCTCTCTCAACTTCCTGCACTTAA-A 
           *******  ** **************** ***************************** * 
 
BECN1      ATATGAAATAGAAACTTTTGTCTTTACTGAGATGAGGATATGTTTGAGATGCACAGTTGG 
Becn1      ATTTGAAACAGCAAAGGTT--------TGAGATGAG---ATGCTTGTGGCACACAGTTGG 
           ** ***** ** **   **        *********   *** *** *   ********* 
 
BECN1      ATAATGTGGGAAAATGACATCTAAGCTTTACCTGGTCACCATGTGATGTGATCAGATGCT 
Becn1      GTGATGTGGGGAAAGGACACC---------------------------GGGTCAGGAGTT 
            * ******* *** **** *                            * ****  * * 
 
BECN1      TGAAATTTAACAC--TTTTCACTTGGTTCTTATACTGAATGCCGACTCTGCTCTGTGTTA 




             ** ****** *  *  *******    *   * ********  ** **** * *  * 
 
BECN1      GAGATATGAAATGGTGTTTGATACTGTTTGAGACATTATGGAGAGATTTAATTATTTGTA 
Becn1      GGACTACAGAATGCTGTTTGATACTGTGTGCGAC---GTGGAGAGATTTAATTATTTGTA 
           *   **   **** ************* ** ***    ********************** 
 
BECN1      ATAAAAGATTTGCTGCAGTCTGAAAACTGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
Becn1      ATAAAGGATTTGCTATGGTCT----ATT-------------------------------- 
           ***** ********   ****    * * 
 
BECN1      A 





























MUSCLE (3.6) multiple sequence alignment 
 
 
C16orf70        GGACACCACCACCCATGCCCCTCTGTCCCGTGGAACTGTGCATCACATCCTGCTCAGTGG 
D230025D16Rik      GGACATCACTGT-----TTTCCCTGT-CCATGGAACTGTGCGTCACATCCAGCTCAGTGG 
                   ***** ***           * **** ** *********** ******** ********* 
 
C16orf70           GCCTCTGTACCACCCTGTGGGTTTTCTTGGACACCTGGCCAGTGCTGAAGGGCTGTTGTG 
D230025D16Rik      GTCTCTGTGCCACCCTGTGTGTTTGCTTGGACACCTTGGCAGTGTTGAAGGGCCCTGGGA 
                   * ****** ********** **** *********** * ***** ********  * * 
 
C16orf70           AT-------GTTCTGAGGTTGGGCTCAGGCTGGGTGCTCTGCCATGGGCTGAGTGGCCCA 
D230025D16Rik      CTCAGAAGGGTTTGGAAGTAGGATTTGGGCTGAGTCCTCTGCCGTGGGACGGAGGACCCA 
                    *       ***  ** ** **  *  ***** ** ******* ****  *   * **** 
 
C16orf70           GATATTCTTCTGTCCATCTTTGGCCTGCTGGTGCCAGCAGGGGACACAGACTGCAAAGAG 
D230025D16Rik      GATACTCT-------GTCCTAAGCCTGCTGTTGCCAGGAGAGAACACAGTGTGCAAAAAG 
                   **** ***        ** *  ******** ****** ** * ******  ****** ** 
 
C16orf70           AAGCACAAAGTTTGAGCCTTGATTCCTGGACCCAGGAGCTCTC--AACTAACAAG-GAGG 
D230025D16Rik      AAGCACAAACTTAGAGCCATGAT----------GAGGGCTCTCATAACTAACATGTAATA 





C16orf70           CAGGAGAGGTCAACCCTTGTCCCATGCACATTGGGAAGACTTGGGGCTCTTTCTGTGACT 
D230025D16Rik      AAGGACACGTCAGCCCCTGCCCTGCTCACATAGGGAAGAC--AGGACTCTTTCTCTAGCT 
                    **** * **** *** ** **    ***** ********   ** ******** *  ** 
 
 
C16orf70           GAGGACACAGGCACCCAGGATAAGGACAAGGTCCTGCCTTTGGCTCCAC----ATTGCCA 
D230025D16Rik      AAGAAAATA--TTCCCAGGATGAGAACAGGCTCCTGCTTTTGGCCGGACATTGATTGCCA 
                    ** * * *    ******** ** *** * ****** ******   **    ******* 
 
C16orf70           CATGACCCTTAAGGC-----AAGCAGGTAGCGTGTCCATAGTACTTGGTTGCGACATTTG 
D230025D16Rik      CGTGGCCCCTAAGGTGAGCAGAGCAGGTAGCGTGTCGGTAGTACTTGGTTGCAATATTTG 
                   * ** *** *****       ***************  ************** * ***** 
 
C16orf70           CACTACATCCACTTTAGTTACTTGATGAGCTGGCTGTGGCCAGGGTGGCCCACCTGCCCT 
D230025D16Rik      CACTCCATCCACTTTAGTGACTTGATGAGCTGGCTGTGGCTGGTGTGGCCCA-CTGCCCT 
                   **** ************* *********************  * ******** ******* 
 
C16orf70           TCCCTGTTCCTTTCTTGCACGCGCTCCCTGCCT------GGGCACACCAAACTGGTTGAA 
D230025D16Rik      TCCCTG--CTTCTCCTGTGAGTGCTCCTTGCCGTGCCCAGGTGGCACCTAAGTGGATGAA 
                   ******  * * ** **   * ***** ****       **   **** ** *** **** 
 
C16orf70           ACACAGCTTTCTACCATCCAGGTACATGCCCAGGCCTGGTTCTCACCCCTGTT---GGAG 
D230025D16Rik      --ATCGTTTCCTACCAGGTATGTA-----CCAGGCCTGGTTCCCACTGCTGCTCTGGGAG 
                     *  * ** ******   * ***     ************* ***  *** *   **** 
 
C16orf70           TCAGCTTTCAAGATTGCCTGTGCCCCTGCTCTGCCCCATCCTGGCTGGCAGGGCTGCATG 
D230025D16Rik      CCAGCCTTTAAGGTCACCTGTGTCTCT----TGGTCCAACCTGGCTGACAGGGCTGCATG 
                    **** ** *** *  ****** * **    **  *** ******** ************ 
 
C16orf70           TTTCCATCCTGTTTGCCTCTTTTATTTAATGCCAAAGTTTTAGCCAAAGACATCTTCCTA 
D230025D16Rik      TCTCCATCTTGTTTGCCTCTTTTATTTAATGCCAAAGTGTTAGCCAAAGACACCTTCCTC 
                   * ****** ***************************** ************* ****** 
 
C16orf70           CTTTTGTTGTGTTTCAGCATTCTGTTCTGCACTGTGGGCTGGCTCTCTGCCCCAACCCTG 
D230025D16Rik      CTTTTGTTACATTACAGCATTCTGTTATGCACTGTGGGCCAGCTCCTTGCCCTAGTTCTG 
                   ********   ** ************ ************  ****  ***** *   *** 
 
C16orf70           GGCACTGGCC---CCTGGCTGGGCC--ATTTCATGGCTCAAAGCCTCTGGGGGCTCAAGG 
D230025D16Rik      GGCACTGGCCTGGCCTGGCCTGGCCTGGCTACTTGGTTTGAGGC--CTAGAGGCTCAAGG 
                   **********   ******  ****    * * *** *  * **  ** * ********* 
 
C16orf70           AAGGCTGGGCTGCTCAGTCCCTT-CATGGGTCTTGCTAATGGAAAGTAGCATATATGTGC 
D230025D16Rik      AACACTAGGCTGCTTGGTTTCTTACATGGGTCTTGCTAATGGGAAGTAGCATATATGTGC 
                   **  ** *******  **  *** ****************** ***************** 
 
C16orf70           TTTAAAAATATTAATCCTTTTGAAAAGAACTGAGAAGAAAAATGTATAATTTTATCCCAT 
D230025D16Rik      TTT-AAAATAGTAATCCTTTTGAAAAGAATTGAGAAGAGAAACATATAATTTTATCCCAT 
                   *** ****** ****************** ******** ***  **************** 
 
C16orf70           TTTTAATATTTTGGTCTAGCAACTTGTGATACATAGATGACAATTTTGTGAGTTTTTCAA 
D230025D16Rik      TTTTAATATTTTGGTCTAGCAACTTGTGATACATAGATGACAATTTTGTGAGTTTTTCAA 
                   ************************************************************ 
 
C16orf70           ATGTGTGTACAGATTTTTGTAAAT-ATGACTCTTTTGTAATTAACTCATGTACAGCCTCA 
D230025D16Rik      ATGTGTGTACAGATTTTTGTAAATAATGA--CTTTTGTAATTAACTCATGTACAGCCTCA 
                   ************************ ****  ***************************** 
 
C16orf70           TCCTGTATAGTTTAATGATGAATGTGCAGGGGACCTGTCTCAGGCTCCTATATGGTTCCT 
D230025D16Rik      TCTTGTATAGTTC-ATGATGAATGTGCAGGGGACCTGCCCCAGCTGTCTGTATGGTTCCT 







C16orf70           GGGCCTTATAGCCAGGTTTGTGTGGCGCTCCCGACTTTTGTGACTGACT-----GGTGTC 
D230025D16Rik      GGGCC-TACAGCCAGGCCTGTGTGGCACTCCC-------ATGACTGATTTGACAGGTGTC 
                   ***** ** *******  ******** *****        ******* *     ****** 
 
C16orf70           TTCCCATTTGGACTGTGGCCTGGCCAGAGCCCCTTGCATATCCCCACTGTCAGGGGCAGC 
D230025D16Rik      TTCCCATTTGGACCTTCGTCTGGCCAGAGACCC-TGCACAT-CCCACTGTCA-GGGTAGC 
                   *************  * * ********** *** **** ** ********** *** *** 
 
C16orf70           CAGGACTGTTCCCATCCTCCTGGAATGGGGGAACCTTCCTTATCCCCTGCCCACATCCCC 
D230025D16Rik      CAGGACTCTTCCCATCCTCGT-GAACAGAGGAGACTTCCT-------------CGTCCCC 
                   ******* *********** * ***  * ***  ******             * ***** 
 
C16orf70           TCTCCAATAAAGCACCTGTGCCCTCAGCAATGGCCTGCCATGTGCTGTTGCTGGGATGTT 
D230025D16Rik      CTTCCAATAAAGCACCTATGCCCACAGTGACAGCGTGCCATGTGCTGCCACTGGGCTGTT 
                   *************** ***** ***  *  ** ************   ***** **** 
 
C16orf70           TGTATTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
D230025D16Rik      TGTACTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
                   **** ******************************************************* 
 
C16orf70           AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
D230025D16Rik      AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA------------------ 
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C7orf23         GGCTGCCAAGGAGAAGTACTTACCAGGACTCTTCAAAATGATACATTAGGACAGTGAGTA 
4930420K17Rik   GGCTGCAGAGACGAAATACTTACCAGGACTCTTGGAAAT------CTATGTGAAT--TTA 
                ******  **  *** *****************  ****       ** *  * *   ** 
 
C7orf23         ATTTTTG-GATAAGGTATGCTGAAGAATCTCCTGCAGAAGTCTGATACATGA--TTTTCA 
4930420K17Rik   ACTGCTGCAAAAAAGTATGCTGAAGACTCATCGACAGACGTGTGGTACATGATGTTTCCA 






C7orf23         TGTTAATTGTAAATGTTAATTCCCTCTTGCAAGGGAGACATATCCTAGATCACTTTGCTT 
4930420K17Rik   TGTTAACTGTAAATCTCAA-TCCCCCCTGCGAGGGGGCTGCAGCATAGAT--CTCTGCTC 
                ****** ******* * ** **** * *** **** *    * * *****  ** **** 
 
C7orf23         TTTCTTTAAGGAGCTGATGTTGCACCTAAACATTCCAACCCTTAAAGCTAAAACAGCACA 
4930420K17Rik   TCCTTTAAA------------ACGCCCACACATTCCAGCCCTC-------AAATAG--CA 
                *   ** **             * ** * ******** ****        *** **  ** 
 
C7orf23         AAAAAATTTCACTTTTGAAATGAAATTTT------------------------------- 
4930420K17Rik   AGGAATTCTCACTTTTGAAAGAATTTTTTTTTTTTGTTTTTGTTTTTTTTTTTTTTAACA 
                *  ** * ************  *  **** 
 
C7orf23         -TATAATTGTATGGCAAAAGGCTATGTAAAAACAAATCTTGCATCTTAAGACAAATATTC 
4930420K17Rik   ATTTAATTGCATGGCTCA---------------AAATCTTGCATTTTAAGACAAATACTC 
                 * ****** *****  *               *********** ************ ** 
 
C7orf23         TTTTATTTCTGTTAAACTGAATATACAATTGTT----CCCTAGGCAACCAACTTTTGCTT 
4930420K17Rik   TTTTATTTCTGTTAAACTGAATATACAATTATTGTTCCCCTAGGCAACCAACTTTTGCTT 
                ****************************** **    *********************** 
 
C7orf23         ATAACTACAATTTAATTTCACGTTGACAAAACACAGTGAAAAGACAACTTTGTGAAGATC 
4930420K17Rik   ATTACTACAGTT------------------------------------------------ 
                ** ****** ** 
 
C7orf23         TAATTACAATAATAAATAAAATAATTTATACAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
4930420K17Rik   ---TTACATTAATAAACAGA-----TGGTG------------------------------ 
                   ***** ******* * *     *  * 
 
C7orf23         AAAAAAAAAAAAA 
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CACNA1H      CTCGGGGCTTGGTGCCGCCCACGGCTTTGGCCCTGGGGTC-TGGGGGCCCCGCTGGGGTG 
Cacna1h      -ACTGGGCTGTGTGTC-CACAGGGCTTTGGCATTGAGGTTGTTGGCTCCCTGCAGGGTGG 





CACNA1H      GAGGCCCAGGCAGAACCCTGCATGGACCCTGACTTGGGTCCCGTCGTGAGCAGAAAGGCC 
Cacna1h      TAGCCCCAGTCAGGGCTATGAGTGGACCCTGGCTTAGGCCCCACCAAG-GCAGAGGGACC 
              ** ***** ***  *  **  ********* *** ** ***  *  * *****  * ** 
 
CACNA1H      CGGGGA---------GGATGACGGCCCAGGCCCTGGTTCTCTGCCCAGCGAAGCAGGAGT 
Cacna1h      GGGAAATACTATCCCGGGAGAGGCAGCAGACGTTCCGTCTCTGCACCATGACACAGGAGC 
              **  *         **  ** *   *** *  *   ******* *   **  ****** 
 
CACNA1H      AGCTGCCGGGCCCCACGAGCCTCCGTC-----CGTTCTGGTTCGGGTTTCTCCGAGTTTT 
Cacna1h      AGCC-TCGGGCCCCACGAGCCTCCCTCGTGGTGATTCAGGTTTGGGTTTTCCTGAGTTTT 
             ***   ****************** **       *** **** ******  * ******* 
 
CACNA1H      -GCTACCAGCCGAGGCTGTGCGGGCAACTGGGTCAGCCTCCCGTCAGGA-GAGAAGCCGC 
Cacna1h      AACCACCACCAGAAGTTGTACCAG-GACCAGGTCATCAGTC--TCAGGAGGAGATACTGT 
               * **** * ** * *** *  *  **  ***** *   *  ****** ****  * * 
 
CACNA1H      GTCTGTGGGACGAAGACCGGGCACCCGCCAGAGAGGGGAAGGTACCA-GGTTGCGTCCTT 
Cacna1h      GTCC-TGAGA--AGGACCAGAAATTCCTCATGGGCAGGAGGGCACCACAGCTCCATCCAT 
             ***  ** **  * **** *  *  *  **  *   *** ** ****  * * * *** * 
 
CACNA1H      TCAGGCCCCGCGTTGT---TACAGGACACTCGCTGGGGGCCC-TGTGCCCTTGCCGGCGG 
Cacna1h      GTGACACACAGGTTGCCGATAGGGAGTACACGCTTGAGCCCCTTGTGCCCTGGTGGGCAG 
                   * *  ****    **  *   ** **** * * *** ******** *  *** * 
 
CACNA1H      ----CAGGT--TGCAGCCACCGCGGCCCAATGTCACCTTCACTCACAGTCTGAGTTCTTG 
Cacna1h      ACATCGGGTCCTGTAGCCGCCACAACCC-ATATCACCTTCGTTCACGGTCT-CGTTCCTG 
                 * ***  ** **** ** *  *** ** ********  **** ****  **** ** 
 
CACNA1H      TCCGCCTGTCACGCCCTCACCACCCTCCCCTTCCA---GCCACCACCCTTTCCGTTCCG- 
Cacna1h      TCCATC-ATCA----CTCGGCATCCTTCCCTCTCACAGTACCCCACCCCCATCATTCCAT 
             ***  *  ***    ***  ** *** ****  **     * ******    * **** 
 
CACNA1H      ---CTCGGGCCTTCCCAGAAGCGTCCTGTGACTCTGGGAGAGGTGACACCTCACTAAGGG 
Cacna1h      CCTCTTAGGTGGTTTAGAAACTTTGCAGTGACCCTGGGAAGGGC--CACATCACCAAGGA 
                **  **   *     **   * * ***** ******  **   *** **** **** 
 
CACNA1H      GC-CGACCCCATGGAGTAACGCGCC-CGGCCCCGATGCGAATCAGGCCTCCCCTACATCT 
Cacna1h      GTACTGGCCCATGCAATAAGACGTCACAGTCCCAACAGAGGCGGGGCTTCCCCTCCATCC 
             *  *   ****** * ***  ** * * * *** *         *** ****** **** 
 
CACNA1H      GGGGGCGTTGGCCGCGAGATTCCCATTGACACC--TTTGTTTCGTGTGCT------TTTA 
Cacna1h      CAGGCTGTCAGGCTCAGCGTTCAT-TTGACATCCATTTGCTTTATGTCATCCGTTCTACA 
               **  **  * * *    ***   ****** *  **** **  ***  *      *  * 
 
CACNA1H      AATTCAGGTTAAATGTTGCAATAATCTGATGCAGAAGACTCAGCTTCTCAAG-------- 
Cacna1h      AATTCAGGTTAAATGTTGCAATAATCTGATGCAGAAAACTTGGCTTCCTAAGTCAAAGCT 
             ************************************ ***  *****  *** 
 
CACNA1H      --GGAGAGGGAGGGGGCGGAGCG-----GAATAAATAGTAACTTATTTAAGAAATGCAAA 
Cacna1h      AAGGGGAGGGGAGGGGCAAAGCAAAGCTGAATAAACACTAACTTATTTAAG--------- 
               ** *****  *****  ***      ******* * ************* 
 
CACNA1H      AAAAAAA 
Cacna1h      --AAAGA 
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CNTD1      GGGAGGCTGAATCCACCAAATATAAACAGCCATCCGTCACTGCACTCATGCCTCCCTCTG 
Cntd1      GGGTGGCTG-ACCCGC---------ACTGCCTT--GTCACTGGACC----TCTTTCCTTG 
           *** ***** * ** *         ** *** *  ******* **      **  *  ** 
 
CNTD1      TTTACTTTCATACTAAGGGTAC-AAAAATTCCAAGTCTCTTTTGAACTGTATTTTGTATG 
Cntd1      TTTACTTTTATACTCAGGGTACAAAAAATTCCAAATTTCCTTTGAACAGTGTTTTGTATT 
           ******** ***** ******* *********** * ** ******* ** ******** 
 
CNTD1      CCAATTTCATGCTTA----TTTTTCCTTTATCAGAGAGAGTTAAGGTGGACGAGCATGCC 
Cntd1      CCAGTTTCAGGCATGTTATTTTTTTCTACATCAGAGATAGTTATGGGAGACAAACATATC 
           *** ***** ** *     ***** **  ******** ***** **  *** * ***  * 
 
CNTD1      CTTTTTGTCATATCAGCCT---GAAAATGTTAAAAAGCTAGGTGGA---GACAGATTAGT 
Cntd1      TGTTGTGTCATGGTAGGCTAAAAAAAACATCAAAGAATTGGACTGAGTTGATGATGAAAC 
             ** ******   ** **    ****  * *** *  * *   **   **      * 
 
CNTD1      TGTTTCATTTTTGTTTAACAAGGTATTTATACTTT--TAGCTTAATTTCATTAAGAGG-A 
Cntd1      TAGTTCATTTTTGTTTGATAATACTTTTAATTTTTCCTAAGTTAATCTAACTAAGAGGTA 
           *  ************* * **    ****   ***  **  ***** * * ******* * 
 
CNTD1      ACATCAGGCATTGCAATCAGTATTAATCAGGGGCTCAAATACAGACTATCTG-GGTGACC 
Cntd1      ATATCAG--ATAGAGATAAGTATT--TTGGGGG----ACTTTAGAGCATTTTCGATGACC 
           * *****  ** *  ** ******  *  ****    * *  ***  ** *  * ***** 
 
CNTD1      TTGACTAAGCATCAAGGAGGTAGCCTTTATT-------TCCCCTTAAAATTAGTTTAACA 
Cntd1      TTGACTGAATCTCTTTGAAGTAACCTTTCTTTCCTTGCTCCCCCTACAGCTGGTTGTTTT 
           ****** *   **   ** *** ***** **       ***** ** *  * *** 
 
CNTD1      TCTCTGTT-----------------------------------------CCATTATTCAG 
Cntd1      GTTCTGTTTTGTTTTGTTTTGTTTTGTTTTATTTTGTTAAGACAGGGTCTCAATACTCAG 
             ******                                          ** ** **** 
 
CNTD1      AT-------------------CTACACAAACAAGGCT------------------TCCTC 
Cntd1      CCCTGGCTGCCTTGCAACTCACTATACACACCAGGCTGGGCTGAAATTCAGAGGGTCACT 




CNTD1      AACAGCTATCTATTTT----TACTAGAG------------------TCTTTTTTTAAAAC 
Cntd1      TGCCTCTCTCTGCCTCTCAGTGCTGGGGCTAAATACCATCATTTGTTTTTCTCTTTAAAC 
             *  ** ***   *     * ** * *                  * ** * ** **** 
 
CNTD1      TAAAACTAACTCTAAAGAAGTTTCAACAGAATTTCCACATACCTGCATTCATTAGAACTT 
Cntd1      TAAGAC-----------ATGTTTCAACAGAATTTCTA-----CTGAACTGACTACAACTC 
           *** **           * **************** *     *** * * * ** **** 
 
CNTD1      GATTCTCCCAGAATACAAAGTACTCTATTTTAAAGAAAAACCCAACAGTGCACCCCTGGG 
Cntd1      AATTCTTTCAGAATACAAAATACTCAATTTTAAGGAAAAACATACAGGCGTACCACTTGG 
            *****  *********** ***** ******* *******  *   * * *** ** ** 
 
CNTD1      CAGTTTTCAGACTGCAGCAAATCTTTTATTACAAATAATTAAATCTCTCCATAATGTCTC 
Cntd1      TAATTAATAGACCATAGCAAATCCTTTATTACAAATAATTAAATCTCTCC---ACGTCGC 
            * **   ****   ******** **************************   * *** * 
 
CNTD1      AAACAGTATCAAACACCATTTCATATCTCTAACACAGAGCAGAGTCGGCATTCAGTATAA 
Cntd1      ACACAGTATCAAACAGCATTCTGTAGTCCCACTAGACAGCACAGGAGGCATTCAATGCTA 
           * ************* ****   **   * *  * * **** **  ******** *   * 
 
CNTD1      GAACCAAGTGAAAA--GTGTTAAATTTCAAGCATCTGATCACATCACATGGTGACCAGGT 
Cntd1      ----CAAGTGAGGACGGAGTTAAACTTGCAACTCCTGACC-------------------- 
               *******  *  * ****** **  * *  **** * 
 
CNTD1      AAAGCTTAGATGTCATTTTCCCACATTATCCAACTGTGCATCTCAAACATATCCTCATCT 
Cntd1      -------CGGTGTCCTTTCCCCACATCACCCAACTGTGTGCCACAAGCAT---CTCATCT 
                   * **** *** ******* * *********   * *** ***   ******* 
 
CNTD1      CAGTAAAGACAAAAGTTTCTATTTCATATTGTTAAGTGCAGGAAGTTGAGAGAGATAAAA 
Cntd1      CA--------AACCTTTGCTGTTTCAAATT-TTAAGTGCAGGAAGTTGAGAGAGAT-AAA 
           **        **   ** ** ***** *** ************************* *** 
 
CNTD1      ATCCAGTGAAAACACATCAATCTCAATTCAACTCAGTTAAAAAAAAGAAAAGCAAATTTA 
Cntd1      ATCCAGTGAAAACACATTAACGTCAATTCAACTTAA--AAAAGAAAACAAAGCAAATTTA 
           ***************** **  *********** *   **** ***  ************ 
 
CNTD1      AATTAGTTTTTTTCAGAGAAGAAAGGGAAAGGAGTCCATGGGGTTAAGAATCAAAACTG- 
Cntd1      AATTAGTTGTTTTCAGGAAAG--AGGGAAAGGA-TGCATGGGGCT--GAGTCAAAACTAT 
           ******** *******  ***  ********** * ******* *  ** ******** 
 
CNTD1      ACCAGGGCTGGCAACTATAGATGGCATGTTGTAGCTCTGGAAAGTATCTGTCACATGATA 
Cntd1      GGCAGGGTTCTTTGCTATACATGGCGT------ACTCTGGAAACTATCTGTC-----ATA 
             ***** *     ***** ***** *       ********* ********     *** 
 
CNTD1      TTTTAAAATAAAGTGGCTTTTGTGG 
Cntd1      TTTGAAAATAAAGTAGCTTTTGTGG 
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CREB3      ATATGAGGATATGTGGGGGGTCTCAGCAGGAGCCTGGGGGGCTCCCCATCTGTGTCCAAA 
Creb3      GTGTGAGGATGTG-GGGTGTCCTCAGCCTGA--------GGACTCCTGTCTGTATTCAAA 
            * ******* ** *** *  ******  **        **   **  ***** * **** 
 
CREB3      TAAAAAGCGGTGGGCAAGGGCTGGCCGCAGCTCCTGTGCCCTGTCAGGACGACTGAGGGC 
Creb3      TAAAAAGGAGCAGGGGAAAGCTGGCCTTTGCTCACGTGCTCTGTTAGGATGCCCAGGAAC 
           *******  *  **  *  *******   ****  **** **** **** * *   *  * 
 
CREB3      TCAAACACACCACACTTAATGGCTTTCTGGGTCTTTTATTTGTACCC--ATGTGTCTGTC 
Creb3      TCAGACACACCACACTAACTAGTTTTCTGAGTATTTTATTTATACCCATATGTATCTGTT 
           *** ************ * * * ****** ** ******** *****  **** ***** 
 
CREB3      ACACCATGAATGTACCTGGGGAAATCAACTGACCTCCCTGAACATTTCACGCAGTCAGGG 
Creb3      GCCCCGTGAATAGATTTGGAGACATTTACTGGCCT---TGAATACTTCATCCATGGAAGG 
            * ** *****  *  *** ** **  **** ***   **** * ****  **   * ** 
 
CREB3      AACAGGTGAGGAAAGAAATAAATAAGTGATTCTAATGCTGCCTAAAAAAAAAAAAAAAAA 
Creb3      ACTGGGTAGGGTAAGAAATAAATAAGTGGTTCCTC------------------------- 
           *   ***  ** **************** *** 
 
CREB3      A 





<Human: DHPS, Mouse: Dhps; no graph, UTR too short for sliding window> 
 
 
MUSCLE (3.6) multiple sequence alignment 
 
 
DHPS       GCGGCTGCGGTCCCAG--GAAGGTCTTACCCCCTCTTCTATTTATTAATTTGCAGACCCA 
Dhps       GAAGAT-TGGTAAAGACTGAGGCTTTTTGCCACACCTTTATTTATTACTTTACATG-CCA 





DHPS       GCCCCTCC-----CCTACTTTTTGGTCAGCTACGTCTCTAGAATAAGATGG-----TATC 
Dhps       GCCCCTCCCTAGGCCCACTCCTTGGTCAGCAGCATCTCTAGAATAA-ATGGCCCTTTGGT 
           ********     ** ***  *********  * ************ ****     * 
 
DHPS       TGAAGTCCTTAAAAAAAAAAAAAAAAAAAAAAAAAA 
Dhps       TGGGTTTTCTGAGTC--------------------- 


























MUSCLE (3.6) multiple sequence alignment 
 
 
DMTF1      AATAATTCTTAGAAATAGGCAGTTCAAGCAAAGAAGGCACACTGTTAATTACAACCTCTT 
Dmtf1      ----ATTATTAGAAACAGGTACTTC-----AAGAAGCCACATTG-TGACTACATTGTCTC 
               *** ******* *** * ***     ****** **** ** * * ****   *** 
 
DMTF1      CAAAGAAATAGGAGCAACCCCCAAGAGGCTTAATTTACCAATT----------TAAATAG 
Dmtf1      CAAAGAA--AGGAGCCA-TCCCAGGAGTTGTGGTTTGCCATTCCTCTGGCTTGTACTTAG 
           *******  ****** *  **** ***   *  *** *** *           **  *** 
 
DMTF1      CCACAGTCCTTAAGCCACACACATTGTTGCTGCTATGACTTTTTACCTCCTTTAAACACA 
Dmtf1      CTGCCATGCTTAAGCCATGCACATTGTTGCTGCTGTTACTTTTACCTCCTTCTCAGTAGA 
           *  *  * *********  *************** * ******  *  * * * *  * * 
 
DMTF1      TCATCTGAGGTTGAGTTTTATGACAGTATGTAGTTGAGTGGAGGCTGGGAGTTTTAAGCA 
Dmtf1      TCATCTGAGGTCCAATTTTATAACAGT-TGTTAT--GATGGAGGATAGG------AAGTG 
           ***********  * ****** ***** ***  *    ****** * **      *** 
 
DMTF1      TAAAT--CCCTGTTTAGT---GTTACATGGGAATAAGGAATTTCATTCACTTCAGCCACT 
Dmtf1      TGAATTGCCCAGACTTGTTAGGTTTTATGTCAAGAGGGAGTTGCAGTCACTGCAGCTACT 
           * ***  *** *  * **   ***  ***  ** * *** ** ** ***** **** *** 
 
DMTF1      AAGAAAAGTTTAGAATCACGAAAGCTTAACTGCTGTGGTTTAAAGTACAGTT-------- 
Dmtf1      TAT-----------ATCACCAGAGCTTAACTACTCTGGTTTAAA-TATAAGTAGTAATAC 
            *            ***** * ********* ** ********* ** *  * 
 
DMTF1      ---TCTCTAAAGATCAGACATGGCACTGTCTCCTCTCAAGC----CTGGTTGTAGTTCAG 
Dmtf1      TCATCTCTGCAG-TTAGACACAGCTCTGTCCAGACTCAAGCTGGGCTGGTTGTAATTCAG 





DMTF1      ATGAGTCTTTTCAACATGGTCTTCAACATGGTCTAGAGCTTACCAGTGATCTTCTGATCT 
Dmtf1      CT------------------------TATG---------TTAGCAGAGACTTTCAGA--- 
            *                         ***         *** *** **  *** ** 
 
DMTF1      TCAAGAAGACTAAGTTTGAGACT-------------TGACCAGCATTCAAGTATAGAGAC 
Dmtf1      -----AAGATTAACTTAGGAGTTGATGACATGACCATGACCAGCATCCAGATACCACATT 
                **** *** ** *    *             ********** **  ** 
 
DMTF1      CTAGGAGGTGGTCTTGTGGTGGTACATTTGGTTAACCCATTGCTGGCAGTGGGAGCTGAT 
Dmtf1      ATGGGGGGTGGTTGTG-----------CTGGTTAACCCATTGCTGGCAGTGGGAGCTGAC 
            * ** ******  **            ******************************* 
 
DMTF1      TTAGGCAGGGTAAACAGG-AAAGCATTA-AAAGTT---AAAATTCACTACAGGTTTTTTG 
Dmtf1      TGAGGCAGGGTAAAGAAGCAAAGCATTACAGAGTTAAGAAAATTCACTACAGGTCTTTGA 
           * ************ * * ********* * ****   **************** *** 
 
DMTF1      TT----ACTTTTAAAGGGAATATGGATAAGCATAGTAACAAAACCCACCAGAATCTAAGC 
Dmtf1      TTTTTAACTTTTAAAGGGAACGTGGTTAAA-GTGGTAACAAAA----------------C 
           **    **************  *** ***   * *********                * 
 
DMTF1      AGTTTTCA--CCCCCTCAGAAACCACTGTCATTAGTTTACAAAGTTAGCACTTTGAAGTA 
Dmtf1      AGTTATCAACTCTCATCAGAAACCA--GTCATTAGTTTAC--AGCTAGCACTTTGAAGTG 
           **** ***   * * **********  *************  ** ************** 
 
DMTF1      AAACTAAATGAGGAAGGAAGTAATGTTACCTATCCTTGAT-ACCATGAC--CATTTATTA 
Dmtf1      AAATTAAATGAGGGGAGAGGTCATATTGCCTGTGTCTGATAACCATGACTTTTTTTATGA 
           *** *********   ** ** ** ** *** *   **** ********    ***** * 
 
DMTF1      GATGTTTTGCTATATAAATTACCGAGAGAATAGTT-------------------TGTCAT 
Dmtf1      CATGTTTTAC-ATATAAATTGCCCAGAAGATAGTGAGGGGTATTAATTAGAGTATGCTGT 
            ******* * ********* ** ***  *****                    **   * 
 
DMTF1      CCACTTAGTGTGTTAGCTGGT-GGGGTACAATATAACCTCTCATCTCAGGCTATTTTAAA 
Dmtf1      TCACTTCGTGCATTACCTGCTGGGGGTACACTATAGCTTCTC-CCTCAGGC-ACTTTTAA 
            ***** ***  *** *** * ******** **** * ****  ******* * *** ** 
 
DMTF1      AAAACAATATTTGCTTCTATAACAAAAGGAAACAAATCTAAGAATCATTCCTGTACTACA 
Dmtf1      AAAACAAAATTTGCTTCTGTATCAAAAGAAAACAAATC-AAGAGTCATTCCT-------- 
           ******* ********** ** ****** ********* **** ******** 
 
DMTF1      GAAGGGTTAAGGCAAAGGTAGCCTTTTGGGCTTTTTAATGAATATGACCCCTATAGAAAA 
Dmtf1      --AAGGTAAAGCCAAAACTAGCCTGTAGGGC--TTTAATG-ATATGATCCTTATAGAAAA 
             * *** *** ****  ****** * ****  ******* ****** ** ********* 
 
DMTF1      GTC-------------AAGAAAAAAAAACCCTTGTATAAATTATTTTATTTATTATTGTA 
Dmtf1      GTCCAAAAAAAGGAGGAAAAAAAAAGGAAACTTGTATAAATTATTTTATTTATTATTGTA 
           ***             ** ******  *  ****************************** 
 
DMTF1      ATTAGATCTTCA----CAAAGTTGTCTTTTCACTGTGT-TTTGTCAACGTGAAATTAAAT 
Dmtf1      ATTAGATCTTCACAATCAAAGCTGTCTTTTCACCATCTGTTTATTAATGTA-----AAAC 
           ************    ***** ***********  * * *** * ** **      *** 
 
DMTF1      TGTAGTTATAAGCAAAAGTTGGTTGCCTAGGG----AACAATTGTATATTCAGTTTAACA 
Dmtf1      TGTAGTAATAAGCAAAAGTTGGTTGCCTAGGGGAACAATAATTGTATATTCAGTTTAACA 
           ****** *************************    ** ********************* 
 
DMTF1      GAAATAAAAGAATATTTGTCTTAAGATACAA---------------------------AA 
Dmtf1      GAAATAAAAGAGTATTTGTCTTAAAATGCAAGATTTTGAGCCATGCAATTAAATTGTTAA 
           *********** ************ ** ***                           ** 
 
DMTF1      AAAAAAAAAAAA-------------------------- 
Dmtf1      AAAAAAAAAAAACAAAAACAAAAAAAAAAAATTCTTTC 





























MUSCLE (3.6) multiple sequence alignment 
 
 
EME1      TTCTAGCCCTCAGGGATGAGGATGAAAAGCTGGAAACTTCCACTTCCCCAACCTCAGAGC 
Eme1      -----------------------------------------ATATCCC--ACCTTGGCTA 
                                                   *  ****  ****  * 
 
EME1      CTGACTGTAATGAAGAGACTGGCAGCACCTCCTGGAACACAAGCCTAGGTGAGGCCCAGT 
Eme1      TTGACAGTA---GACAGGCCAGAAGTACCTCCTTG-GTACAG--TTAGG---GAGCAAGT 
           **** ***    * ** *  * ** ******* *   ***    ****   *  * *** 
 
EME1      CTTTCTTGGGTCTTATTATTTGTGAAGGTCTCTCTGCCTGTCGGCTGGGGCAGAGA---C 
Eme1      CTCTC------------------------ATCTCTG----------GGAACAGAGAAGGC 
          ** **                         ******          **  ******   * 
 
EME1      TGAAATACTGCCACCTACCTTTGGCAT----TTAATGTTCCTCTCCTGGCAA---AAATT 
Eme1      TGAGTCACTTGAATCTACCTCCACCATAGCACTCATGTTCCTCTCCCGGCAAGCGAGA-- 
          ***   ***   * ******    ***     * ************ *****   * * 
 
EME1      CACTGCCACAGACAAACCACCCCCACTCCTACCCAGCCAGCCCTCAAAACACAAAGGAAC 
Eme1      ---TGCCATGGAC-AGCCA-TCCCACCCCATCCCAGTTGACCCTCACAGCACAAAGGAG- 
             *****  *** * ***  ***** **  *****    ****** * ********* 
 
EME1      AAAGACAGTCCACTCAGACACTTATTTAATAACTGTAGAAATCCAAAAGAATTAGCATCA 
Eme1      AAAGGCAGACCACTCAGACATGGATTTAATAATTGTAGAAATCCAAGA-AATAAGCATCA 
          **** *** ***********   ********* ************* * *** ******* 
 
EME1      AATCTTGAAGTCGTGAGTGAA------GCTGCGGGTTGGCTTGACTGGGCTCAGCCACTG 
Eme1      AATCTCGAAGTCA-GAGTGAACTCTTGCCTGCGGGTTGGCTTGACTACGCCCAGCCACTG 
          ***** ******  *******       ******************  ** ********* 
 
EME1      AGCTGCCTCAACCGGCCAAGGAACGGGATTATGATGACTATGCGGACTTCTATATTGTCT 
Eme1      AGCTGCCTCAACCAGCTAGGGAGC-----TATGATG---AGGCTGACTCC--TGTTTTCA 
          ************* ** * *** *     *******   * ** **** *  * ** ** 
 
EME1      TCATCTCAT----TGTGTGTATTATGTATTTAGTTTCAATAAAGCATTTGTACCAATG 
Eme1      TGATGTCACCATATGTATGTAGTATGTATTTTGTCTCAATAAAGCCTTTGTACCT--- 






























MUSCLE (3.6) multiple sequence alignment 
 
 
FAM13C1          GGTTCAGGAAATGTTATGATCACTTTCACCCATGATATAAAGTAAAGTTTATTTTCCTCT 
1200015N20Rik    GGTTCA------GCTCTGCTCACTTCC-CTCTCAAGATGAAGTCAAGTTCATTTTGCTCT 
                 ******      * * ** ****** * * *   * ** **** ***** ***** **** 
 
FAM13C1          GCCATCCTTGCTAAGTAGTTTTGACACAATGAAAATGGAAGCACTTTAGTGGTAGTATTA 
1200015N20Rik    ACTGTTCTTGCTACGTAGTTTTGATGTACTGAAAACGGAAGCACTTTAGAGATAGTATTA 
                  *  * ******* **********   * ****** ************* * ******** 
 
FAM13C1          GCTGTTTTTAAGAAGGAATAGCAAGTTTAATTATATACAAGGAGAAGGGATTTAAACGGG 
1200015N20Rik    GCTGTTTTGACAAAGGAAAAGCTAGTATAATTATACCCAA--CCAAGGCATTTAAATAGG 
                 ******** *  ****** *** *** ********  ***    **** *******  ** 
 
FAM13C1          GGGAAGAATACAACAGGTAGCCATATAATTGGGAAAAA—ATTCAGTGTCCTCCATGCCA 
1200015N20Rik    G------AAATAACAGGTAATGTTGGGATTGGCAAAAAGCATTTAG---CCTCCATGCCC 
                 *      * * ********    *   ***** *****  *** **   ********** 
 
FAM13C1          AGCAGAAAACTCATAGTC-AATACAAGTATTTTTAAAAATGTCTAATATTTTATCAAATC 
1200015N20Rik    AACTGAAATC-CAGAGTCAAATGTAAGTGTCTCAAAAACTGTCTAATATCTTGTCAAACC 
                 * * **** * ** **** ***  **** * *  **** ********** ** ***** * 
 
FAM13C1          TAAA---TAACATAGCTAGGACACTTGTTAGGGAAAGTTTATTTAGTATCCAAAGACTGT 
1200015N20Rik    TAAAATCACACGTAGGCAGGCTACCTGCTAGCGAAGATTTA-GTAGTGGCCCCAAATTGA 
                 ****     ** ***  ***  ** ** *** ***  ****  ****  **  * * ** 
 
FAM13C1          TTATGTTGATGTATGGAAAAGAGCATGATTTTAAAAAATCAATCATAGGAGGAAAAGAAA 
1200015N20Rik    TTTTATTGATGTATGG-AAAGAGCATGGTTTAAATACATTGGT-----GAGACAAAGAAA 
                 ** * *********** ********** *** ** * **   *     ***  ******* 
 
FAM13C1          ---TTCGCTTTTCAAGTAGGAAGGAATACAGCTAGCAAGAAAGCAATTTATTTGAAACTT 
1200015N20Rik    ATTTTTGCTCTTCACCCAGGGAGGAAAACAGCTAGAAGGAAGGTAATTTA---------- 







FAM13C1          CTAATGGATTTTTGAGTGATAAAACATTTACTACCTTGTCCTTTAAGTCTGCTAGGCTCT 
1200015N20Rik    --------------AGCGAGACAACATCCACTACCTTGTCCTGTAAGCCTG-TAGGCGTT 
                               ** ** * *****  ************* **** *** *****  * 
 
FAM13C1          CAGTACCCTAAAATAAACTAGATTGTGTTGCTATT--TTTTTTCTTTCTCTATAAAAATA 
1200015N20Rik    CAGCACTCTAAAAT-AACTCGACTGTGTCACTGCTAATCTCTTATTTCTATATGAAAGTA 
                 *** ** ******* **** ** *****  **  *  * * ** ***** *** *** ** 
 
FAM13C1          ACACATTATTTTATCCGTTATTTGAAATTTTACATTTCTGGTTACCAAAGTTCATTCTGA 
1200015N20Rik    GTGCATTATTTTATCTGTTATTTGAAAATTTACATTTCCAGTTACCAAAGTTCACTTGGA 
                    ************ *********** **********  ************** *  ** 
 
FAM13C1          TAGCATGTACTTTGTGAATTATTATCTTTGTCTATAACTGACAGATGTTTATATTAAAAT 
1200015N20Rik    TGGCATGTACTTTGTGA---ATTATCTTTGTCTATGACTGACAAATGTTTATATTAAAGT 
                 * ***************   *************** ******* ************** * 
 
FAM13C1          AAAATATTGTATTAAAAATTTAAAATAGGTATTTTGGATAGATATGTGTCTGTAGTATAT 
1200015N20Rik    AAAATA-------------TTAAAATAGGTATTTTGGATAG--ATGTGTCTGCAGTA-AT 
                 ******             **********************  ********* **** ** 
 
FAM13C1          AATCTAATGTGTCCATAGTATTATTGCTAATCTTTTGGTTTACTA---TAAGATGATATA 
1200015N20Rik    AACCTAATGTGACCATAGTACTATTGCTGATTTTCTTGTTTCCTATACTAAGATTATATA 
                 ** ******** ******** ******* ** ** * **** ***   ****** ***** 
 
FAM13C1          ACTATTTTTTCATTGGGAATATACATTTTTCTTAATGTTCCAACATCTATACTTTGTAAA 
1200015N20Rik    ACTATTTTTCCATTGGGAATATGCATCTTTCTTAATGTTCCAAGGTCTGTACTTTATAAA 
                 ********* ************ *** ****************  *** ****** **** 
 
FAM13C1          GTCAAA-ACATTTCCCATGAGCTGTAGTTATTCATCCTTCTGTACAAAATGAAAAGTTTG 
1200015N20Rik    GTGAAATAACTTTCTTGTGAGCTGCATTCA-------TTCTGCACAGGGTGAAAAGCTTG 
                 ** *** *  ****   ******* * * *       ***** ***   ******* *** 
 
FAM13C1          GAAATTGTTTGCCCTGATACCTTGAAAAAGAAGCCAGAATATTTATTTGCTTCATCAACT 
1200015N20Rik    GAAA----TCACCAAGAGACCT-------------------TTTATTTGCTTTA-----T 
                 ****    *  **  ** ****                   *********** *     * 
 
FAM13C1          TCAGTGTATATCATTTTGTGTTATTTTATACGAAAACATGTTTATTATTTTCATTTTTGT 
1200015N20Rik    TTAGTGTATCTTGCT--------TTTTCTCCACTCACACACTTACTGGTTTGGTTTTTGT 
                 * ******* *   *        **** * *    ***   *** *  ***  ******* 
 
FAM13C1          AAAAGGAAGTAAAAGGTCAACATTTTCTCTCATGTACCAACCTTGTTTGTATTTCTATTT 
1200015N20Rik    AAAATCAAGTAACAGGTAGACATTTTCTCAT---TATCAACATTGTTCCTATTTCTGTTT 
                 ****  ****** ****  **********     ** **** *****  ******* *** 
 
FAM13C1          TCTGTAATGTTTAAGTATGATGTTGAAGAAATTCACATTCTCTTATAGTTTGGATGGGAA 
1200015N20Rik    TCTGTCATGTTTAAGCATGGTGTTGAAGAAACTCAGATTTTCCTATTGCTTGGGCGGAAA 
                 ***** ********* *** *********** *** *** ** *** * ****  ** ** 
 
FAM13C1          GA-----CTATTGACTATTTCAGAAACAGACTTATTTCAGAGGCTTATTGTTTTCTCTGT 
1200015N20Rik    AAAAAACCCAACCCAGATTCTAGACACAGAC-TATGTCAGAGGCGTGTTGTTCTCTCTGT 
                  *     * *      ***  *** ****** *** ******** * ***** ******* 
 
FAM13C1          ATTTACCTAATATTTTATAACTTTTATGAATCAGAATAATGTCCTTCATAAATTTGTTTA 
1200015N20Rik    ATTCACCTGCTG----------TTTATGAATCAGAGTAATGGCCTTCATAAATTTGTTTA 
                 *** ****  *           ************* ***** ****************** 
 
FAM13C1          ATTGAAGTCATCTACTTCTAACAGGACAGATACACAACTATTTGAGGTTTACAAATTACA 
1200015N20Rik    ATCGAAGTCATCTACTTGTAACAGGACAGATACACAACTATTTGAGGTTTACAAATTACA 
                 ** ************** ****************************************** 
 
FAM13C1          TCTTTGATAAGGGAAATGGTTTCGTGACATGTACACAGTTGCTATTAAAATGTAACTCTA 
1200015N20Rik    TCTTTGATAAGGGAAATGGTTTCGTGAGATGTATACAATTGCTATTAAAATGTAAC---- 





FAM13C1          TATATTCTATATGATTGTAAATATTTTATACAACAATACAAATAAAATATTTTTCTATTA 
1200015N20Rik    TATATTCTATATGATTGTAAATATTTTATACAAC-GTACAAATAAAATATTTTTCTATTA 
                 **********************************  ************************ 
 
FAM13C1          TAAAAAA 
1200015N20Rik    T------ 
     




























MUSCLE (3.6) multiple sequence alignment 
 
 
GBA2      -GCCGTCTGAACTGTGGGAGGGAAGTGCTAACAGCCCAGCCTCCAGCCTGGCCTTTCCTC 
Gba2      ATCCCTCTGAACTGTGGA--------------GGCCCAGCCTCCACACTGGAC-CTCCTC 
            ** ************                ************  **** *  ***** 
 
GBA2      CTTCCCCTCTGAACCTCCTGCAACCCTGAGCCATCAGGACAATCATACCCCTTCCCTTCT 
Gba2      CTTCCTCCCACAA-GTCCTGCAGCCCTGAGCCAATAGGACAATCGCGCCCC------TCT 
          ***** * *  **  ******* **********  *********   ****      *** 
 
GBA2      CTCCACCCAATTGTGCCAGTAAATGGGGGTTGAGGGTGACCTAGGCAGCATTAGAATCAC 
Gba2      TCCTTCCCAGCTGTGCCAGTAAAAAGGGGCTGAG-------------------GAACCAC 
            *  ****  ************  **** ****                   *** *** 
 
GBA2      TTATTTATTTCTTTCCTCACCTGTTCCCTGACTGCGTGAAATGTTCAGGGAGGTCAGTTG 
Gba2      TTATTTATTTCTTACCCTACCCAGTCCTTCCATGGATGAAGTATTCA---AGGCCAGTAA 
          ************* **  ***   *** *   **  **** * ****   *** **** 
 
GBA2      ATTTCCCCAGGTACATTCATGGTGTGACAG--ACACATGGGTACAAATAAAAGACCCAGA 
Gba2      ATGTCTCCAAATCTATTCACGGGGCAACAGATACATATGGGTATAAATAAAATACTC--- 
          ** ** ***  *  ***** ** *  ****  *** ******* ******** ** * 
 
GBA2      AAGCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 


































MUSCLE (3.6) multiple sequence alignment 
 
 
LRIG1      GTTTTGTCTACCTCAGTTCTTGTCATACCAATCTCTACGGGAAAGAGAGGTAGGAGAGGC 
Lrig1      GCTTCATCTACCTCAGCTCTT-TTAAAGCAGTCGCTACAGGAA--AGAGGTAGGAGAGGC 
           * **  ********** **** * * * ** ** **** ****  *************** 
 
LRIG1      TGCGAGGAAGCTTGGGTTCAAGCGTCACTCATCTGTACATAGTTGTAACTCCCATGTGGA 
Lrig1      CGTG-GAAAGCTTGTGTCCAGACGTCACTC-----CGGACAGTC-CGACTTCCGTGTGGA 
            * * * ******* ** **  ********        * ***    *** ** ****** 
 
LRIG1      GTATCAGTCGCTC----ACAGGACTTGGATCTGAAGCACAGTAAACGCAAGAGGGGATTT 
Lrig1      ATGTCAGTCAGTCGGCTAGAGGAGTGGCATCTGGAGCTCAG-AAACGTGAGAGACTATTT 
            * ******  **    * **** * * ***** *** *** *****  ****   **** 
 
LRIG1      GTGTACAAAAGGCA-AAAAAAGTATTTGATATCATTGTACATAAGAGTTTTCAGAGATTT 
Lrig1      GTGTACAAAAGGCAGGAAAAAGTATTTGATACCACTGTACATAAGAGTTTTCAGAGATTT 
           **************  *************** ** ************************* 
 
LRIG1      CA-------TATATATCTTTTACAGAGGCTATTTTAATCTTTAGTGCATGGTTAACAGAA 
Lrig1      CATATATATTATATATCTTTTACAGAGACTATTTTAATCCTTAGCGCATGGGT------- 
           **       ****************** *********** **** ****** * 
 
LRIG1      AAAAATTATACAATTTTGACAATATTATTTTTCGTATCAGGTTGCTGTTTAATTTTGGAG 
Lrig1      --------CCCGCTTTTGGTGATA----TTTTCACATTAGGTTGCTGTCTAATTTTGGAG 
                     *  *****   ***    *****  ** ********** *********** 
 
LRIG1      GGGGTGGGGAAATAGTTCTGGTGCCTTAACGCATGGCTGGAATTTATAGAGGCTACAACC 
Lrig1      AGGGTCAGG-AATCGTTCTGGTGCCTTAATGCACAGCTGGAATTCA-------GGTAAAC 
            ****  ** *** *************** ***  ********* *          ** * 
 
LRIG1      ACATTTGTTCACAGGAGTTTTTGGTGCGGGGTGGGAAGGATGGAAGGCCTTGGATTTATA 
Lrig1      ACATC----------AGCTGTTGCTGGCGGTTGGAAAGGAGGGCA--TCTTGG--CTGTG 





LRIG1      TTGCACTTCATAGACCCCTAGGCTGCTGTGCGGTGGGACTCCACATGCGCCGGAAGGAGC 
Lrig1      TGGCACTTA--------------------GTGGTCAGATTCGA-GTGCACTGGCCAGACC 
           * ******                     * ***  ** ** *  *** * **   ** * 
 
LRIG1      --TTCAGGTGAGCACTGCTCATGTGTGGATGCCCCTGCAACAGGCTTCCCTGTCTGTAGA 
Lrig1      TATGCAGGCGTG----------GTGTTG-----------GCAG-----CCTCACTGTAGA 
             * **** * *          **** *            ***     ***  ******* 
 
LRIG1      GCCAGGGGTGCAAGTGCCATCCACACTTGCAGTGAATGGCTTTTCCTTTTAGGTTTAAGT 
Lrig1      GC--AGGGTGCACGGGTC---------TGTAGT--------------------------- 
           **   ******* * * *         ** *** 
 
LRIG1      CCTGTCTGTCTGTAAGGCGTAGAATCTGTCCGTCTGTAAGGCGTAGAATGAGGGTTGTTA 
Lrig1      ------------------------------------TGAGGACGAGATTGAGAGCTGTTA 
                                               * ***   *** **** * ***** 
 
LRIG1      ATCCATCACAAGCAAAAGGTCAGAACAGTTAAACACTGCCTTTCCTCCTCCTCT-TATTT 
Lrig1      ATCCACCAAATGCAATGGCTCAGAACAATTAAGCACTGCCTTTCGTCTTTCTTTGTAACT 
           ***** ** * ****  * ******** **** *********** ** * ** * **  * 
 
LRIG1      TA--TGATAAAAGCAAATGTGGCCTTCTCAGTATCATTCGATTGCTATTTGAGACTTTTA 
Lrig1      CACTTGGTAAAAGCAAATGT---CTT----GTCTCCTTCAGTGGTTCTTTGAAGCTT--- 
            *  ** *************   ***    ** ** ***  * * * *****  *** 
 
LRIG1      AATTAAGGTAAAGGCTGCTGGTGTTGGTACCTGTGGATTTTTCTATACTGATGTTTTCGT 
Lrig1      -AGTGAGGCGGAGGCTGCCAGTGTTGGTACCTGTGGATTTTCCAATAGTGAGGGTT---- 
            * * ***   *******  ********************* * *** *** * ** 
 
LRIG1      TTTGCCAATATAATGAGTATTACATTGGCCTTGGGGGACAGAAAGGAGGAAGTTCTGACT 
Lrig1      --------------------------------------------------AGCTCTGCC- 
                                                             ** **** * 
 
LRIG1      TTTCAGGGCTACCTTATTTCTACTAAGGACCCAGAGCAGGCCTGTCCATGCCATTCCTTC 
Lrig1      -TCCAGGGCCCGCTAAGTTCTGCT---------GAGCAGGCCTGTCCACGCTGTTCCTT- 
            * ******   ** * **** **         *************** **  ****** 
 
LRIG1      GCACAGATGAAACTGAGCTGGGACTGGAAAGGAC---AGCCCTTGACCTGGGTTCTGGGT 
Lrig1      --ACCGGTGAGACTGGGCTTGGACTGTACAAGACTTGAGTCCTAGACCTGGGTGT----- 
             ** * *** **** *** ****** * * ***   ** *** ********* 
 
LRIG1      ATAATTTGCACTTTTGAGACTGGTAGCTAACCATCTTATGAGTGCCAATGTGTCATTTAG 
Lrig1      ---ATTTGCACTTTGGGGCCCTGTTGCTAGCCATCTTGTGAGTGCCAATGTATAATGCAG 
              *********** * * *  ** **** ******* ************* * **  ** 
 
LRIG1      TAAAACTTAAATAGAAACA------AGGTCCTTCAAATGTTCCTTTGGCCAAAAGCTGAA 
Lrig1      TAAAGACTACATGGAAACACAAACTCAGTCCTTAAAAC---------CCCAGGAGTTGAG 
           ****   ** ** ******        ****** ***           ***  ** *** 
 
LRIG1      GGGAGTTACTGAGAAAATA---------GTTAACAATTACTGTCAGGTGTCATCACTGTT 
Lrig1      GGGAAGTGTTGGCACAGTGATGGCCTGTGTCACCGTGTAGTGTCATAGGCCATCACTGTG 
           ****  *  **  * * *          ** * *   ** *****   * ********* 
 
LRIG1      CAAAAGGTAAGCACATTTAGAATTTTGTTCTTGACAGTTAACTGACTAATCTTACTTCCA 
Lrig1      CCAGA-GCAAGCACGCTGAGAAGGCTAGTCTCCATAGTTGA-TGGTTAATGTTACTTCCA 
           * * * * ******  * ****   *  ***  * **** * **  **** ********* 
 
LRIG1      CAAAATATGTGAATTTGCTGCTTCTGAGAGGCAATGTGAAAGAGGGAGTATTAC-TTTTA 
Lrig1      CAAAATATGTGAATTTGCTGCTTCTGAGAGGCAATGTGAAAGAGGAAGTATTACTTTTTA 
           ********************************************* ******** ***** 
 
LRIG1      TGTACAAAGTTATTTATTTATAGAAATTTTGGTACAGTGTACATTGAAAACCATGTAAAA 
Lrig1      TGTACAGAGTTATTTATTTATAGAAATTTTGGTACAGTGTACATTGAAAA-CATGTAAAA 





LRIG1      TATTGAAGTGTCTAACAAATGGCATTGAAGTGTCTTTAATAAAGGTTCATTTATAAATGT 
Lrig1      TATTGAAGTGTCTAACAAATGGCA-TAAAGTGTCTTTAATAAAGGTTCATTTATAAATAC 
           ************************ * ******************************* 
 
LRIG1      CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
Lrig1      TAA------------------------------------------------- 


























MUSCLE (3.6) multiple sequence alignment 
 
 
LRRC59      GCTTGTCCCCAGCACCTGCTGCCTCCCAGCCTTGGAGTTTGGATTCCTATGGAATTGGGT 
Lrrc59      GCTCACCCTCAGCACCCGCTGCCTCCCAGCCTTGGAGCTTGGATTCCTATGGAATTGGGT 
            ***   ** ******* ******************** ********************** 
 
LRRC59      TCTGCTGGACACAACCTCTTTTTAGCATCAGACCTACCTGCCATCATCAAATGGCTGCAG 
Lrrc59      TCTGCTGGACACAACCTCTTTTTAGCGTCAGACCTACCTGCCATCATCACATGGCTGCTG 
            ************************** ********************** ******** * 
 
LRRC59      ATTGGTACATGAGACCTCCTCTTTGTAGGACTTCTTCATTCCTTAGTCAGGGTTCCCTGA 
Lrrc59      G-TGGTACTTGAGATCTCCCCTTTGTAGGACTTCT--GTTCCATAGTCAGGGTTCCCTGG 
              ****** ***** **** ***************   **** **************** 
 
LRRC59      AGGAATGAGGAGAAATGGGAGGTGGCGGGGGGGCGTGGGGGGCAGTTACCTGCATGCCTA 
Lrrc59      TGGAATGAGGAGAAATGGAGAGGGGGGAGGAAG----------AGTTACCTGCATGCCTA 
             *****************   * ** * **  *          ***************** 
 
LRRC59      AAGGAGTAGGCTTGGGGGTGGGGAGAGAGAAAACATAGCCTTTTCTAGTTGTTATATAAA 
Lrrc59      AAGGAGTAGGCTTAGGGGTGGGGAGAGAGAAGGCATAGGCTTTTCTA---GTTATACAAA 
            ************* *****************  ***** ********   ****** *** 
 
LRRC59      GCTGTGTAAAGGCAAGGCTCGTTTCTACTAAATGGTCAGCTGTCACTACATTTATACTTT 
Lrrc59      GCTGTGT-AAGGCAAGGTTCCTTTCTACTAAATGGTCAGCTGTCACTACATTTATACTTT 
            ******* ********* ** *************************************** 
 
LRRC59      TGTATGCCACAAACC----CTTTCATTCCTCCCTGGGAATCAGGGTAGATCAGGAGGAAC 
Lrrc59      TGTATGTCATAAACCCTTTCTTTCATTCCTCCCTGGGTAACCAGGACAATCGGAGGGCAG 




LRRC59      TGGG----GGGGACTAGAACACC----ACGCTCAGTAAATCCAGTCTAAACTGGGAGGTA 
Lrrc59      TGTGTTACTGGGATTAGAGGACTAGCAATACTGGGT-AACCCAGCCTAAGCTGGGAAGGT 
            ** *     **** ****  **     *  **  ** ** **** **** ****** * 
 
LRRC59      GGGGTATTCCTGTTTTCTTTAGGACCTCAGAGATGTAAGCATTTTAGCAGCCACACAAAA 
Lrrc59      GACGTAATAC--GTTTCTTTAAAGATTCAGTCAGTCAAGCAGTTTAGCAA-TATCCAAAA 
            *  *** * *   ********     ****  *   ***** *******   *  ***** 
 
LRRC59      TCTCTGGCTATGAAAGGGACTTCATGACCATCCAGTCCAATATAACACTTGCAGACAGAG 
Lrrc59      TGTCTGGCT--------------------GTTTGGTCCAGTGTCACATGTTGAGGC--AG 
            * *******                     *   ***** * * ***  *  ** *  ** 
 
LRRC59      AAACTGAGGTCT--TCCATGACTTGCC--TAGTCTCCCAGCTAGTTTGAGGCAAAACTGG 
Lrrc59      GAGGTGCCGTCTCATCCATGACTTGCCAGCAGTGTTCAGGCTAGTCTGAGGCACAACCAG 
             *  **  ****  *************   *** * *  ****** ******* ***  * 
 
LRRC59      ATTCCCACTCTGGTATTCTTTCTTCCCTTTACATCATTTTCCCTCCTTTATAATGTCCTG 
Lrrc59      GCTCTCATTCCAGTTTTCCTCCTTCCCTTTATGTCATTCGACCTCCTATATAATACCCAA 
              ** ** **  ** *** * **********  *****   ****** ******  ** 
 
LRRC59      AGAGACCAGAACTCACACCAGAATCGATTATTCCTCAGGTGAAGCATAGACTCTTTCATG 
Lrrc59      GAGGAT--GAACTCACACCAGAGTTG------TCTCAGCTAAAGC---GAATCTTTCATA 
               **   ************** * *       ***** * ****   ** ******** 
 
LRRC59      GTAGACAGATTTCACGACTCAGAGATAGAAATCTCTTGCTATCATCAGGTCACGGG---- 
Lrrc59      ACAG-----TCTTACCACCCACAAATAG--ATCTCATATCATCA--GGGTCCTGGGAAAC 
              **     * * ** ** ** * ****  ***** *   ****   ****  *** 
 
LRRC59      -CAGCTCCTGTGGAGTCCTGCC-CAAC--TTATGTGGCTTCCATAAAATGGCAACAGTCC 
Lrrc59      TTAACTCCTGTGGAATTTTGCCTCAACTTTTAAATGGCTTCCACAAAATGGCAGCAGGCC 
              * ********** *  **** ****  ***  ********* ********* *** ** 
 
LRRC59      AGGCTCCTTGCCT-AATTTTAGAGCATTAACTCCCTAATTGCCAGTAAGCAAGGAGGTGG 
Lrrc59      GGGTTCCTTGCCTCAGTTTTAGAGCATTAACTCCCGAATGGCCTGGAAGCAGAG----GG 
             ** ********* * ******************* *** *** * *****  *    ** 
 
LRRC59      ATCTCTGCAAACCTACACTGTCTATGACAGCTCTAGTTGTACTTGGTGTGACTAAATACC 
Lrrc59      AACTCTGCAAAGCCGTACTG----TGGCTGCTCCACTAGCACTCGGTGTGATGAAATACC 
            * ********* *   ****    ** * **** * * * *** *******  ******* 
 
LRRC59      TCAAAGGCAACCTGCTTCTGCAGGTTTTGAAGTGTCAGCTTCATAAGACACTGAGGTTTA 
Lrrc59      TCAAAGGCAACCTA--------------GAAAC-TTGACTTCATGGAA---GCAGGTTTA 
            *************               ***   *   ******   *     ******* 
 
LRRC59      GAATTGTTTGATTCTAGACC-ATAACTGAAGGGCATAAATGGAAACA------GGATATG 
Lrrc59      GAG----TTGATTCTGGACCTGTAACAGAAGGGAAGGAAGGAAGAGAACAGTGGGAGTCA 
            **     ******** ****  **** ****** *  ** * * * *      *** 
 
LRRC59      AAGGGAAAC-AAGTAGCATCATGGAGCTGAAAAGTGGTGCATCACCCAATGGCTAGCACA 
Lrrc59      AAGGGAAACAAAGTCACATGGTGGCGCTGCAGAGTGATACATAACTAAAC-ATTAGCACA 
            ********* ****  ***  *** **** * **** * *** **  **    ******* 
 
LRRC59      GACAAGGATCACACTGTCCATTCTCTTGTCTGCTA-AATTAAGCATTTTCTTGCCTCCTT 
Lrrc59      -ACCAGGGCAGAGCCGCCCACCTCCCTG-CTGCTACAAGAAAGCATTCTC------CCCT 
             ** ***      * * ***    * ** ****** **  ******* **      ** * 
 
LRRC59      TGCTTCATCTTTTCACAACAGCTGGATAGAGGGATCAGAAATGACTGTGTCATGGTGCTC 
Lrrc59      TTCCCAGTCTCTTCACAACAGCTGCATGAAGGGATCAGAAACAACTGTGTCTCGGTGCTT 
            * *    *** ************* **  ************  ********  ****** 
 
LRRC59      ATTCACTGCAAACTCCCAGTTGCAAGCTCCTTGGCTCCCCCGGAGGGAGCAAGAATC--T 
Lrrc59      ACTTGCTAAAAACTCCCATTTGCAAGCTCCCTAG----------AGGAGCAAGGACCTGT 





LRRC59      CATAGTTCAGAGACACAGAGGGCCTTTTAGCCCTAATGACCT-TTTGGATGGGACTGCAA 
Lrrc59      CATAGTTCAG-----CAG-------TGTAGCCCTAGTGGCCCATCTGGATAGGTCTGCCA 
            **********     ***       * ******** ** **  * ***** ** **** * 
 
LRRC59      CTCATGACTATCCTGATATTAGAAGAAAGGACTTTGTTAATCTTCTCCCCC--ATAGCTC 
Lrrc59      TTCAAAACTGTCCTGACACTGGAAGAAAGGCCTTGG--ATTTTTCCTCCCCAGACAGTTC 
             ***  *** ****** * * ********* *** *  * * ***  ****  * ** ** 
 
LRRC59      TGCTGCGTAGGTCTACATCT-------------TACTCAGAATCACTACACATTCCTTTA 
Lrrc59      TGCCATGTAGGCCCACACCTCCTCAGCATCACCTCCTCAGCATCACTACACGCTCCTTTA 
            ***   ***** * *** **             * ***** **********  ******* 
 
LRRC59      GTCTTCCTCCAAGCTCCAGAGCCATTGGTACAAATGCTTTATTGAAACTAAATACATAAT 
Lrrc59      GTCTTCCTCCAAGCTCCACAGCCATTGGTACAAAGGCTTTATTGAGACAAAATACATACT 
            ****************** *************** ********** ** ********* * 
 
LRRC59      ACACACA----ATGAGATGAAGACAATATAGAAGTCCGCATAGTCATCATAATCCCGTTC 
Lrrc59      ACATACATATGGTGACATCATGAAA--ACAGGAGTCAGCC---TCATCATA-----GCTC 
            *** ***     *** ** * ** *  * ** **** **    ********     * ** 
 
LRRC59      CTTGGCCGGTTGAGGCAGCTCAGTGGCTGAGCCCAGTCAAGCCAACCCGCAG------CT 
Lrrc59      CCTAGCTGGTTGAGGCAGCTCAGTGGCTGGGCGTAGTCAAGCCAACCCGCAGGCAAGAGT 
            * * ** ********************** **  ******************       * 
 
LRRC59      TCACTCACGACTTCAAGATTTGATGCTAATTCTTTTGGATTTCTACAGTTATTAAATAAG 
Lrrc59      TCACTC-TGACTTCGAGATTTGATGCTTATT-TCTTGGATTTCTACAATTATTAAATCCA 
            ******  ****** ************ *** * ************* ********* 
 
LRRC59      TGTCTGAGTGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
Lrrc59      TGTCTGAGTGGTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA---- 

























MUSCLE (3.6) multiple sequence alignment 
 
 
MGC4655     CTCCCCACTACAGCCCCAAGCTCCTA--ACTCAGACCCAGAATGGAGCC----------- 
C76566      TTATCTCTCACGGTATCAAACTTCTCTTACTCAGCTGCAGGACAGAACATGAAAGAACCC 





MGC4655     -----GGTTTCCCAGATTA--TTGCCGTGTATGTGGTTCTTCCCTGATCACCAGGTGCCT 
C76566      AAAGGGGTTTTCCATGTGGGTTTATGGTGTACATGACTTTTCTCCA-------------- 
                 ***** ***  *    **   *****  **  * *** * 
 
MGC4655     GTCTCCACAGGATCCCAGGGGATGGGGGTTAAGCTTGGCTCCTGGCGGTCCACCCTGCTG 
C76566      ------------------------------------------------------------ 
 
MGC4655     GAACCAGTTGAAACCCGTGTAATGGTGACCCTTTGAGCGAGCCAAGGCTGGGTGGTAGAT 
C76566      -----------------------GATCACTCACTGAGAGAGCTAGGGCTGG------GAT 
                                   * * ** *  **** **** * ******      *** 
 
MGC4655     GACCATCTCTTGTCCAACAGGTCCCAGAGCAGTGGATATGTCTGGTCCTCCTAGTAGCAC 
C76566      GA-------------AACAA-----ACACAAGTGGATATACCC----------------- 
            **             ****      * *  *********  * 
 
MGC4655     AGAGGTGTGTTCTGGTGTGGTGGCAGGGACTTAGGGAATCCTACCACTCTGCTGGATTTG 
C76566      -------------------ATAGCCAGGCCTCAG------------CCCTCGTGGACCTG 
                                * **  ** ** **            * **  ****  ** 
 
MGC4655     GAACCCCCTAGGCTGACGCGGACGTATGCAGAGGCTCTCAAGGCCAGGCCCCACAGGGAG 
C76566      G-------------------------------------------CAGGCATTTTCGTATA 
            *                                           *****      * 
 
MGC4655     GTGGAGGGGCTCCGGCCGCCACAGCCTGAATTCATGAACCTGGCAGGCACTTTGCCATAG 
C76566      GTTACTAGCTTCCTTCCTTCTCTCATTGGATTCCCAG--------------TGGCCATAT 
            **     *  ***  **  * *    ** ****                  * ****** 
 
MGC4655     CTCATC---------TGAAAACAGATATTATGCTTCCCACAACCTCTCCTGGGCCCAGGT 
C76566      CTTATCTGTTCCCTTTGAGGTCTGGTGTTAGAGCTAACTAAGCCCTTC--AGGTCGAGGT 
            ** ***         ***   * * * ***    *  *  * **  **   ** * **** 
 
MGC4655     GTGGCTG-AGCACCAGGGATGGAGCCACACATAAGGGACAAATGAGTGCACGGTCCTACC 
C76566      TTGCCTGTAGCATGTGGGGCGGGGCCAT------------CATGTGT-CACCGTCTTGCC 
             ** *** ****   ***  ** ****              *** ** *** *** * ** 
 
MGC4655     TAGTCTTTCCTCACCTCCTGAACTCACACAACAATGCCAGTCTCCCACTGGAGGCTG--- 
C76566      CA--CTATACACAC-------ACACACAAAACCATGCCAGTGTACTTCTGAAGGGTGACC 
             *  ** * * ***       ** **** *** ******** * *  *** *** ** 
 
MGC4655     TATCCCCTCAGAGGAGCCAAGGAATGTCTTCCCCTGAGATGCCACCACTATTAATTTCCC 
C76566      CATCCCCCTCCCGG----AAGGAGT-------CCTAAGATTCCTCCACTATAAGATTGCT 
             ******     **    ***** *       *** **** ** ******* *  ** * 
 
MGC4655     CATATGCTTCAACCACCCCCTTGCTCAAAAAACCAATA-CCCACACTTACCTTAATACAA 
C76566      CATATTCTTCAACTCCAGCTTCA---AGGAAATCAACAGCTCACATT----TTAGTACAA 
            ***** *******  *  * *     *  *** *** * * **** *    *** ***** 
 
MGC4655     ACATCCCAGCAACAGCACATGGCAGGCCATTGCTGAGGGCACAGGTGCTTTATTGGAGAG 
C76566      ACAGCCCAGTGGCAGCACATGGCACGCTGTCACTGTGGGCATAGGTGCTTTATTGGAAGG 
            *** *****   ************ **  *  *** ***** ***************  * 
 
MGC4655     GGGATGTGGGCAGGGGATAAGGAAGGTTCCCCCATTCCAGGAGGATGGGAACAGTCCTGG 
C76566      GGGACG-------------AGGAAGTCTCCTCTGAT-CACGAGGATGGGAAGAGTCCTGG 
            **** *             ******  *** *   * ** *********** ******** 
 
MGC4655     CTGCCCCTGACAGTGGGGATATGCAAGGGGCTCTGGCCAGGCCACAGTCCAAATGGGAAG 
C76566      CTA-CCCTGACAGT-GGGATGTGC-AGGGTCTCTGGCCAGACGAAGGTCCAAATGGGAAG 
            **  ********** ***** *** **** ********** * *  ************** 
 
MGC4655     ACACC-----AGTCAGTCACAAAAGTCGGGAGCGCCACACAAACCTGGCTATAAGGCCCA 
C76566      ACACCTGTCAAATCAGTCA-------TGGGAGTGCCACACAGGCCTGGCTGT-AGGCCCA 





MGC4655     GGAACCATATAGGAGCCTGAGACAGGTCCCCTGCACATTCATCATTAAACTATACAGGAT 
C76566      GGAACCATACAGACAGCTGGGGCAGGTCCCCTGCACATTCATCA-TGAACTATACAAGAT 
            ********* **    *** * ********************** * ********* *** 
 
MGC4655     GAGGCTGTACATGAGTTAATTACAAAAGAGTCA-TATTTACAAAAATCTGTACACACATT 
C76566      GAGGCTGTACATGAGTTAATTACAAA—AGTCATTATTTACAAAAATCTGTACACACATT 
            **************************  ***** ************************** 
 
MGC4655     TGAAAAACTCACAAAATTGTCATCTATGTATCACAAGTTGCTAGACCAAAATATTAAAAA 
C76566      TGAAAAACTCACAAAATTGTCATCTATGTATCACAAGTTGCTAGACCAAAATATTAAAAA 
            ************************************************************ 
 
MGC4655     TGGGATAAAATTATAAAAAAAAAAAAAAAAAA 
C76566      TGGGATAAAAT--TAAAAAAAAAAAAAAAAAA 











MUSCLE (3.6) multiple sequence alignment 
 
 
MORG1           AGCCAGGGGACCCACCAACAGGACCAAGGACCGAGACACAGACATGGAAGGACT--TCAG 
1500041N16Rik   GGCTTACGGACCTGAC------ACCAAGGATGCAG--ACTGACTCAGAAAACCCAACCAA 
                 **    *****   *      ********   **  ** ***   ***   *    ** 
 
MORG1           ATACCATCTTATTCTAGAGACGTAGCTGACCAAAAAGTAG-----GGGAGGGGCTGGGTC 
1500041N16Rik   AGGGCCATTTATTCTAGAGATGCTGCTGACCAAGGAGTGGGCCTAGGGAGGGGCT-GGCA 
                *   *   ************ *  *********  *** *     ********** ** 
 
MORG1           TGCAAATTAATAAATAGAAGAGGGGGTAAGACCTTCCTGGGACCGCAAAAAAAAAAAAAA 
1500041N16Rik   TGTAAAGTAATAAATAAAGGTGTGGCAAAAAGCCTC---AGTCTTTACCAA--------- 
                ** *** ********* * * * **  ** * * **    * *   *  ** 
 
MORG1           AAAAAAAAAA 

















































MUSCLE (3.6) multiple sequence alignment 
 
 
PDSS1      CAACTCTTTCTGTTCTTTCTGGCAGCTATCTTACCAGACTGTGCCTAAAGAATTTTGTGG 
Pdss1      CAATTCCTCCTCTTCTTTCTGGCAGCTATTTTACCAGACTGTGCCTAATG-ATTTTGTGA 
           *** ** * ** ***************** ****************** * ******** 
 
PDSS1      AATACACTTTGTTTGCTTCATGTGCAGATAACCAAAAATCATTTTAAAAGATA---TCAA 
Pdss1      AACAC----TATTTGCTTCATGTGCAGAAAACCAAAAATCATTTTAAGAAATAATTTCAA 
           ** **    * ***************** ****************** * ***   **** 
 
PDSS1      ACTTATTGATGGGCAATTTATTTTTTTTTATTGCAAAAGTTTTTTCAGAAAACTTTTTAA 
Pdss1      CCTTATTGATGGGCAA--------TTTTTATTGGCAAAG-TTTTTCGGAAAACTTTTTAA 
            ***************        *********  **** ****** ************* 
 
PDSS1      ATGTAATTAATAAACCACCTGAATCTGTCATTCTAGTCCTATAAATTATAATCAAGGTAT 
Pdss1      ATGTAATTAA------ACCAG----TGTCATTATAGTCCTATAAATTCTAATCGAGGTAT 
           **********      *** *    ******* ************** ***** ****** 
 
PDSS1      CTTGATGGTTATATGTGGTATTGTTTACACTGTTAATATCCACATGTAAGGCCATTACAC 
Pdss1      CCTGATGGTTATATGTGGTATTGTTTACACTGTTAATGCCCACATGTAAAGCCATTACAC 
           * ***********************************  ********** ********** 
 
PDSS1      AAATAAATAACCAATGTTAAAATTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
Pdss1      AAATAAATAATCAACGTT------------------------------------------ 
           ********** *** *** 
 
PDSS1      AAAAAAAAAAAAAAAAAAAAAAAAAAAA 
Pdss1      -----------------------AAAAA 












MUSCLE (3.6) multiple sequence alignment 
 
 
PHYHIPL      TGCCCACTTTTCTTATTCTTACTCAGCC-------CCTTTTCCTCCCTTAGGAGCATTGG 
Phyhipl      ---ACACCACTTTCGCCCCTTCCCCGCCCCACACACCCTGTCTTCCCATAGGAGCATT-A 
                 ***   * *    * * * * ***       ** * ** **** ********** 
 
PHYHIPL      TCCTCTGTTGTCCATTTTTATCACCAGATGTTTTCCACTGAAGCATGCACATGCCACTGT 
Phyhipl      CCCTCTGTTGTCCA--TCTGCCATCAGATG-TCCCCACTGAAGCATGCATATGCCGCTGT 
              *************  * *  ** ****** *  *************** ***** **** 
 
PHYHIPL      CACCAAAA-CAAACAACTACCACTTTCCAAATTTCATTCAGAACCATTTTAGTGTTTTCC 
Phyhipl      CACCAAAAGCAAAC-----------TC----TGTCATTCAGAGCC-TTTCCGTGTCTCCT 
             ******** *****           **    * ********* ** ***  **** * * 
 
PHYHIPL      TATTCCCTACCCCTCCCACTACTTTCAATGATGAAATACCCTAAGTTAAGTTCTCCTTTT 
Phyhipl      CTTGCCCGCCCTTGTCCACCACTTTCAACGATG----TCCCCAGGTTG--------TCCT 
               * ***  **    **** ******** ****     *** * ***         *  * 
 
PHYHIPL      GACACTTTATTGCCTAGATGCTGCAATGTTTTTATGTTTCCTTTATGCCAAACATAACAA 
Phyhipl      GACACTGT-TTGCCTAGATGCTGCAATGCTTTTATGTTTCCTTTATGCCAAACATAACAA 
             ****** * ******************* ******************************* 
 
PHYHIPL      AACAGTTATATAGACTGCTTTAGCAAAGTACACAATAATGGCTTATAAATGGTGTTTAAA 
Phyhipl      GACAGTTATATAGACCGCTTTAGCAAAGTACAAAATAATGGCTTATCAATGGTGTTTAAA 
              ************** **************** ************* ************* 
 
PHYHIPL      TATGCATTCATTTTAATCTACTGAACAAATATTGGGATAACTCCAAACCGCATGAAAGGG 
Phyhipl      TGTGCATCCATTTTAATCTACTGAATAAATATCGGGATAACTCCAAACCGCATGAGAGAG 
             * ***** ***************** ****** ********************** ** * 
 
PHYHIPL      TGTAATTGCAGCATGAGTTAAATCTT-GAAGCCTAGAATTGTCAGCACTTCCAACTTCTT 
Phyhipl      AGTAATTGCAGCATGAGTTAAATCCTAAAAGCCTAGACTTGTCAGCACTTCCGCCTTGTT 
              *********************** *  ********* **************  *** ** 
 
PHYHIPL      GTTTGACAGTGTTATTTATGTTATTTATATTAGCTAACAGGAAACAACTACTGTG-TTTC 
Phyhipl      GTTTGACAGTGTTATTTATGTTATTTATATTAGCTAACAGGAAACAGTTACTGTGCTTTC 





PHYHIPL      AACATAATAAATATAATAGAAAAATATTTTATTTGTATTGTTGTATAAAATATTTACAAT 
Phyhipl      AACATAATAAATATAATAGAAAAATATTTTATTTGTA-CGTTGTATAAAATATTTACAAT 
             *************************************  ********************* 
 
PHYHIPL      CATATAGAATATATAGAGTTACATTTTAATAGCAACTGTGTACATGTCACGAAACCATTT 
Phyhipl      CATATAGAATAT----AGTTACATTTTAATAGCAATTGTATACATCTCACGAAACCATTT 
             ************    ******************* *** ***** ************** 
 
PHYHIPL      CCCTTATCAAAGATGTAATTTGTAAACCTCAAATAGTTGTGTATCTGTCCTGTTAGAAGT 
Phyhipl      CCCTTATCAAAGATGTAATTTGTAAACCTCAAATAGTTGTGTATCTGTCCTGTTACAAGT 
             ******************************************************* **** 
 
PHYHIPL      AGATGACTTCAATTAAACAAATTTATGAAGGACATTATTCTGATTCATAAAAGTTATAAA 
Phyhipl      AGATGACTTCGATTAAACAAATTTATGAAGGCCATTACTCTGATTCAT----------AA 
             ********** ******************** ***** **********          ** 
 
PHYHIPL      ATATTAGGTAAATACAGAGAAAACAATAAGCCTCTGAAATAAGTCTGTTTCTGAAATAGT 
Phyhipl      ACAGCAGGTGAATACAGAGAGAACAACACGCCTCTGACAT-AGTCTGTGTCTAGAATCTG 
             * *  **** ********** ***** * ******** ** ******* ***  *** 
 
PHYHIPL      CAATAG-----TCTTCCCATCCAAACTATAAGAGAATGTGAATTTCTTCAACATCATACT 
Phyhipl      GGTTGGGTTTTTTTTTCCGCCCAAGCAATAGGAAAATCTGAGTTTCTTCAACACCATGCT 
                * *     * ** **  **** * *** ** *** *** *********** *** ** 
 
PHYHIPL      TAAACATTACAGAAAATAGAAATACAAACAAGGTTGGTACATGAGAGAAAATGTTGACCT 
Phyhipl      TAAACATGACAGAAAACAGAAATAGGAACAATGTTGATA---ATGAGAAAATGTCTACCT 
             ******* ******** *******  ***** **** **     **********  **** 
 
PHYHIPL      TTTACTTCCTTTTACAAAAATGAAAATAATAAACATGTTTTCGTATAAAATAACACAAAA 
Phyhipl      GTTACTTGATTTTACAAAAACCAAACCAGTAAGTGTGTGAGTGGAGAA--------AAAG 
              ******  ***********  ***  * ***   ***    * * **        *** 
 
PHYHIPL      TGATATACACTGAAGTTGATGAAGCAAATAAATATTCTGGCTTCTTTTTCAAGGTATCAG 
Phyhipl      CAAGATACACTAA-----ATAAAGCAAATAA-------------------AAGGTCTCTT 
               * ******* *     ** **********                   ***** ** 
 
PHYHIPL      GGCAAACAATTTCCAAACTTTTCATTTTGTACAGAAGGATGAATAACTACAGCTCATGGG 
Phyhipl      GG----TGATTTCCAAGCTTTTCACCCTGTGCA-------GAATGAATGCAGCTCACAAG 
             **      ******** *******   *** **       **** * * *******   * 
 
PHYHIPL      AAATGT-TTTGACTTTACAAAGTATAGATGTTGGAACATTAAGAAAAATGTATATTCCCA 
Phyhipl      AAAGTTATTTCACTTTATAAAGTACAGACCTTGGAACATTAAGAAAGATGCATATTCCCA 
             ***  * *** ****** ****** ***  **************** *** ********* 
 
PHYHIPL      ATGAAAAAATAGTTATATCATCT---TATAGTAAACCAAAAGATTAGCAATAATACTATG 
Phyhipl      ATGGAAAAATAGTTATATAATCTTAGTATAGGAAACAAGAAAATCAGCAATAGTACTATG 
             *** ************** ****   ***** **** * ** ** ******* ******* 
 
PHYHIPL      GACACATTAGATTATATACTACAGACACATATCTATCCAAAATACCTATTTTAAATTTTT 
Phyhipl      GTCACATTAGGTTAT-TACTGCAGACAC--ATCTATCCAAAATACCTATTTT-------- 
             * ******** **** **** *******  ********************** 
 
PHYHIPL      AATACAATATTTTATTTTAATATAAACATCTGTCAGTTATAGACAAAGATAATAATTCAC 
Phyhipl      -----AATATTTTACTTTAATATAAACATTTGTCAGTCATAGACAAAG---ATAATTCAC 
                  ********* ************** ******* **********   ********* 
 
PHYHIPL      AAAGTACATGCTATCAGAATGAACTTTGGTAACCAGAAATGTAAAATTTCAAATAACGGA 
Phyhipl      AAAGTACATGCCATCCAAGTGAACTTTGGTAACTGGAAATGTAAATTTTCAAATAACAGA 
             *********** ***  * **************  ********** *********** ** 
 
PHYHIPL      TAAAATAATGTGTTATTTTTATAGAGAAAGAAAAAA--AATAGCAACACAATCTAGTTTA 
Phyhipl      TAAAATAATGCACTACTTTCATATAGAAATAAGAGATTACCAGTGACACAGTCGAG-TTA 





PHYHIPL      TTTTAGGGTACTGAGAGCCTAGCAGACTTAAAGGACAAGGTAGTAAATGTTTTATCACTC 
Phyhipl      TTTTAGAGTGCTGAACGCCTA-CAGGCTTACAGGACAAGGTAGTGGATGTTGTCTCGCT- 
             ****** ** ****  ***** *** **** *************  ***** * ** ** 
 
PHYHIPL      AAAAATCCATTAGAAGTTTCAAATAAATTGCTTTCTTGCTAGCTGTATTCCTTCCTACTT 
Phyhipl      -----------------------TAAATTACCTTCCTTCTAGCTGTTTTCCTCCCTGGGT 
                                    ****** * *** * ******** ***** ***   * 
 
PHYHIPL      GAAAAGCGAA---TTTCTTTTCCTCCTATGATTGATTTTTTAAAATCATGCTCTTTTCCA 
Phyhipl      GAAGAGCAGAAATTTTCTTTGTCTC-----ACCAATGTATTTAAACCATGCTC-TTTCCA 
             *** ***  *   *******  ***     *   ** * ** *** ******* ****** 
 
PHYHIPL      TACATCAACATAAACAGTCTTTGGATACTAAATAAACTTTCCCTAACAAGAAAAAAAAA 
Phyhipl      TACATCAATAAAATCAATTTGGGGCCACTA-----------CC---------------- 


























MUSCLE (3.6) multiple sequence alignment 
 
 
PPIL2      CAGCAGCAACTTGCAGGCTGTACCTCTGCCCTTCCTTTTCTCATCAATCACTGATGCTGA 
Ppil2      CAGCAG------GCTGGC---------------------CTCAGGGATC----CTGTGGA 
           ******      ** ***                     ****   ***     **  ** 
 
PPIL2      AGCTGCAGGCCTGAGCCCTTTGTCTCCCTGGATGCTGGGTGGCGCCTCATCTGCATCTCT 
Ppil2      TGCTGCAGGAACGAAC----------------------GTGGC------------TCGCC 
            ********   ** *                      *****            ** * 
 
PPIL2      GCCTCACCC-CATCCACTGCCACAGGCTGCCTGATGACCACTAGAGGTATGTCTGCCCCT 
Ppil2      GCCGCCCCCACCTCCACCCCCA----------------------------------CCCT 
           *** * *** * *****  ***                                  **** 
 
PPIL2      CGTCACCCTGCTGCACACCAATCTGTGGCCCTTCATCATGCTAAGAACAAGAACTGCGCC 
Ppil2      GGGAACCTTGCTG----------TGTGAC----------------GACAGGAGCT----- 
            *  *** *****          **** *                 *** ** ** 
 
PPIL2      ATGGCTGGCTCCTTCTCTTCTCCAGCCCATCCCTCTGCAGCCTGTCATCCCTGTCTGTGA 
Ppil2      -----TTATTTTATACCTCCCACAG-ACACGCCACAGAGGGCTGACAGCTTTGGCTAGGA 





PPIL2      CCATTGGTCGGGCCCCTGGGCTCTAGAGTGACTTTTGACGCCCTCCATCCCTCCCGCCAG 
Ppil2      -----GACAGGG----------------------------------------------AG 
                *   ***                                              ** 
 
PPIL2      GCACTGTCCTCCGCAAGGCCTGGTGCAGCCCTGGCAGTAACTGGCTTGTAAGAGGCTCAG 
Ppil2      GC-----------CAAGGC--------GCTCT-----------GTTTGCTCGAGCTT--- 
           **           ******        ** **           * ***   ***  * 
 
PPIL2      ACACCAAGCTGGGCCTGCAGAGGAGGGGCACAGTAGGACACAGTGACTGCCCAGGTGTCC 
Ppil2      -------GCTGGTCCTGCTG----------------------------TTCTTGGTGAAC 
                  ***** ***** *                              *  ****  * 
 
PPIL2      ACACACCTGTAGGCCTCTGAGCCAGCGTCCAGGGTACAGGTGCGGGTGGTGGGGATGAAG 
Ppil2      TC---CCTGTGGGT-------------TCCACAGCAC---TGCAGTC-----------AG 
            *   ***** **              ****  * **   *** *             ** 
 
PPIL2      GCCTGACCAGGGAGGGAGAAGCAGGTTTGGAGAGGACCCTGTGCCCACCCTGACAGACAC 
Ppil2      CCTTGCTCAGCAGCCGACA------------------CCTGTCCCCA---GGGCAGGCA- 
            * **  ***     ** *                  ***** ****    * *** ** 
 
PPIL2      CCTGGCTGGCCCTGACTGACTGTATTCTCTGGCCACATTCAAGTCCCCCATTGGTGGGGG 
Ppil2      ------------------GCTGTGTCCTC---------TCCTGTCCTCCA---------G 
                              **** * ***         **  **** ***         * 
 
PPIL2      CAGAGAAGTAGGACCAGGCCATCCTTGGCTCCAGAGCTCGAAGACCCCAAGACAGCCCTC 
Ppil2      CACAGAGGACAGACCA--------------CCAGGGCTTGCA------------------ 
           ** *** *   *****              **** *** * * 
 
PPIL2      TGCTCTCAGCGGCGCCACAGAGAGCCTGGGCTCAGCCTTCTGCATC----AGGACATGGC 
Ppil2      ---TTTC-----------------CATGGG-TCGGTTGTCTATAGCTTAAATGGTAGTGT 
              * **                 * **** ** *   ***  * *    * *  *  * 
 
PPIL2      CTCGTCCACTGAGGGCACGATTTAAACATTTGACATCAGAAGCTTTATTTGTAAACCTCA 
Ppil2      TTTAGACAGTAAAGACAC----------TTGGATTTTGAAAAC--TGCCTGATGAGCTCA 
            *    ** * * * ***          ** **  *   ** *  *   **   * **** 
 
PPIL2      CACAGATAAGGACCAAGGGCTGGCGGTGTGGCCAGAGGACAGGGGAAGCTGAAGGCCCCG 
Ppil2      T-CAGAAA---ATAAAGGACTTTTG---------------AGGGGAAA--AAAAATCTCA 
             **** *   *  **** **   *               *******    **   * * 
 
PPIL2      TGCTTGAGCTCGGCAGTCCTGCTCCTTGCAGTGAAGCCACCATGGGTGACCGTCCAGCCT 
Ppil2      TTTCTGATCTCTTCAA----ATACCTGACA--GATGCCATCAAGAATAAGCATT------ 
           *   *** ***  **        ***  **  ** **** ** *  * * * * 
 
PPIL2      CACCCGGTGGCCTGCACAGTGAGGGAAGGGCTTCAGGGCCATCTGCTCCCAGGGCAGGGG 
Ppil2      --------------------------AAGGTATAAAAATACTATGTATACA------GTA 
                                     * **  * *      * **    **      * 
 
PPIL2      ACAGGCCACCAAGGACCTTTGGCAAATGAAGGTTTACATTTCTGTAGTTTGTTTGTTTTA 
Ppil2      ACAAGACAACAAGG---------AAATAAA---CCACATTTCT----------------- 
           *** * ** *****         **** **     ******** 
 
PPIL2      GAGCTTAATTTGTAGTTTTTTAGCTATTAAAACCATTTGAATTTTTAACGACCTGAAAAA 
Ppil2      ------------------------------------------------------------ 
 
PPIL2      AAAAAAAAAAAAA 
Ppil2      -----AAAGCAAA 





























MUSCLE (3.6) multiple sequence alignment 
 
 
PPP1CA      CCCCCGCACACCACCCTG-TGCCCCAGATGATGGATTGATTGTACAGAAATCATGCTGCC 
Ppp1ca      CCTCCATGTGCTGCCCTTCTGCCCCA-------GATCGTTTGTACAGAAATCATGCTGCC 
            ** **     *  ****  *******       *** * ********************* 
 
PPP1CA      ATGCTGGGGGGGGGTCACCCCGACCCCTCAGGCCCACCTGTCACGGGGAACATGGAGCCT 
Ppp1ca      AT---------GGGTCACACTGGCCTCTCAGGCCCACCCGTCACGGGGAACACACAGCGT 
            **         ******* * * ** ************ *************   *** * 
 
PPP1CA      TGGTGTATTTTTCTTTTCTTTTTTTAATGAATCAATAGCAGCGTCCAGTCCCCCAGGGCT 
Ppp1ca      TAA-GTGTCTTTCCTTTA-TTTTTTAAAGAATCAATAGCAGCATCTAATCTCCCAGGGCT 
            *   ** * **** ***  ******** ************** ** * ** ********* 
 
PPP1CA      GCTTCCTGCCTGCACCTGCGGTGACTGTGAGCAGGATCCTGGGGCCGAGGCTGCAGCTCA 
Ppp1ca      CCCTCCCACCAGCACCTGTGGTGGCTGCAAGTGGAATCCTGGGGCCAAGGCTGCAGCTCA 
             * ***  ** ******* **** ***  **  * *********** ************* 
 
PPP1CA      GGGCAACGGCAGGCCAGGTCGTGGGTCTCCAGCCGTGCTTGGCCTCAGGGCTGGCAGCCG 
Ppp1ca      GGGCAATGGCAGACCAGATTGTGGGTCTCCAGCCTTG--------CATGGCTGGCAGCCA 
            ****** ***** **** * ************** **        ** *********** 
 
PPP1CA      GATCCTGGGGCAACCCATCTGGTCTCTTGAATAAAGGTCAAAGCTGGATTCTCGCAAAAA 
Ppp1ca      GATCCTGGGGCAACCCATCTGGTCTCTTGAATAAAGGTCAAAGCTGGATTCTC------- 
            ***************************************************** 
 
PPP1CA      AAAAAAAAAAAAA 











































MUSCLE (3.6) multiple sequence alignment 
 
 
RAD9A      A-CCAAGAACCTGAAGCCTGTACCCAGAGGC-CTTGGACTAGACGAAGCCCCAGCCAGTG 
Rad9a      ATTTGAGAAATTAAAGTCTGTGTTCAAAGGCTCACGGACCAGAAGCAGGCCCGCCCA--- 
           *    ****  * *** ****   ** **** *  **** *** * ** ***  *** 
 
RAD9A      GCAGAACTGGGTCT-----CTCAGCCCTGGGGATCAGAAAGGTGGGCTTGCTGGAGCTGA 
Rad9a      -CTGAGTTGGGCGTCAGTCCTTAGACATGGACATGGAAATGGAAA-------------AA 
            * **  ****  *     ** ** * ***  **   ** **                 * 
 
RAD9A      GCTGTTTCACTGCCTCTCGCAGGCCCCAGCTGGCTGTC-ACTGTAAAGCTGTCCCACAGC 
Rad9a      G-----------------GCATACCCCACTTGGCTGTCTGCTGCAGAGCTGCC---TAGG 
           *                 ***  *****  ********  *** * ***** *    ** 
 
RAD9A      GGTCGGGCCTGGGCCGT----TATCTCCCCACAACCCCCAGCCAATCAGGACTTTCCAGA 
Rad9a      AACCATGTTTGGTCTGTGTTCTGTATTTATTCAGCCTATA-CCAATCATGTCT------- 
              *  *  *** * **    * * *     ** **   * ******* * ** 
 
RAD9A      CTTGGCCCTGAACTA----CTGACGTTCCTACCTCTTATTTCTCATTGAGCCTCAGGCTA 
Rad9a      -CTGGTGCCCACCTGTCACCTGACAGATC--CCTCATCCTTTACTTTGAGGCTCTAGA-A 
             ***  *  * **     *****    *  **** *  **  * ***** ***  *  * 
 
RAD9A      TACTCCAGCTGGCCAAGGCTGGAAACCTGTCTCCCTCAGGCTCACCTTCCTA----AGGA 
Rad9a      TACAAATTCTGGCCAAAGCCAGAAACTTAGCTTCCTCAGTCTCCTGCCTCTAAAACAGGA 
           ***     ******** **  ***** *  ** ****** ***      ***    **** 
 
RAD9A      AAATGTCATAGTAGGTGCTGCTGGCCCCTGGTGATCCAGCTTCTCTGCCAATCATGACCT 
Rad9a      AGAT------------------------CAGTATTGAACACCCTCTGCCAATCATGAAC- 
           * **                          **  *  *    *************** * 
 
RAD9A      GTTCCTTCCTGAAGTCCTGGGCATGCATCTGGGACCCCCGTG-GAGCTGACAAGTTTTCC 
Rad9a      --------------TCCCCGCCA---------GACCCTCCTGTGGGCCAAAGGAACTGTT 





RAD9A      TTGCTTTCCTGATACTCTTTGGCGCTGACTTGGAATTCTAAGAGCCT-TGGACCCGAGTG 
Rad9a      TCTCTTTCCTAACA--CTTGGGCCTTGGCCTAGAATCCTAATAGCCTCTGGACCTGATTG 
           *  ******* * *  *** ***  ** * * **** **** ***** ****** ** ** 
 
RAD9A      TGTG--GCTAGGGTTGCCCTGGCTGGGGCCCGGTGCCGAGA-----------CTCCCAAG 
Rad9a      TGTGTCACTGGTGTTGCCCTGGCTGGGCCCATGTTCAGCCACTCAGTCTGCCCTCCCAGG 
           ****   ** * *************** **  ** * *  *           ****** * 
 
RAD9A      CGGCTCTGTGCAGAAGAGCTGCCAG-GCAGTGTCTTAGATGT-------GAGACGGAGGC 
Rad9a      TGGCTTTGTACCAAAGAACTGCTGGCCCACTGTCTGGGACGGGACAAGAGAGACAGAGGC 
            **** *** *  **** ****  *  ** *****  ** *        ***** ***** 
 
RAD9A      CATGGCGAGAATCCAGCTTTGACCTTTATTCAAGAGACCAGATGGGTTGCCCCAGGATCC 
Rad9a      TATGGTGAGAATCCAGCTTTGACCTTTATTCAAGAGACCAGATGGGTTGCCCCAGGATCT 
            **** ***************************************************** 
 
RAD9A      GGCTGCCAGCCCTGAGGCCAAGCACGGCTGGAGACCCACGACCTGGCCTGCCGTTGCCCT 
Rad9a      GGCTGCCAGCCAT--------GCAAGGCTGGAGACCCACAATCTGGTCTGCCATTGCCCT 
           *********** *        *** ************** * **** ***** ******* 
 
RAD9A      GAGCTGCAGCCTCGGCCCCAGGATCCTGCTCACAGTCACCGCAGGTGCAGGCAGGAAGCA 
Rad9a      GAGCTGCAGCCTTGGCCCCAGGATTCCACTTGCAGCCACCACAGGTGCTGGTGGGAGGGA 
           ************ *********** *  **  *** **** ******* **  *** * * 
 
RAD9A      GCCCTGGGGGACTGGACGCTGCTATTGATTCATTAAAAAAAGAAAAGAAAAATACAAAAA 
Rad9a      GCCCTGGGAGATTAGATGCTGCTATTGATTC-TTTAAAAAATAAAGGAAAGACACTT--- 
           ******** ** * ** ************** ** ****** *** **** * ** 
 
RAD9A      AA 



























MUSCLE (3.6) multiple sequence alignment 
 
 
SLC12A6      CCTACTCTGAATGACCGTGCTTGACCTGTTTTCTTAAAAGGCCTACGTCCTCCATGGAAG 
Slc12a6      TCAGCTGTGGGAGATTCTGCGTGGTCCGACTTCCCTAAGA---CTCATCGTCCATGGAGA 





SLC12A6      TGCCAGCTCATTACTACCACTCCCACTCAACTAGAAGCCTGTGTTCTGTACACATCATAC 
Slc12a6      TGATAGCTCTTTCCTACCACTCCCACTC-------------------------------- 
             **  ***** ** *************** 
 
SLC12A6      TGAACTCTTGATGAGCTGAGCCTCAAGTA----CCTGTGTAAAAGAGCTCCCATCTGATC 
Slc12a6      --TATTCTTGCAGAGCTGAGCCCCATCTATGCTCTTG---------GCTGCAACATGATC 
                * *****  ********** **  **    * **         *** * *  ***** 
 
SLC12A6      TGCAGTCATTACAGAAAAAGCAAATATTCCCTCAACATCAGAACAATGCTCAAGTCTTTC 
Slc12a6      TGC---CATCCCAGCAGAAACAAATAATCCCTCAA---CAGAAGAATGGTCAAGTCCTAA 
             ***   ***  *** * ** ****** ********   ***** **** ******* * 
 
SLC12A6      AAGCCACGTCTG-AGCAGTCAAAGGCAAATTAGAATTAACAAGCTGAGCCAATA------ 
Slc12a6      AAGCTATTTCTATGGCAGGAGAAGGCAAGTCAAAATTAACAAGCTAAGCCAAAGGGAACC 
             **** *  ***   ****   ******* * * ************ ****** 
 
SLC12A6      ------------------AATGAATTGGTAAAAGGGATGCTAGAAATTCAACTGAAGAAA 
Slc12a6      TTTTGGCACACAGAAGGTAATGAGTTAGTAAAACATATGCTAGAAATGTAACTGGCAACA 
                               ***** ** ******   ***********  *****   * * 
 
SLC12A6      AAAAGCAAGTCAAGTACGTATTCAGCATTAAAGATGAATCTCAGAAGTCATGGTTCAATG 
Slc12a6      GAAAGCAAT----GTTCATATCTAACATTCAGGACGAGTTTCAGAAGACACGGGTCAGTG 
              *******     ** * ***  * **** * ** ** * ******* ** ** *** ** 
 
SLC12A6      TTGACACTGTGAGGATAACAACTAGAGACAGCTTCATCTTACTAAAGAATTTATGGTCAA 
Slc12a6      --AGCACCAGAAAGTTAACAGGCAGTTA-AGCTTCACCTTAGTAAAAAATGAGTTCCCA- 
                 ***    * * *****   **  * ******* **** **** ***   *   ** 
 
SLC12A6      GTATATTTGGACCTATTATCCTCGGCAAGCCAAGATGCAAACATTTTTTAGCTATATTTC 
Slc12a6      --TTATAGAGAC-----AGCCTGCAGCAGCCAGGATGGAAAC------------------ 
                ***   ***     * ***     ***** **** **** 
 
SLC12A6      TTTAGTATACCCACTGCTGTAATTTTATATTAGGATACTAACTTGAAACATGGCTGCAGC 
Slc12a6      ---AGGATACTGA------------TATATAA-------AACCTGAGACATAGCTGCAGC 
                ** ****  *            ***** *       *** *** **** ******** 
 
SLC12A6      CTCTACTTCTTCAAAAACATCCCCCCAAAATACCAGATTTAAATATCCAAATACTGTGTC 
Slc12a6      CACTACTTCTTC-------------------CTCATGGTTTATTGTCT--GTACTGTACC 
             * **********                     **   ** * * **    ******  * 
 
SLC12A6      AGTGTATACTTCAACTGTTTTGTTTCTCTTAACTCAAAACCCATTCTGTCATTGTAACAC 
Slc12a6      ACTGTACATTTTAACTGTCTTTGTT--------TTAAAACCCATTCTGTGGTTATAATGC 
             * **** * ** ****** **  **        * **************  ** ***  * 
 
SLC12A6      AG---GCAGTGTTACCATGGAAATTGTTTTTGGTAAGGTAAAAATTATTTCTTTCAGGTT 
Slc12a6      AGACAGTAGTGTTACTATAGAAATGTTTTTTTGAAAGGCTAGAAATGTTT-TTTCAGGT- 
             **   * ******** ** *****  ***** * ****  * ** * *** ******** 
 
SLC12A6      CCTTTCAAATGGCCGAACTAAGAGAACTCCAAAAGGAAGCTATTAACATTTACTGAAATA 
Slc12a6      --TTTCAAAT-GCTGAACTAAGGGGATTCCAAAGAGTGCGTATTAAAATATATAGAAACA 
               ******** ** ******** * * ******  *    ****** ** **  **** * 
 
SLC12A6      GTCTGTGGTTCTCTATACAACATGGACAAAACATACAAGCTGTTGTC-TAAGAAATGCAG 
Slc12a6      --CAGTGGTTAGCTATGCAACAT----AAAGCACACAAGCTATTATCTTAACAAATGTGG 
               * ******  **** ******    *** ** ******* ** ** *** *****  * 
 
SLC12A6      GTCATGGTGCACATTAATCAACAGGTTCTTCTCCCCCCGCCCCCACCCCCGCGCCTTTTT 
Slc12a6      GTTGTTATGTA-GTTAACCAGAAGGGTCTCTTCTACTC-------------------TTA 
             **  *  ** *  **** **  *** ***  **  * *                   ** 
 
SLC12A6      TTATGCCCTCTTATTAAGCACAGGTCAAA--AAATCT-TAAGGAACAAATACTAGGAAAA 
Slc12a6      GTAGGCATTGGTCTTAAAAACCAAACAAACCAAACCTGTAAGGAAGAGACGCCAGG---G 




SLC12A6      CTGGCTAAACATCCTTCCCTGAAAGCACTGGACCATCTTTTAAAGGGCACATCTAGCAAT 
Slc12a6      CTGTGTG---ATGCCACCTCCAAGGCCCCAGG-----GTTCAGAGG-----TTCAGCAGT 
             ***  *    ** *  **   ** ** *  *       ** * ***     *  **** * 
 
SLC12A6      GGAATTGGAAGTTCTAGAGCCACACTCTTTCTTTAGTGCCAACGTTACTGAGCGGCTACT 
Slc12a6      GGAACTGGGGGTGTGAAAGCCATACCCTTTCCACTGTGCCAA-------AATCGTCTGCT 
             **** ***  **   * ***** ** *****    *******        * ** ** ** 
 
SLC12A6      CTCCTTACCTACTTTACTAAAATGGCATACAGATTGGC-ATTGACCTGTTGAAGAAA--- 
Slc12a6      C-------------------ACTGGCAGACAGGTTTGCAAGTGGCCTGACACAAGCACCT 
             *                   * ***** **** ** ** * ** ****    *   * 
 
SLC12A6      -TTTTACCACTAAGAA---ATCTTTTGCCTCATCTACAAAGCCATAGTTAAGACTTGAGG 
Slc12a6      TTTCTTTCACAAGAAATCCATCTGTGGCCTCTTCACCAAAGCCATAGTGCAGATTTGAGG 
              ** *  *** *  **   **** * ***** **  ************  *** ****** 
 
SLC12A6      CATTCAA-CTTAATGCCAAGTATAAGCATTTCCCCCTTTTTCTTTCAA---TTTTATTCT 
Slc12a6      CACTCGACCTCCATGCCCAG----AGCTTTTCCC-------GTCTCAATATTATTATTAT 
             ** ** * **  ***** **    *** ******        * ****   * ***** * 
 
SLC12A6      TCATTCTGACTACAGAAACTTGGCCCTGAACTACGAGATTAGCCAAGCCAACAGTCTTCT 
Slc12a6      TCATTCTGACTTCGGAAACTTGGCTCTGAAACAAATGGTTCACTAAGCTAATGATCTGCT 
             *********** * ********** *****  *   * **  * **** **   *** ** 
 
SLC12A6      AATTTGTTTTCAGAAACTTCAGGCCGGGTGCCGTGGCTCACACCTGTAATCCCAGCACTT 
Slc12a6      GTATTGGTTT-------------------------------------------------- 
                *** *** 
 
SLC12A6      TGGGAGGCCAAGGCAGGTGAATCACTTGAGGTCAGGAGTTCGAGACCATCCTGGCCAACA 
Slc12a6      ------------------------------------------------------------ 
 
 
SLC12A6      TGGTGAAAACCTGTCTATACTAAAAATACAAAAATTAGCTGGGCATGGTGGTGCATGCCT 
Slc12a6      ------------------------------------------------------------ 
 
 
SLC12A6      GTGATCCCAGCAACACGGAAGGCTAAGGCAGGAGGATCATTTGAACCCAGGAGGCGGAGG 
Slc12a6      ------------------------------------------------------------ 
 
 
SLC12A6      TTGCAGTGAGCCAGGATTGCACCTCTGCACTCCAGCCTGGGTAACAGAGTGATATGTTTC 
Slc12a6      -------------------------TGC----------------------------TTTC 
                                      ***                            **** 
 
SLC12A6      AAAAAGAAAGTTCAGTGTGCCAAGGAAATACTTGTGTAAGCTCAG----CTTTTTATTTA 
Slc12a6      AAAAAG--CTCTAACTGTGCCAAGGAAATACTTGTGTAAGATCAGATTTTTTTTTTTTTT 
             ******     * * ************************* ****     ***** *** 
 
SLC12A6      CTAATATACTGAT--CAAACATCTGGCTTACAAGCATAGGGAAACTACTTATGTGGCTGG 
Slc12a6      TTAATTTACTGATCACAAACACTTGGCTTACCAGCATAGG----CAGCCTTTG----TGG 
              **** *******  ******  ******** ********    *  * * **    *** 
 
SLC12A6      CTGAGCAGTAATTTCAAGTATGTGAAATCTTCATTTCTTTTACAGAATAGTTATTTAGAG 
Slc12a6      CTGAGCAGT-ATTCCCAGGGTGTGAAACCTCCATACCCTTTCCAAGATAGTTACTGA-AG 
             ********* *** * **  ******* ** ***  * *** **  ******* * * ** 
 
SLC12A6      AAAC--TTTTCTTGCCTGTATTCATGGCTGTTTTTGAATTTCAATTTATTAGTCATAAAT 
Slc12a6      AAACTGTCTTCTTGCTTAGATTCACGGCTGCTTTTACATTTCCTTTCACTGACAGTAAAT 
             ****  * ******* *  ***** ***** ****  *****  ** * *     ***** 
 
SLC12A6      AGTGCCACTCTTCTTTGATTACTAAATAGGACATGGAGCAAGCTGACCTAGGTGTCACAA 
Slc12a6      TGTGCCACTCTCC-----ATACCCTGTAGGACAATGAAC------ACCCAGA-------- 





SLC12A6      ATTATTCATTTGACCTGTAAGGACAG-AGAAAACCCTTCAATATAGCTTAAGAAATTGAG 
Slc12a6      -------ATTCAACCC---AAGACAGAAGAAAACCCTCAAATATGGCTTAAGAAGCTGAG 
                    ***  ***    * ***** **********  ***** *********  **** 
 
SLC12A6      TAATTTTGGGCCGGGTGCAGTGACTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGG 
Slc12a6      TCA--------------------------------------------------------- 
             * * 
 
SLC12A6      CAGGCGGATCACGAGGTCAGGAGATTTGAGACCATCCTGGCTAACACGGTGAAACCCTGT 
Slc12a6      ------------------------------------------------------------ 
 
 
SLC12A6      CTCTACAAAAATACAAAAAAATTAGTCGGGCATGGTGGCGGGCGCCTGTAGTCCCAGCTA 
Slc12a6      ------------------------------------------------------------ 
 
 
SLC12A6      CTTGGGAGGCTGAGGCGGGAGAATGGCGTGAACCCGGGAGGTGGAACTTGCAGTGAACCG 
Slc12a6      ------------------------------------------------------------ 
 
 
SLC12A6      AGATTGCACCACTGCACTCCAGCCTGGGCGACAGAGGGAGACTCCATCTCAAAAAAAAAA 
Slc12a6      ------------------------------------------------------------ 
 
 
SLC12A6      AAAAAGAAAGAAAGAAAGAAATTGAGTAATTTTGATTTGTTCCCTTTGCTTGCTTCAACC 
Slc12a6      ------------------------------TATGGTTTGTTCTTCCTCCT---------- 
                                           * ** *******    * ** 
 
SLC12A6      TCCAGGCCCACTGAGGATGGCAAAGCGGATAGGATCTTAAGTCTTTTTTTCTGTTACTTC 
Slc12a6      CCCAGGCCCACTT-GAGTAGCAA-------AGGATCC--AGCATGTTTTCCT-TTGCTTC 
              ***********  *  * ****       ******   **  * **** ** ** **** 
 
SLC12A6      CTACAGATGGTAGAAGCATTATTTACAACTCCCACTGCAACACTCCATTGCTTAGTTGAG 
Slc12a6      CTGCAGAGGGTAGAAAC--TACTCGTAGTTCTCTTTCCAACACTCCATTGCATACTTGAG 
             ** **** ******* *  ** *   *  ** *  * ************** ** ***** 
 
SLC12A6      TTTAACAGTAGTGAGTCATGTCCTGCAGGATCCAGTATCTTTTTTTTTTTTTTCCGAGAC 
Slc12a6      TATAA------------------------------------------------------- 
             * *** 
 
SLC12A6      GTAGTTTCGCTCTTGTTGCCCAGGCTGGAGTGAAATGGCACAATCTTGGCTCACCGCAAC 
Slc12a6      ---------------TCCCCTAGGCT---------------------------------- 
                            *  ** ***** 
 
SLC12A6      CTCTGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGAATTACA 
Slc12a6      ------------------------------------------------------------ 
 
 
SLC12A6      AGCATGTGCCACCACACCCAGCTAATTTTGTATTTTCAGTAGAGACGGGGTTTCTCTACT 
Slc12a6      ------------------------------------------------------------ 
 
 
SLC12A6      GAAACTGATGTTGGTCAGGCTGGTCTCGAACTCCCAACCTCAGGTGATCCGCCCGCCTTG 
Slc12a6      ------------------------------------------------------------ 
 
 
SLC12A6      GCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACTGTGCCCAACCAGGATCCAGTATC 
Slc12a6      -----CCAAGGCATTGG------------------------------------------- 







SLC12A6      TTAAAGGCCCATACTGTAAAGGTCAGCCTGCCTAGGAATTCTGCCACATTTACACACACC 
Slc12a6      ---AGCGCCCATTCTGTAAAAGCCAGCCTGCCCAGGAA--CTGCCTAA--CACATCCACC 
                *  ****** ******* * ********* *****  *****  *   ***  **** 
 
SLC12A6      CCTGGCCAAAGTAATATTTTTTTTTTCCATGTAGAACAAATTATGGGCAGAAAGTAAAGT 
Slc12a6      CCTGACCAAAGTGACACATACTTTTTCCATATCAAACAAA-CATGGGAAGAGAATAAGGT 
             **** ******* * *  *  ********* *  ******  ***** *** * *** ** 
 
SLC12A6      TAGTTTTAGAAGTGCTGTTTGTGGTTGGAGAATTGTAAAAATCTTTTAAAGGGATAAGGG 
Slc12a6      TTCTTTAAGAAAGGCTGTTTGTGGTTAGAGCTACATAAGAATCTGTTAAAGGG------- 
             *  *** ****  ************* ***     *** ***** ******** 
 
SLC12A6      AATTAGTGGCTTTTAATATAACCACTGCTTCAGCCCGAAACACAAAATCACTGTTACATG 
Slc12a6      ---TAG--------AGTATAGTCTTCATTC---CCCAAGATA-AAAATCACTGTTACATG 
                ***        * ****  *     *    *** * * * ***************** 
 
SLC12A6      GAAAACTGGTTATTAGGCCAGATTTATATTCATGTCTGTCTAGAGTATTTCATGTGTGTA 
Slc12a6      GACAAATGGTTATTAGGCCAGATTTGTACTCATCTCTGTCTAGAACATTTCA--TGTCTA 
             ** ** ******************* ** **** **********  ******  *** ** 
 
SLC12A6      TGTGTTGCTTACGTTGTCTGTCTCCAAAGTCTCTCATCTCTTTTAATCACTGCAAATAAA 
Slc12a6      TGTGTTGCTTATGTTGTCTGTCTGCAAAGTGTCTTAGCTCTTTTAATCACTGCAAATAAA 
             *********** *********** ****** *** * *********************** 
 
SLC12A6      GCAATACTGAAAACTTGAGAG----AATGCACCTTAGGGGAAGGGGC----TATTTCAAG 
Slc12a6      GCAATACTGAAAACTTGAGAGAGAAAATGCACCTTAGGGGAAGGGGCCAAATGTTTCTAG 
             *********************    **********************    * **** ** 
 
SLC12A6      ACAGAAAACAAAGGAAATA-CCTGCCTTTTGAATAAGATCCCGCTTTTGAGTCTTACCTA 
Slc12a6      AGGGAAGAGGAAGACCTTCTCCTGCCTTTCTTATAAGACCCAGC--TTGTGTCTTACCCA 
             *  *** *  ***    *  *********   ****** ** **  *** ******** * 
 
SLC12A6      TGACTTTAC---CAGGGTAGATTAGAAATACACATCCTCCT---GCTGACCCTCTGCCTT 
Slc12a6      TGAGTTTATTAGCAGGGCAGGCT-GTAACATTCGTTCTCCCCCAACTGGTCCTCAGCCTT 
             *** ****    ***** **  * * ** *  * * ****     ***  **** ***** 
 
SLC12A6      CAATAGCTATCTATCTTAAAAGCTGAAGTTTGAACTGCAGCATCTGCTTGACAGGTGCCA 
Slc12a6      CCGTAG----CTACCTTAAAAGCTGGAGTTTGAATTGCAGGGCCTGGTTGACAGGTGCCA 
             *  ***    *** *********** ******** *****   *** ************* 
 
SLC12A6      GGTTCCTT-CGGCAGGGGGACGATCACT-CTATATATCTTCCGTTGCCTCAGATTCCTGT 
Slc12a6      GCTTCCTCGTGGCAGAGCAAAAGCTGCTGCTTTTCATATTCTG-TGCCTCCTTTTCTTGT 
             * *****   ***** *  *      ** ** *  ** *** * ******   *** *** 
 
SLC12A6      GG-CCCAAGGATCCCACCAATCCTCGTTCCCCCTAAACATGCTAACA-AAAATCCCTTAT 
Slc12a6      GGCCCCAAGGATCCCACCAATCCTCATTCCCCCTAA--ATGTTAAAAGAAAATTCCTTAT 
             ** ********************** **********  *** *** * ***** ****** 
 
SLC12A6      CGTGGGTATTAAAATAATAACAGTTACACTGTATGCATATTTATGTGCTCCTTTT---GT 
Slc12a6      TGTGGATATTA----------AGTTACACTGTAAGCATATTTACATGCTCTTTTTCCCCC 
              **** *****          ************ *********  ***** **** 
 
SLC12A6      CTGGTTTTTCTTTTCATCATGTATAAGCTGAATTCAGCATTAGTTTCTCACATCTTCCCC 
Slc12a6      CTGGTTTTTCTTTTCATCATGTATAATTTGAATCCAGTGATAG--TCTCACATCTT---- 
             **************************  ***** ***   ***  *********** 
 
SLC12A6      CAGGTATCCCCAACAGAATTTTTATGTCCCAGCTTGTATTAAATAGAAGTGAAATATTAA 
Slc12a6      ---------CCAAAAAAGTCT----------GCTTATGTGATATAGAAGAGAAATATTAA 
                      **** * * * *          **** * * * ******* ********** 
 
SLC12A6      GGAAAAT----AAGGAACTTGTGCAACTTTTTTTATGCATTGTTCTCAACCATTTAATTT 
Slc12a6      AGTAGACTGAAGGGGAACTTGTGAAAC----ATTAAGCATTGTTCTCAACCGTTTAATTT 





SLC12A6      ATTGAAAGGAGATGCTGCAACAGTTCTTGATTTAGCAGCAGTTATTCTCTTGTTTACATA 
Slc12a6      ATTGAAAGGAGAAGCTGCTAC----------TGAGCAGCTGCTATTCTTTTGTTTACATA 
             ************ ***** **          * ****** * ****** *********** 
 
SLC12A6      GTTATGTTTTTTTGTTGTTGTTTTGCTCTGTACTGGAAACAAAAATAAAGTTTTCTACAT 
Slc12a6      G---AGTCTGGTTTTGTTTGTTTTGCTCTGTGCTGGGAACATAAATAAAGTTTTCTACAT 
             *    ** *  ** *  ************** **** **** ****************** 
 
SLC12A6      TATTTTCA---------------- 
Slc12a6      TATTTTCAAAAAAAAAAAAAAAAA 





























MUSCLE (3.6) multiple sequence alignment 
 
 
SLC25A26      -------AGCAGAGACAAGCCTCACCTCCACTTCTGTCAAGAGAGGGGCCTGCAGTGCAA 
Slc25a26      GCTTGCTGTTAGAGGTGGGC--------------------AGGAAGAGCCCATGAAGCAG 
                        ****    **                      ** * ***      *** 
 
SLC25A26      ACCCTCTTCCGCTGAGCAG--CTGTCTGAACTATAGGCCCCAGTG-------CTGAAGAC 
Slc25a26      ACACTACATGTCCTTGCAGTCCTTCCTGTGCCTGGGGCTCCAGTGTGGCTCCCTGAAGA- 
              ** **      *   ****  **  ***  *    *** ******       ******* 
 
SLC25A26      CAGTTGTGCTAAGATACCGGCATGGAGATTGTGCCATCCGTGGTATAGGCTGGCTGGTAT 
Slc25a26      TGGCTGC----AGAGAGCAGCTTAATGAAGG------CCAAAGCACAGGCTGCC------ 
                * **     *** * * ** *   **  *      **   * * ****** * 
 
SLC25A26      GAAGTCATTGGCCTGTATGCCAGAGAGCTAAGAGAAGAAAACGGGGTCTGTGGCGGTACT 
Slc25a26      -------------------CCAGGAAACT----------------TTTCTTGGTGAAACT 
                                 ****  * **                 *   *** *  *** 
 
SLC25A26      CTGAACAATTTCCTCAGAACCTCTTAATAAATAAGTTTGGTAATGCTGAGGCCAGGCCTT 
Slc25a26      -GGGGCCACCGTCTCAG-TCCTCTCAATAAATACTCCCGGTAAGGCCAAGGCCAGGCCCT 





SLC25A26      TTAGAGCTTTCATTTGATCTGTATCTG-ATCTTTCATTTCCTGCCACCTGATGGTGGATT 
Slc25a26      TCAGAA--------TGCTTTTTATTAGCATCCTGTGCTTTCTGCTGTCTGTTGGAGTCAC 
              * ***         ** * * ***  * *** *    ** ****   *** *** * 
 
SLC25A26      CAGCAGAAGGCAAGATGGTTATAATTCTAAAAGAATAGCTTGTTTGTTTGTTTGGGAAAA 
Slc25a26      CAG--GAAAGCAAGCTGGCTACAACTGC-AGTGAATGAC--------CAGACTGGGAAAA 
              ***  *** ***** *** ** ** *   *  ****  *          *  ******** 
 
SLC25A26      GGAGACTTGGGGAAGAGTTGTGTATGTGGGTGTTTCTCCCCCTAGTTAATTCCTGTTGTG 
Slc25a26      GGAAG--GGGGCAAGAACCGTGCGTGTGGCTGTTTCTCCCCTGGGCGGGTGCCTATTGTG 
              ***     *** ****   ***  ***** ***********   *    * *** ***** 
 
SLC25A26      TAAGGGTA-GGCTTTGTTGAAAAAGAAAGAAAGATTGAACTACAGGTGCATAGCAAGCAC 
Slc25a26      TAAGATTATAGCTTTGTTTAAAAAGCA--------TGAGCTACAGGTGCATAGCATGCAT 
              ****  **  ******** ****** *        *** **************** *** 
 
SLC25A26      TCTTTCTGGGTAACTAGGCTGCTGGTTTTAATTACCCTCAGATTTCACCCATAAAAACGC 
Slc25a26      TCTTTCTGG----TGAGGATGCTGTTTTTAATTA-CCTTGTATTTCTCCTATAAAAACAC 
              *********      *** ***** ********* ***   ***** ** ******** * 
 
SLC25A26      ACAATTGTATTATTTTACAGAGATGTGTCCAGCGCCCCCTGTGGTGTGTGAGAGAAAG-- 
Slc25a26      ATGATTATATTACTTTACAGCAAAGTGCCCCAAAGTCCCTGGAGTGTGTGACAGACAGCA 
              *  *** ***** *******  * *** **      *****  ******** *** ** 
 
SLC25A26      --CAGCTGCAACTCAAGTGACTAGGTGGGCCCAGCTGGCTTCGTGCAGGAGGGCACGGTG 
Slc25a26      GACAGCTGCAGCGCCAGTGAGTGGGTGGGCCCAAGTGACTTCAGTTAGGA--ACATGTTG 
                ******** * * ***** * **********  ** ****    ****   ** * ** 
 
SLC25A26      GGTGAG-------CCATTCTCGCCATTCTCATGTCAGACTGAAAGGAGGGCCTGGGCCAG 
Slc25a26      AGGGAAGCAAAGCCCATGCCCACCACTGTC-CGTC--CCTGGAGGCCAG--CTGGAGCAG 
               * **        **** * * *** * **  ***   *** * *   *  ****  *** 
 
SLC25A26      ---CTTTG----------AAAAGGCAGGATGAAATGGAAAGGTCACCACACTTAGGGATT 
Slc25a26      CTCCTTTGTCCTCATGGTATATGCCAGCAGGAGGTGGGAGGGTCAGCATACTTGGGGAGC 
                 *****          * * * *** * **  *** * ***** ** **** **** 
 
SLC25A26      TTAGACCTTGACTAACAAGCTCCAGGTGTAGAAAAATTCAAAACAAAATGTCAGGAATCT 
Slc25a26      ATAAGGCTTGACTAACCAACTCCATGTGGAAAAAAA---AAAGCTATCTG--AGGAATGC 
               **   ********** * ***** *** * *****   *** * *  **  ****** 
 
SLC25A26      AGCAGTGTTGTCTGCCCTGGAGCAAACAAACAGTATGTGATTT----TGCTTCGCCTATT 
Slc25a26      AGTGCCACTGTCT-TTCTGGGGC-----AACAGTGTGTAGTCTATGCTGCTTCGTCTAAG 
              **      *****   **** **     ****** ***  * *    ******* *** 
 
SLC25A26      TTTTTTTTCTTTTTTGGGGGAAGATAATTAAAGGCAGAATGACTGCGTTTGTAAAAGAAG 
Slc25a26      TATTCTCCTTTT------GGAGAAACATTAATAGCAGAATAA----------AAGAGCAG 
              * ** *   ***      ***  *  *****  ******* *          ** ** ** 
 
SLC25A26      -GACCACCAACTATACTGA-CATTTATAAATGAACCTTTATTAAAGACACTTCAATGCCA 
Slc25a26      TGACCGCCGCACACACTTAGTATTTATAAATGAACCTTTATTAAAGACACTTT-ATGCCA 
               **** **    * *** *  *******************************  ****** 
 
SLC25A26      TTTGTTAGACACTTCAATATTTTACATGGTTTTCAATGTACACTGTACCAAAATTTCTAT 
Slc25a26      TTTGTTAGACACTTCAATATTTTACAT-GTTTTCAATGTACACTGTACCAAAATTTCTAT 
              *************************** ******************************** 
 
SLC25A26      AAATAAATAACTTTGTACATAAAAGT---------------AAAAAAAAAAAAAAA 
Slc25a26      AAATAAATAACTCTGTACATAAAAGTAATACTTCCTCTTTCAAAAAAAAAAAAAAA 
































MUSCLE (3.6) multiple sequence alignment 
 
 
TMEM85      A-CATGAGAAAGCAGCGCCTGGTCCCTATGTATTTGGGTCTTATTTACATCCTTCTTTAA 
Tmem85      ACCCCCAGAAAGCA-----------CCATGCATATGGACCTCATCTGCAT-----TTTAA 
            * *   ********           * *** ** ***  ** ** * ***     ***** 
 
TMEM85      GCCCAGTGGCTCCTCAGCATACT--CTTAAACTAATCACTTATGTTAAAAAGAACCAAAA 
Tmem85      G-CTGTTGACTCCTAAATATCCTCCCTTAAAACAGTCATGCATGTGGAGAAGAGCC---- 
            * *   ** ***** *  ** **  ******  * ***   ****  * **** ** 
 
TMEM85      GACTCTTTTCTCCATGGTGGGGTGACAGGTCCTAGAAGGACAATGT---GCATATTACGA 
Tmem85      ---------TCCTGTGGTG-----------------AGGCCAGTGTGCAGCATGTTACAG 
                       *  *****                 *** ** ***   **** **** 
 
TMEM85      CAAACACAAAGAAACTATACCATAACCCAAGGCTGAAAATAATGTAGAAAACTTTATTTT 
Tmem85      CAGA---AAAGAAACTACAGCACAACTTATGACTGAAAATAATGTAGAAAACTTTATTTA 
            ** *   ********** * ** ***  * * *************************** 
 
TMEM85      TGTTTCCAGTACAGAGCAAAACAACAACAAAAAAACATAACTATGTAAACAAGAGAATAA 
Tmem85      TGTTCCCAGCACAGAGCAAAACAAACAAAACCAGAC---TCTATGTAAACAAAAGAATAG 
            **** **** **************  * **  * **    ************ ****** 
 
TMEM85      CTGCTGCTAAATCAAGAACTGTTGCAGCATCTCCTTTCAATAAATTAAATGGTTGAGAAC 
Tmem85      CAGCTGCT----------CAGTAGCAGCTTCTCCTTTCAATAAATTAAACGGTTGAGAAC 
            * ******          * ** ***** ******************** ********** 
 
TMEM85      AATGCATAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
Tmem85      AATG-------------------------------- 













<Human: TPSG1, Mouse: Tpsg1; no graph, UTR too short for sliding window> 
 
 
MUSCLE (3.6) multiple sequence alignment 
 
 
TPSG1      --------TGGCAG-GAATCCAAGTGCATTTCTTAAATAAGTTACTATTTATTC-----C 
Tpsg1      ATGAGGTGTAGCAACCAACCCAAGTGTCTTTCTTAAATAAGTTAGTGTTTATTCAGCTTT 
                   * ***   ** *******  **************** * ******* 
 
TPSG1      GCTCCGCCCCCTCCCTCTCC----------CTTGAGAAGCTGAGTCTTCTGCATCAGATT 
Tpsg1      GCTTTGCCCCTCCCCTCCCCTTAGCTTTGACTTAGGAAGCCAAGTTTTCTGCATCAGATT 
           ***  *****  ***** **          ***  *****  *** ************** 
 
TPSG1      ATTGCAACATTTAACCTGAATTTAAA------AGCACACGAAACAAA------------A 
Tpsg1      ATTGCAACATTTAACCTGAATTTGTAGAACGGATGACATAAAGCAAATGGATGTCAAATG 
           ***********************  *      *  ***  ** **** 
 
TPSG1      AAAAAAAAAAAAAAAAAA 
Tpsg1      AAAAAAAAAAAAAAAAAA 



























MUSCLE (3.6) multiple sequence alignment 
 
 
YPEL1      -TGTGCGAACTTTCCCTTCTCCTTTGAATGCTGTTTTGTGAAAGAAACTGTGAATGTAAT 
Ypel1      AAGTG-AAGCGGTCCACTCCTGTTTGAATCCTATTTTATGAAAGC-----TGAGTGTACA 
             ***  * *  ***  **   ******* ** **** ******      *** **** 
 
YPEL1      GGAAACGTAGGAGCATC-TGGTGACAGCCTTTCTTGCCCTCTGACCTCAAAGGCTAGCTG 
Ypel1      GAAGACCT---AGCTTCTTGGTGACAATGCTTCTTGAACT-TAACCTCACAGGCCAGCCC 
           * * ** *   *** ** ********    ******  ** * ****** **** *** 
 
YPEL1      CG-CATAGCTCTTGA------CACTCTCGGCCATCTCTGTGGGTAAGGTGTCCCTCGGAT 
Ypel1      AGTCTCAACACTTGAAGGTGTCTCTCTAGGCTATC-CACTTGGTAAGGTGCCCATTTGA- 






YPEL1      CTGTCCTCTTCGTGTACACAGTTGTTTCTGAAAATTTTCAATGAG--CTTTTTCTAACTT 
Ypel1      --ATCCCTGTCGTGTAAATG--CGTTTTTGGAAGTC-----TGAGTTCTTTTTCTAACAT 
              ***   ******* *     **** ** ** *      ****  *********** * 
 
YPEL1      CTCAAGTTCTAGAGAAAGAATTAACCAACTGATGACTTACCTGCCTAGTTAATATCTTCC 
Ypel1      CTTAAGTTCTAGAGAAAGAATTGACCAGCTGGTGACTCACCTGCCTAGTGAATACTTTCT 
           ** ******************* **** *** ***** *********** ****  *** 
 
YPEL1      TTTCACCTTTGTCTTCAATATAGTTGGGCTCTGCTTTTTTAAGGTTCAGTTGAAAACCAA 
Ypel1      TTTACCCTACGCCTGCAAT----------------------------------------- 
           ***  ***  * ** **** 
 
YPEL1      ACTGGGGCCGGGTGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCAAGATGG 
Ypel1      ------GCCTGG---------------CTGTGTTCTCACCA-------AGCCCAAG---- 
                 *** **               ****  ** ** **       ** ***** 
 
YPEL1      GTGGATCACCTGAGGTCAGGAGTTCTAGATCAGCCTGGCCAACATGGTGAAACCCCATCT 
Ypel1      ---------------------------------------------------------TCC 
                                                                    ** 
 
YPEL1      CTACTAAAAATACGAAAATTAGCCGGGCATGGTGGCGAGTGCCTGTAATCTTAGCTACTC 
Ypel1      CT------------AAAAGCAGAGAAGCAAGGT---------------------CTCCTC 
           **            ****  **    *** ***                     ** *** 
 
YPEL1      AGGAGGCTAAGGCAGGAGAATCACTTGAACCTGGGACACGGAGGTTGCAGTGAGCTAAGA 
Ypel1      A-CAAGCAAAGGCAT---------------------------AGTTAC------------ 
           *  * ** ******                             *** * 
 
YPEL1      TCATGCCATCGCACTCCAGCCTGGGGGACAAAAGTGAGACATCGTCTCAAAAAAAAAAAA 
Ypel1      ----------------------------CAGAAGTAAAGCAT-GTCTCCAAAAACTGAAA 
                                       ** **** *  *** ***** *****   *** 
 
YPEL1      AAAAGCTGGGTATGGTGGCGCATGCCTTTAATCCCAGCTACTCGGGAGGCTGAGGCACGA 
Ypel1      ---------------------------------CCAGCCACTGG---------------- 
                                            ***** *** * 
 
YPEL1      GAATCACTTGAACCCAGGAGGCGGAGGTTGCAGTGAGCCAAGATCGCGCCACTGCACTCC 
Ypel1      ------------------------------------------------------------ 
 
 
YPEL1      AGCCTGGCAATAGGGCGAGACTCCGTCTCAATTTAAAACAAAAGAGAACCAGACTGAGTC 
Ypel1      ---------------------------------TAACATGGAAGAGAAGC---------- 
                                            *** *   ******* * 
 
YPEL1      TCTGAAGACCACAGGGACAGGGTCTCTTTAGATAGCAAGTCTCACCATTCCCTTTTTTAG 
Ypel1      ----------------------------TAGGAAGCAAG------CATT----------- 
                                       ***  ******      **** 
 
YPEL1      AGAAAAGGTATTGTAGCCCACCCTCCACCCCGCTGTTTTTCTTAAATTTGCAGAACTTCA 
Ypel1      ------------------------------------------------------------ 
 
 
YPEL1      AATTGGCTATTCCTCTTGCAAATGAACCCTTAAAGTACAGTGTTATTTAAGAATCTTCCA 
Ypel1      -------------------------------------CAGTGT----------------- 
                                                ****** 
 
YPEL1      GAGGCAGTCAACAGACTTATACACTAAGGGCATTTTTGGTTTTTAGCTTGTTCAAAAACA 
Ypel1      ------------------------------------------------------------ 
 
 
YPEL1      GAGGCCAGCACAGATGACATTTTAGATACACTCTAAATTGAGAATGGTGTCTAGTGGAAC 
Ypel1      ----------------ACATCTTAAGCA--------------AATAG------------- 




YPEL1      ATGTTTATTTAAGCCAGTAGATTCCTTATCTAGAAAGCAGGTGAGCTAGCCCTTAGAGAA 
Ypel1      ----------------GGAGGTTCCTGATGTAGAAGGCGAGTGACTTACTGGTGGCTGAA 
                           * ** ***** ** ***** **  ****  **    *    *** 
 
YPEL1      GG--CTGTCCCGGGGCC-CGCAGAGGTGCCCTTACTGAGGTGACAGCCTCACAGGGTCTG 
Ypel1      CGCTCTGTCCCAGGGCTACCCAAGTCTGCC---ACTGAGCTGACTCCCT---------TG 
            *  ******* ****  * **    ****   ****** ****  ***         ** 
 
YPEL1      GTACCAGGGGTTGTGCCCTCAGCAGTGACAGCAGCTTAGGTGTCAGGCAGTTGCTGAGTG 
Ypel1      GTGCTGCGG----------CAGC----ACAGCGGCTCAGA----ATGTAG---------G 
           ** *   **          ****    ***** *** **     * * **         * 
 
YPEL1      GCTGGTCCATGTCTATAGAGTAACACACTGGACCGAGGAAAAGTCAGATTTCATTTTCTA 
Ypel1      GCTGGTCCCTG-CCACAGAGCAACAGGCTG----------------GGTTTCACTTTATA 
           ******** ** * * **** ****  ***                * ***** *** ** 
 
YPEL1      CCCTGGATGTACTTGAAGAAAAAGAATTATTTTTGCATATGAAAGAGGCCAGAACCCACA 
Ypel1      CCCTGGATGTACTTGAAA---------TAGTTATGCATAC---AGAGGCCAGAGCCAGTA 
           *****************          ** ** ******    ********** **   * 
 
YPEL1      GGAAAAACTTCAAAACTTGACATTTGCCAGAATGTTTAAAATTTGTTCAGAAAAGGTTAA 
Ypel1      CGGGAAACTGCAAAACATG---------AGAGTTTTCCAAG---GTAAAGGAAGAGTTAG 
            *  ***** ****** **         *** * **  **    **  ** **  **** 
 
YPEL1      AGCAACAAGTTTAGCCTTTGTGCATGAAGACGCCTGGCCTGCTAGACGCGTTGCCCGTCC 
Ypel1      ---------------CTTAGTATGGGA-------------GCTA----------CCTTTT 
                          *** **    **             ****          ** * 
 
YPEL1      CTGCGTGGTGCTGTCCCATGTCACTTGAACTGATA--GAGGGGCCTGTGCAATCTCCTAA 
Ypel1      CTGCCTGGAATCACCTCA-------TGACCTGACAAGGGAGGATCTGGGCCATCCCCCAA 
           **** ***      * **       *** **** *  *  **  *** ** *** ** ** 
 
YPEL1      GGCCTGTGTTTCTGCCATATATTTTATTATAAATTACAATCCACTCATCCACCTGCCCTC 
Ypel1      GCCCAGGCTCTCAG-----------ATTTTAAGTCACAACACA-TCAT------------ 
           * ** *  * ** *           *** *** * ****  ** **** 
 
YPEL1      CACCAGGAGTGGGCACCCCATAAGGGTTTAGGCCACTTTGC--AGAGGATGGAGGTCAAA 
Ypel1      --------------ACTCTATAAGGAGT--GGCCAATTTGCAGAGAGGATGGAGGCC-AG 
                         ** * ******  *  ***** *****  ************ * * 
 
YPEL1      AACCACTCCCAGATAAGTTTGGTTTTCAACATTTAGTAACTTGTCTCAGGGCAG-AGGGC 
Ypel1      AACCATTCCCAGATAAG------TTTCATTGTTTTGTACCCT-CCCCAGGGCAGAAGGGC 
           ***** ***********      *****   *** *** * *  * ******** ***** 
 
YPEL1      AGGCAG---------GGGGACCGAGGGGC----AGCAGATAGGAGAGCACTGAGCCCGGA 
Ypel1      AGGCAGTAGGCCTGTGAAGGCTGAGAGCCCTTGAGCTGCAAAGGCAGCATTA---CAGGA 
           ******         *  * * *** * *    *** *  * *  **** *    * *** 
 
YPEL1      TAGTTCTCAGCCTGGCAAGTGGCTCTGAAGCTGCCTTCAGACAAGGCTAGTCTAGGGGCA 
Ypel1      AAGCGCTTAGC---ACCGGCTGCTCTAGAGCTGCCT------------------------ 
            **  ** ***    *  *  *****  ******** 
 
YPEL1      AGAGTGCGAGCTGGCTGACAATAAGAACGTGGCCACCTGCCCAGCTTCACACCTC----C 
Ypel1      -GGGTG-----TGGTAGTCAAAAAGCA-GTTTCTATCT----------AGACCTTTGGGC 
            * ***     ***  * *** *** * **  * * **          * ****     * 
 
YPEL1      CCCGACTTCAGCCCTTCCTAAACCCAGACCTGCGGTCCAG-GCAGGCACTGGGCTGTGCC 
Ypel1      TCCAGCCCCAGACCTG-CTAAACCCACATCCTCTGGCCAGCACAGGCACTCG-------C 
            **  *  *** ***  ********* * *  * * ****  ******** *       * 
 
YPEL1      CACTCGAGCTCACTGCCCACACACAGCATGCCTTTGGGTGCCATCTCTTTGCCCAAGCCT 
Ypel1      TACTCCTCTTCACTT------CAAAACCTACATTTTGGTGCCATTTCTTTGCCCAAGATT 





YPEL1      GGAAGCCTTGGCAGGTGGGAAATGCCGCTGCCCTGGTGGGCATGGCACTGAGATGCATCC 
Ypel1      GGAAGGCTGGTAATACAGGAAATGCCTGCGCAATGCTGGTCCTAGCCC------------ 
           ***** ** *  *    *********   **  ** *** * * ** * 
 
YPEL1      ACTCAGCAGGAGTGACAGAGGCAGAAGTTCCTTTAAAGCACATCTTCCACTTAGGAAAGG 
Ypel1      ------------------------AAGCTGCTTT----------TTCC------------ 
                                   *** * ****          **** 
 
YPEL1      AAGGAAATCTTTGTACTGTCTTGGAAGCCTCCACATCCGGCTATGGCCCTGCAAGCTGCT 
Ypel1      ---------------------------------------------------CCAGCTACT 
                                                              * **** ** 
 
YPEL1      TTATCCCTGCGCTAGTCTCCCCCGAGGGTTTAGGCTGGCCCAGCACATCCTGTCCTCCTG 
Ypel1      T----------CCAGTTTCCCTCTA-GACTAAGGCTGGCAAAGCAAA------------- 
           *          * *** **** * * *  * ********  **** * 
 
YPEL1      AGCTCGCGTGCAGCCACCCAGAGCGCAGGGGTCACTGCACGCTGCAGGGCTCTTGCTGCC 
Ypel1      ------------------------------GTGACTCTAC-CAGTAAGGTAAGTGCT--- 
                                         ** ***  ** * * * **    **** 
 
YPEL1      ATGGTCTCAAGCCTGAAGAGGCTCCGCCCACAAGCTGGCCCATGAAGTTAGCAATGCCTG 
Ypel1      -----------------GAAACTCAG--CACAAGCAGCCGTGTGACCTTGGCA------- 
                            **  *** *  ******* * *   ***  ** *** 
 
YPEL1      TGGCTTCAGTCAATTGTCTTGAGACTGTGAAGAGGCTGAAAGACACCTTCCCGGGTGGAA 
Ypel1      --------------------------------AGGCTCAGGGCCATCCTT----ATCTAG 
                                           ***** *  * ** * *      *  * 
 
YPEL1      GAAGGAGTTCACTG---AAAACTTATCTTAAACTGACCCTTCCCTTTGAGTGAGTCTTCA 
Ypel1      GAATGAA--CACTGGTCAACAGTCTGCTCAAACTGGACATGCCCGCCTGGCTAGTTTTTA 
           *** **   *****   ** * *   ** ******  * * ***     *  *** ** * 
 
YPEL1      TTCCTCTCCCATGTGGGAACCCAGCCTCCGATGCCCCGGGGACTAGGGGAAACAGTTGGA 
Ypel1      ATACTTTTCAGAGTGGGAACTTGGTGGCTGAGGCATGGGCG------------------- 
            * ** * *   ********   *   * ** **   ** * 
 
YPEL1      GGTTCGTGCCGTCCCCAGCCTGCCACGGGTGCGAGGACAGCCAAGTCCTGAGTGACTCA- 
Ypel1      -------GCTTTCCCCAG--TGGGAAGGCGGCAAGGGAGAC--AGACCCGAGTACGTCCT 
                  **  *******  **  * **  ** ***    *  ** ** ****   ** 
 
YPEL1      TGGCTTCAGTCAATTGTCTTGAGACTGTGAAGAGGCTGAAAGACACCTTCCCGGGTGGAA 
Ypel1      --------------------------------AGGCTCAGGGCCATCCTT----ATCTAG 
                                           ***** *  * ** * *      *  * 
 
YPEL1      GAAGGAGTTCACTG---AAAACTTATCTTAAACTGACCCTTCCCTTTGAGTGAGTCTTCA 
Ypel1      GAATGAA--CACTGGTCAACAGTCTGCTCAAACTGGACATGCCCGCCTGGCTAGTTTTTA 
           *** **   *****   ** * *   ** ******  * * ***     *  *** ** * 
 
YPEL1      TTCCTCTCCCATGTGGGAACCCAGCCTCCGATGCCCCGGGGACTAGGGGAAACAGTTGGA 
Ypel1      ATACTTTTCAGAGTGGGAACTTGGTGGCTGAGGCATGGGCG------------------- 
            * ** * *   ********   *   * ** **   ** * 
 
YPEL1      GGTTCGTGCCGTCCCCAGCCTGCCACGGGTGCGAGGACAGCCAAGTCCTGAGTGACTCA- 
Ypel1      -------GCTTTCCCCAG--TGGGAAGGCGGCAAGGGAGAC--AGACCCGAGTACGTCCT 
                  **  *******  **  * **  ** ***    *  ** ** ****   ** 
 
YPEL1      ---AGATGCTTCACTTACATGGAAGAAACTTCTAAAACTCTACCGAGTGGTTTTTGTATA 
Ypel1      TATAGATGCCTCAGTAAAGCTGAAGAGTCTTGGAGAAGTC-----------TTCTGTATA 







YPEL1      TACTAAAGTTCTATTTAGAGCTTTTCTGTTTTGGGCAAGTTCGCTGCTCCTTCTATTTGG 
Ypel1      TACTAAGATTATATTTAGA--CTTTATGCTCTGGGCATGCTATCTGCCCCT--CAACTGA 
           ******  ** ********   *** ** * ****** * *  **** ***   *  ** 
 
YPEL1      GCACTTTGGTTTTTGTACTGTCTTTTGTGACGGCATTGATTGAACATTTTTTACTAGTAG 
Ypel1      GCAC-------TCTGTATTATCTTTTGTGAGAGCTCTGACTGGAACGTTTTTGCTAGTAC 
           ****       * **** * **********  **  *** ** *   ***** ****** 
 
YPEL1      TCT-TATGACTT--TTGTATTTTTTTTTTTTTTTGTAATTTATACCAACAACACTTTTAT 
Ypel1      TCTATATGACTTACCTGTA--------TTGGGGAGTAATGGATATAAACAAACCATTTAT 
           *** ********   ****        **     *****  ***  *****  * ***** 
 
YPEL1      CACTTTTTTTTT---------GTTGGGCTTCTGCAAAATACAAGCTCATTTTTAAACCAA 
Ypel1      CAAGGTTTTTTTGGATTTTGCGTTGGCCTTCTGTGAAATA------------TAAACCAA 
           **   *******         ***** ******  *****            ******** 
 
YPEL1      ATGAACAGACCATGAGCTGGCTTCAGGGGAAGTGCTATTCACAGGACCATATCCA----- 
Ypel1      AAGAACTGACCATGAGCTGGCTTCAGGGTAAGTGAT----GCAAGACCACAACCAGGCAT 
           * **** ********************* ***** *     ** ***** * *** 
 
YPEL1      ---------------------CCACCCTCTTAAATTCCTAAACAATATCA-TCTAGGACT 
Ypel1      GCTGGTAAACCACTGAATGTCTCACCTCCTTACATTTGTAAACAGCACCATTCTGTGAC- 
                                 ****  **** ***  ******  * ** ***  *** 
 
YPEL1      TCTATTTAAGTTATTTAAAATAAATCTTCCTTGAGAGCCTTGGGAGGTGATGTCAGGGTT 
Ypel1      -----------TATTTTAAAGAGG--TTTCCTCAGAACAGTGGGAGGTGATACCA-GGTC 
                      ***** *** *    ** * * *** *  ***********  ** *** 
 
YPEL1      ATAAATGGCACAGTGCATTTGCTGTAGGAATGTGGTTTG----------GCATTGTT-TT 
Ypel1      ATGAACGCCAC------TTTGCTTTAGAAATGTGGTTTATTTCCTTGTTGTCTTGTTACT 
           ** ** * ***      ****** *** **********           *  *****  * 
 
YPEL1      ATACACACAGTATTTTTTATACCTTAATGCTTATTCTTGATGGCATCTGTCAGATATTAG 
Ypel1      GTATACATAGTA-TTTTTATACCTTAATGCTTATTCTTGATGGCATCTGTCAGGTATTTG 
            ** *** **** **************************************** **** * 
 
YPEL1      AATTGAAAATAAGAATCTTCCCAAAATCCTTTAATTTACCTGATGCCCTCATCAGGTCGT 
Ypel1      AAGAGA------------------------------------------------------ 
           **  ** 
 
YPEL1      TAAAAATTCAAATGGTTTTAATAGCTAAAAAACTACAAATTAAGCTCTAAAACAAACAAA 
Ypel1      ------------------------------------------------------------ 
 
 
YPEL1      CTACAGAAATGTAAACCTTCATTTGCCAAAGGTCCTTGGTGGCCTGTCCCCTGCCCTGGG 
Ypel1      --TCAGAAATG------------------AGATTTTT----------------------- 
              ********                  ** *  ** 
 
YPEL1      AGCAGATGGCCCTGAAGCCCTTCCCTCACTGTGCAGGCCACCGGGTGAGGCTGGACGGTC 
Ypel1      ------------------TTTCCCCTCG-------------------------------- 
                               * ***** 
 
YPEL1      ACCCATGGTGGCTTCACTGCAAGGAGCAGGACTGCCGAGCTCAAGCACGGGGCCTTCAGC 
Ypel1      ------------------------------------------------------------ 
 
 
YPEL1      TTCCCCTGTCCTCTGGCCACACCGCCAGCCCTTGGTCCTTATCTGTGTGAGGTTTACAAA 
Ypel1      ------------------------------------------------------------ 
 
 
YPEL1      TAAAGCTTCTGATGTCAAATGTTTAAAAAAAAAAAAAAAAAAA 
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